cancer.type	eQTL.type	tagSNP	LD	SNP.ID	SNP.position.hg19	Gene.symbol	Gene.position.hg19	Beta	t-stat	P-value	GWAS-Traits	
LAML	cis	1	rs1000113	chr5:150240076	LOC134466	chr5:150310000-150326146:-	0.96	5.16	1.29E-6	Crohn's disease	
LAML	cis	1	rs10002332	chr4:129875301	C4orf33	chr4:130014829-130033842:+	0.6	4.81	5.44E-6	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs1003719	chr21:38491095	PIGP	chr21:38437664-38445458:-	-0.45	-5.53	2.63E-7	Eye color traits	
LAML	cis	1	rs1004467	chr10:104594507	SFXN2	chr10:104474298-104498946:+	-0.63	-5.28	7.52E-7	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LAML	cis	1	rs10051747	chr5:56083289	C5orf35	chr5:56205103-56213010:+	0.88	7.67	1.19E-11	Type 2 diabetes	
LAML	cis	1	rs10069077	chr5:110170026	TMEM232	chr5:109624934-110062381:-	-0.72	-4.2	5.9E-5	Mortality in heart failure	
LAML	cis	1	rs10136948	chr14:75511075	EIF2B2	chr14:75469612-75476292:+	0.44	4.5	1.84E-5	Height	
LAML	cis	1	rs10138183	chr14:75615227	EIF2B2	chr14:75469612-75476292:+	0.46	4.47	2.07E-5	Height	
LAML	cis	1	rs10140851	chr14:75512612	EIF2B2	chr14:75469612-75476292:+	0.45	4.46	2.13E-5	Height	
LAML	cis	1	rs10142626	chr14:75555636	EIF2B2	chr14:75469612-75476292:+	0.42	4.2	5.82E-5	Height	
LAML	cis	1	rs10143132	chr14:75525850	EIF2B2	chr14:75469612-75476292:+	0.45	4.46	2.13E-5	Height	
LAML	cis	1	rs10149880	chr14:75633008	EIF2B2	chr14:75469612-75476292:+	-0.44	-4.38	3.0E-5	Height	
LAML	cis	1	rs10157597	chr1:45990278	CCDC163P	chr1:45960581-45965646:-	-1.26	-14.53	2.71E-26	Homocysteine levels	
LAML	cis	1	rs10169714	chr2:73808773	ALMS1P	chr2:73872046-73912692:+	0.54	5.2	1.09E-6	Metabolite levels	
LAML	cis	1	rs10169714	chr2:73808773	NAT8	chr2:73867850-73869537:-	0.66	6	3.32E-8	Metabolite levels	
LAML	cis	1	rs10175180	chr2:73673123	ALMS1P	chr2:73872046-73912692:+	0.53	5.18	1.19E-6	Metabolite levels	
LAML	cis	1	rs10175180	chr2:73673123	NAT8	chr2:73867850-73869537:-	0.63	5.83	7.04E-8	Metabolite levels	
LAML	cis	1	rs10178409	chr2:73855507	ALMS1P	chr2:73872046-73912692:+	0.5	4.45	2.26E-5	Urinary metabolites	
LAML	cis	1	rs10178409	chr2:73855507	NAT8	chr2:73867850-73869537:-	0.67	5.78	8.56E-8	Urinary metabolites	
LAML	cis	1	rs10179134	chr2:73637519	ALMS1P	chr2:73872046-73912692:+	0.56	5.37	5.26E-7	Metabolite levels	
LAML	cis	1	rs10179134	chr2:73637519	NAT8	chr2:73867850-73869537:-	0.66	6.1	2.07E-8	Metabolite levels	
LAML	cis	1	rs1018184	chr6:86648475	SNHG5	chr6:86386726-86388451:-	0.59	5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs10184268	chr2:73627044	ALMS1P	chr2:73872046-73912692:+	0.55	5.28	7.8E-7	Metabolite levels	
LAML	cis	1	rs10184268	chr2:73627044	NAT8	chr2:73867850-73869537:-	0.63	5.69	1.29E-7	Metabolite levels	
LAML	cis	1	rs10186501	chr2:73697844	ALMS1P	chr2:73872046-73912692:+	0.53	5.18	1.19E-6	Metabolite levels	
LAML	cis	1	rs10186501	chr2:73697844	NAT8	chr2:73867850-73869537:-	0.63	5.83	7.04E-8	Metabolite levels	
LAML	cis	1	rs10187192	chr2:73713500	ALMS1P	chr2:73872046-73912692:+	0.55	5.27	8.12E-7	Metabolite levels	
LAML	cis	1	rs10187192	chr2:73713500	NAT8	chr2:73867850-73869537:-	0.68	6.22	1.19E-8	Metabolite levels	
LAML	cis	1	rs10187416	chr2:73713741	ALMS1P	chr2:73872046-73912692:+	0.55	5.31	6.65E-7	Metabolite levels	
LAML	cis	1	rs10187416	chr2:73713741	NAT8	chr2:73867850-73869537:-	0.65	5.97	3.72E-8	Metabolite levels	
LAML	cis	1	rs10189574	chr2:73698518	ALMS1P	chr2:73872046-73912692:+	0.54	5.27	7.99E-7	Metabolite levels	
LAML	cis	1	rs10189574	chr2:73698518	NAT8	chr2:73867850-73869537:-	0.64	5.96	3.94E-8	Metabolite levels	
LAML	cis	1	rs10189996	chr2:240908800	NDUFA10	chr2:240900158-240964798:-	0.47	5.27	8.12E-7	Odorant perception (isobutyraldehyde)	
LAML	cis	1	rs10190219	chr2:73658331	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs10190219	chr2:73658331	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs10193610	chr2:240940618	NDUFA10	chr2:240900158-240964798:-	0.46	5.18	1.16E-6	Odorant perception (isobutyraldehyde)	
LAML	cis	1	rs10193972	chr2:73717656	ALMS1P	chr2:73872046-73912692:+	0.54	5.26	8.42E-7	Metabolite levels	
LAML	cis	1	rs10193972	chr2:73717656	NAT8	chr2:73867850-73869537:-	0.65	6.04	2.75E-8	Metabolite levels	
LAML	cis	1	rs10206993	chr2:240900919	NDUFA10	chr2:240900158-240964798:-	0.48	5.28	7.69E-7	Odorant perception (isobutyraldehyde)	
LAML	cis	1	rs10207220	chr2:73785046	ALMS1P	chr2:73872046-73912692:+	0.55	5.39	4.82E-7	Metabolite levels	
LAML	cis	1	rs10207220	chr2:73785046	NAT8	chr2:73867850-73869537:-	0.67	6.32	7.55E-9	Metabolite levels	
LAML	cis	1	rs10208155	chr2:61115039	AHSA2	chr2:61404553-61414058:+	-0.35	-4.26	4.61E-5	Inflammatory skin disease	
LAML	cis	1	rs10247443	chr7:50620586	FIGNL1	chr7:50511834-50518088:-	-0.34	-4.59	1.3E-5	Malaria	
LAML	cis	1	rs10250513	chr7:50621488	FIGNL1	chr7:50511834-50518088:-	-0.34	-4.59	1.3E-5	Malaria	
LAML	cis	1	rs1030831	chr4:130025037	C4orf33	chr4:130014829-130033842:+	-0.54	-4.64	1.07E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs1036554	chr2:86236099	LOC90784	chr2:86247339-86250991:-	-0.92	-5.52	2.74E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs1037147	chr4:130025873	C4orf33	chr4:130014829-130033842:+	-0.54	-4.64	1.07E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs10404486	chr19:53284135	ZNF600	chr19:53268750-53290034:-	0.51	4.38	2.95E-5	Phospholipid levels (plasma)	
LAML	cis	1	rs10431505	chr12:58178589	FAM119B	chr12:58166383-58176323:+	0.65	8.75	5.88E-14	Multiple sclerosis	
LAML	cis	1	rs1043674	chr14:75549370	EIF2B2	chr14:75469612-75476292:+	0.44	4.37	3.07E-5	Height	
LAML	cis	1	rs10445300	chr17:2114587	SRR	chr17:2207248-2228553:+	-0.61	-4.91	3.63E-6	Esophageal cancer (squamous cell)	
LAML	cis	1	rs1044717	chr1:45976587	CCDC163P	chr1:45960581-45965646:-	-1.26	-14.53	2.71E-26	Homocysteine levels	
LAML	cis	1	rs10455158	chr6:86672825	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs10455449	chr6:86592226	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs10455455	chr6:86670214	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs10455456	chr6:86670322	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs10456362	chr6:28221816	ZNF187	chr6:28234788-28245978:+	0.43	4.36	3.14E-5	Depression	
LAML	cis	1	rs10456622	chr6:49396453	MUT	chr6:49398994-49431031:-	0.46	6.72	1.19E-9	Folate pathway vitamin levels	
LAML	cis	1	rs10461617	chr5:56104308	C5orf35	chr5:56205103-56213010:+	0.89	7.89	4.1E-12	Type 2 diabetes	
LAML	cis	1	rs1047418	chr14:75605792	EIF2B2	chr14:75469612-75476292:+	0.45	4.44	2.34E-5	Height	
LAML	cis	1	rs10487488	chr7:127149291	FSCN3	chr7:127231463-127241843:+	0.72	4.43	2.48E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs10496191	chr2:73673798	ALMS1P	chr2:73872046-73912692:+	0.53	5.18	1.19E-6	Metabolite levels	
LAML	cis	1	rs10496191	chr2:73673798	NAT8	chr2:73867850-73869537:-	0.63	5.83	7.04E-8	Metabolite levels	
LAML	cis	1	rs10496193	chr2:73773503	ALMS1P	chr2:73872046-73912692:+	0.54	5.25	8.85E-7	Metabolite levels	
LAML	cis	1	rs10496193	chr2:73773503	NAT8	chr2:73867850-73869537:-	0.63	5.87	5.76E-8	Metabolite levels	
LAML	cis	1	rs10498958	chr6:86649705	SNHG5	chr6:86386726-86388451:-	0.57	5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs10540	chr11:494662	RNH1	chr11:494512-507273:-	-0.5	-5.24	9.06E-7	Body mass index	
LAML	cis	1	rs1056964	chr22:51017476	CHKB-CPT1B	chr22:51007291-51021428:-	-0.62	-4.48	2.03E-5	Narcolepsy	
LAML	cis	1	rs1056964	chr22:51017476	CPT1B	chr22:51007291-51017096:-	-0.75	-4.53	1.68E-5	Narcolepsy	
LAML	cis	1	rs10732856	chr11:116907113	TAGLN	chr11:117070040-117075507:+	0.51	4.61	1.22E-5	Protein quantitative trait loci	
LAML	cis	1	rs10736426	chr1:45984353	CCDC163P	chr1:45960581-45965646:-	1.09	10.84	1.65E-18	Homocysteine levels	
LAML	cis	1	rs10744482	chr12:131298195	STX2	chr12:131274149-131323811:-	0.48	5.68	1.36E-7	Plasma plasminogen activator levels	
LAML	cis	1	rs10747783	chr12:58176614	FAM119B	chr12:58166383-58176323:+	0.63	8.36	4.13E-13	Multiple sclerosis	
LAML	cis	1	rs10749860	chr1:46328210	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs10749860	chr1:46328210	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs10750100	chr11:116917244	TAGLN	chr11:117070040-117075507:+	0.53	4.99	2.6E-6	Protein quantitative trait loci	
LAML	cis	1	rs10750101	chr11:116979689	TAGLN	chr11:117070040-117075507:+	0.54	4.63	1.1E-5	Protein quantitative trait loci	
LAML	cis	1	rs10760118	chr9:123641616	LOC253039	chr9:123605320-123616644:+	-0.5	-4.7	8.57E-6	Rheumatoid arthritis	
LAML	cis	1	rs1076539	chr22:18439598	MICAL3	chr22:18270418-18507325:-	-0.4	-6.14	1.74E-8	Presence of antiphospholipid antibodies	
LAML	cis	1	rs1076540	chr22:18439958	MICAL3	chr22:18270418-18507325:-	-0.4	-6.14	1.74E-8	Presence of antiphospholipid antibodies	
LAML	cis	1	rs1076541	chr22:18440026	MICAL3	chr22:18270418-18507325:-	-0.4	-5.88	5.53E-8	Presence of antiphospholipid antibodies	
LAML	cis	1	rs1076542	chr22:18446452	MICAL3	chr22:18270418-18507325:-	0.39	6.05	2.61E-8	Presence of antiphospholipid antibodies	
LAML	cis	1	rs1076543	chr22:18446490	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs1076544	chr22:18446565	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs10773819	chr12:131279022	STX2	chr12:131274149-131323811:-	0.48	5.6	1.91E-7	Plasma plasminogen activator levels	
LAML	cis	1	rs10773822	chr12:131289107	STX2	chr12:131274149-131323811:-	0.52	5.97	3.79E-8	Plasma plasminogen activator levels	
LAML	cis	1	rs10783847	chr12:58196447	FAM119B	chr12:58166383-58176323:+	0.64	8.68	8.18E-14	Multiple sclerosis	
LAML	cis	1	rs10783848	chr12:58196528	FAM119B	chr12:58166383-58176323:+	0.64	8.68	8.18E-14	Multiple sclerosis	
LAML	cis	1	rs10789307	chr1:38717502	POU3F1	chr1:38509523-38512450:-	-0.45	-4.2	5.86E-5	Waist-to-hip circumference ratio (interaction)	
LAML	cis	1	rs10789475	chr1:46304177	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs10789475	chr1:46304177	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs10789481	chr1:46383583	CCDC163P	chr1:45960581-45965646:-	-0.61	-5.01	2.4E-6	Body mass index	
LAML	cis	1	rs10789481	chr1:46383583	PIK3R3	chr1:46505813-46642160:-	0.38	4.53	1.63E-5	Body mass index	
LAML	cis	1	rs10789487	chr1:46420221	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs10789487	chr1:46420221	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs10790172	chr11:116927740	TAGLN	chr11:117070040-117075507:+	0.51	4.61	1.22E-5	Protein quantitative trait loci	
LAML	cis	1	rs1079576	chr22:18446318	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs10804632	chr3:134294501	ANAPC13	chr3:134196547-134204865:-	0.37	4.92	3.47E-6	Height	
LAML	cis	1	rs10838738	chr11:47663049	MTCH2	chr11:47638859-47664206:-	-0.39	-4.42	2.51E-5	Subjective well-being	
LAML	cis	1	rs10848205	chr12:131280714	STX2	chr12:131274149-131323811:-	0.48	5.68	1.36E-7	Plasma plasminogen activator levels	
LAML	cis	1	rs1085243	chr1:46544768	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs1085243	chr1:46544768	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs1085244	chr1:46563680	CCDC163P	chr1:45960581-45965646:-	-0.6	-5.06	1.91E-6	Body mass index	
LAML	cis	1	rs1085244	chr1:46563680	PIK3R3	chr1:46505813-46642160:-	0.38	4.64	1.08E-5	Body mass index	
LAML	cis	1	rs10857712	chr10:135225666	MTG1	chr10:135207621-135234173:+	0.43	5.05	2.04E-6	Systemic lupus erythematosus	
LAML	cis	1	rs10864167	chr1:207421572	CD55	chr1:207494817-207534309:+	0.39	4.53	1.63E-5	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs10864175	chr1:207433349	CD55	chr1:207494817-207534309:+	0.39	4.55	1.5E-5	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs10864178	chr1:207445678	CD55	chr1:207494817-207534309:+	0.39	4.55	1.5E-5	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs10864180	chr1:207445761	CD55	chr1:207494817-207534309:+	0.39	4.55	1.5E-5	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs10864181	chr1:207448051	CD55	chr1:207494817-207534309:+	0.48	5.51	2.89E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs10864231	chr1:207506329	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs10873275	chr14:75531460	EIF2B2	chr14:75469612-75476292:+	0.47	4.64	1.06E-5	Height	
LAML	cis	1	rs10874122	chr1:75235866	CRYZ	chr1:75171175-75199092:-	-0.47	-4.62	1.16E-5	Resistin levels	
LAML	cis	1	rs10877012	chr12:58162085	FAM119B	chr12:58166383-58176323:+	0.64	8.36	4.12E-13	Multiple sclerosis	
LAML	cis	1	rs10877013	chr12:58165085	FAM119B	chr12:58166383-58176323:+	0.64	8.68	8.18E-14	Multiple sclerosis	
LAML	cis	1	rs10877014	chr12:58167661	FAM119B	chr12:58166383-58176323:+	0.64	8.68	8.18E-14	Multiple sclerosis	
LAML	cis	1	rs10877015	chr12:58167788	FAM119B	chr12:58166383-58176323:+	0.64	8.36	4.12E-13	Multiple sclerosis	
LAML	cis	1	rs10877019	chr12:58172929	FAM119B	chr12:58166383-58176323:+	-0.63	-8.36	4.13E-13	Multiple sclerosis	
LAML	cis	1	rs10890352	chr1:46283628	CCDC163P	chr1:45960581-45965646:-	-0.6	-4.95	3.08E-6	Body mass index	
LAML	cis	1	rs10890352	chr1:46283628	PIK3R3	chr1:46505813-46642160:-	0.38	4.6	1.24E-5	Body mass index	
LAML	cis	1	rs10890354	chr1:46305347	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs10890354	chr1:46305347	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs10890361	chr1:46346234	CCDC163P	chr1:45960581-45965646:-	-0.59	-4.93	3.38E-6	Body mass index	
LAML	cis	1	rs10890361	chr1:46346234	PIK3R3	chr1:46505813-46642160:-	0.37	4.52	1.75E-5	Body mass index	
LAML	cis	1	rs10890363	chr1:46356148	CCDC163P	chr1:45960581-45965646:-	0.6	5	2.53E-6	Body mass index	
LAML	cis	1	rs10890363	chr1:46356148	PIK3R3	chr1:46505813-46642160:-	-0.39	-4.65	1.05E-5	Body mass index	
LAML	cis	1	rs10890383	chr1:46588503	CCDC163P	chr1:45960581-45965646:-	-0.57	-4.84	4.79E-6	Body mass index	
LAML	cis	1	rs10890383	chr1:46588503	PIK3R3	chr1:46505813-46642160:-	0.37	4.58	1.35E-5	Body mass index	
LAML	cis	1	rs10908419	chr1:154567699	CHRNB2	chr1:154540257-154552351:+	-0.38	-4.27	4.47E-5	C-reactive protein levels or triglyceride levels (pleiotropy)	
LAML	cis	1	rs10935120	chr3:134233092	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.27	8.01E-7	Height	
LAML	cis	1	rs10937158	chr3:183708439	ABCC5	chr3:183637726-183735727:-	-0.41	-4.31	3.79E-5	Anterior chamber depth	
LAML	cis	1	rs10944161	chr6:86630376	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs10944163	chr6:86658693	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs10944169	chr6:86683036	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs10944170	chr6:86685469	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs10946198	chr6:167404432	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs10946199	chr6:167404492	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs10953730	chr7:112911410	LOC401397	chr7:112756774-112758637:-	-0.36	-4.82	5.2E-6	Metabolite levels	
LAML	cis	1	rs10988125	chr9:131572903	ENDOG	chr9:131580779-131584954:+	0.45	5.95	4.05E-8	Blood metabolite levels	
LAML	cis	1	rs11039255	chr11:47495746	MTCH2	chr11:47638859-47664206:-	-0.39	-4.51	1.81E-5	Subjective well-being	
LAML	cis	1	rs1106369	chr12:131300095	STX2	chr12:131274149-131323811:-	0.52	5.97	3.79E-8	Plasma plasminogen activator levels	
LAML	cis	1	rs11072603	chr15:76881138	SCAPER	chr15:76640529-77197744:-	-0.4	-6.02	2.95E-8	Blood metabolite levels	
LAML	cis	1	rs1110659	chr22:18444675	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs1110660	chr22:18444693	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs1110662	chr22:18444908	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs11120733	chr1:207506649	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs11123170	chr2:113978940	LOC654433	chr2:113993107-114024579:+	-0.63	-4.8	5.66E-6	Renal function-related traits (BUN)	
LAML	cis	1	rs111315781	chr2:201738724	PPIL3	chr2:201735680-201753999:-	-1	-7.04	2.55E-10	Triptolide cytotoxicity	
LAML	cis	1	rs11132254	chr4:185611592	MLF1IP	chr4:185615220-185655286:-	-0.36	-4.45	2.29E-5	Kawasaki disease	
LAML	cis	1	rs1114380	chr2:73804708	ALMS1P	chr2:73872046-73912692:+	0.54	5.2	1.09E-6	Metabolite levels	
LAML	cis	1	rs1114380	chr2:73804708	NAT8	chr2:73867850-73869537:-	0.66	6	3.32E-8	Metabolite levels	
LAML	cis	1	rs11150589	chr16:30482494	LOC440354	chr16:29454226-29625038:-;chr16	-0.46	-5.09	1.67E-6	Ulcerative colitis;Inflammatory bowel disease	
LAML	cis	1	rs11150589	chr16:30482494	LOC595101	chr16:30278914-30346695:-	-0.53	-4.97	2.78E-6	Ulcerative colitis;Inflammatory bowel disease	
LAML	cis	1	rs11157696	chr14:50105746	RPL36AL	chr14:50085407-50087349:-	-0.38	-4.62	1.15E-5	Carotid intima media thickness	
LAML	cis	1	rs11159117	chr14:75584867	EIF2B2	chr14:75469612-75476292:+	0.44	4.36	3.14E-5	Height	
LAML	cis	1	rs11159856	chr14:88883929	PTPN21	chr14:88932123-89021123:-	0.67	6	3.19E-8	Coronary artery calcification	
LAML	cis	1	rs11167515	chr5:150239471	LOC134466	chr5:150310000-150326146:-	0.96	5.16	1.29E-6	Crohn's disease	
LAML	cis	1	rs11168936	chr12:49645240	H1FNT	chr12:48722763-48724061:+	-0.48	-4.46	2.13E-5	Cancer (pleiotropy)	
LAML	cis	1	rs11172333	chr12:58170335	FAM119B	chr12:58166383-58176323:+	0.63	8.36	4.13E-13	Multiple sclerosis	
LAML	cis	1	rs11172335	chr12:58175201	FAM119B	chr12:58166383-58176323:+	0.63	8.36	4.13E-13	Multiple sclerosis	
LAML	cis	1	rs11172342	chr12:58187758	FAM119B	chr12:58166383-58176323:+	0.63	8.36	4.13E-13	Multiple sclerosis	
LAML	cis	1	rs11172343	chr12:58188157	FAM119B	chr12:58166383-58176323:+	0.63	8.36	4.13E-13	Multiple sclerosis	
LAML	cis	1	rs11172344	chr12:58193448	FAM119B	chr12:58166383-58176323:+	0.65	8.75	5.88E-14	Multiple sclerosis	
LAML	cis	1	rs11172349	chr12:58212528	FAM119B	chr12:58166383-58176323:+	0.63	8.36	4.13E-13	Multiple sclerosis	
LAML	cis	1	rs11172351	chr12:58213485	FAM119B	chr12:58166383-58176323:+	0.63	8.36	4.13E-13	Multiple sclerosis	
LAML	cis	1	rs1117367	chr15:76872330	SCAPER	chr15:76640529-77197744:-	-0.41	-6.33	7.21E-9	Blood metabolite levels	
LAML	cis	1	rs11174650	chr12:63179929	C12orf61	chr12:62995531-62997214:-	-0.88	-4.84	4.7E-6	Sense of smell	
LAML	cis	1	rs11185760	chr10:91331304	FLJ37201	chr10:91451057-91457685:-	-0.52	-4.6	1.25E-5	Metabolic traits	
LAML	cis	1	rs11185773	chr10:91349331	FLJ37201	chr10:91451057-91457685:-	-0.53	-4.68	9.07E-6	Metabolic traits	
LAML	cis	1	rs11185780	chr10:91363624	FLJ37201	chr10:91451057-91457685:-	0.53	4.68	9.07E-6	Metabolic traits	
LAML	cis	1	rs11191416	chr10:104604916	SFXN2	chr10:104474298-104498946:+	0.63	5.3	6.96E-7	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LAML	cis	1	rs11191419	chr10:104612335	AS3MT	chr10:104613967-104661653:+	-0.66	-7.47	3.18E-11	Schizophrenia	
LAML	cis	1	rs11191419	chr10:104612335	C10orf32	chr10:104613967-104624718:+	-0.59	-6.44	4.3E-9	Schizophrenia	
LAML	cis	1	rs11191425	chr10:104625970	SFXN2	chr10:104474298-104498946:+	-0.63	-5.3	6.96E-7	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LAML	cis	1	rs11201297	chr10:81793749	LOC219347	chr10:81805991-81838949:-	1.21	9.17	6.9E-15	Chronic obstructive pulmonary disease-related biomarkers	
LAML	cis	1	rs11201298	chr10:81793751	LOC219347	chr10:81805991-81838949:-	1.19	9.35	2.79E-15	Chronic obstructive pulmonary disease-related biomarkers	
LAML	cis	1	rs11201312	chr10:81795778	LOC219347	chr10:81805991-81838949:-	1.27	8.08	1.63E-12	Chronic obstructive pulmonary disease-related biomarkers	
LAML	cis	1	rs11201660	chr10:81854531	LOC219347	chr10:81805991-81838949:-	-1.25	-9.57	9.29E-16	Chronic obstructive pulmonary disease-related biomarkers	
LAML	cis	1	rs11201799	chr10:81881954	LOC219347	chr10:81805991-81838949:-	-1.25	-9.57	9.29E-16	Chronic obstructive pulmonary disease-related biomarkers	
LAML	cis	1	rs11209718	chr1:41688938	SCMH1	chr1:41492875-41707788:-	-0.34	-5.7	1.26E-7	Height	
LAML	cis	1	rs11211132	chr1:45990516	CCDC163P	chr1:45960581-45965646:-	-1.26	-14.53	2.71E-26	Homocysteine levels	
LAML	cis	1	rs11211199	chr1:46287869	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs11211199	chr1:46287869	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs11211208	chr1:46334256	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs11211208	chr1:46334256	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs11211230	chr1:46406767	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs11211230	chr1:46406767	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs11211234	chr1:46438787	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs11211234	chr1:46438787	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs11211241	chr1:46452683	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs11211241	chr1:46452683	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs11216316	chr11:117081500	TAGLN	chr11:117070040-117075507:+	-0.52	-4.7	8.45E-6	Protein quantitative trait loci	
LAML	cis	1	rs112262605	chr2:242055156	MTERFD2	chr2:242034545-242041747:-	-0.69	-4.27	4.52E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs11231757	chr11:64106317	PPP2R5B	chr11:64692180-64701945:+	-0.4	-4.6	1.27E-5	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LAML	cis	1	rs11249608	chr5:178426319	ZNF879	chr5:178450776-178461387:+	-0.51	-4.75	6.99E-6	Pubertal anthropometrics	
LAML	cis	1	rs1127311	chr1:154556663	CHRNB2	chr1:154540257-154552351:+	-0.4	-4.49	1.94E-5	C-reactive protein levels or triglyceride levels (pleiotropy)	
LAML	cis	1	rs1127313	chr1:154556425	CHRNB2	chr1:154540257-154552351:+	0.4	4.49	1.94E-5	C-reactive protein levels or triglyceride levels (pleiotropy)	
LAML	cis	1	rs1131498	chr1:169676486	C1orf112	chr1:169631245-169822227:+	-0.47	-5.31	6.8E-7	Amyotrophic lateral sclerosis	
LAML	cis	1	rs113333037	chr17:2200106	SRR	chr17:2207248-2228553:+	-0.66	-5.36	5.41E-7	Esophageal cancer (squamous cell)	
LAML	cis	1	rs113638727	chr15:40706101	IVD	chr15:40697686-40713512:+	-0.47	-4.39	2.89E-5	Heschl's gyrus morphology	
LAML	cis	1	rs1137	chr2:74939176	TET3	chr2:74273450-74335300:+	0.36	4.28	4.31E-5	Myopia (pathological)	
LAML	cis	1	rs113807377	chr2:242052354	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs1138273	chr3:134261437	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs114079739	chr2:203825106	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs114110842	chr2:203823400	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs114123510	chr2:203831212	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs1141321	chr6:49412433	MUT	chr6:49398994-49431031:-	0.43	6.36	6.39E-9	Folate pathway vitamin levels	
LAML	cis	1	rs114155121	chr2:203718682	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs1143438	chr19:46889161	PPP5C	chr19:46850294-46894103:+	-0.38	-5.19	1.14E-6	Crohn's disease;Inflammatory bowel disease	
LAML	cis	1	rs114393235	chr2:203795987	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs114395475	chr2:203769112	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs114520702	chr2:203697092	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs114527590	chr2:203787405	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs114702158	chr2:203821793	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs114899426	chr2:203771652	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs115396314	chr2:203721314	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs11557072	chr15:40713374	IVD	chr15:40697686-40713512:+	-0.47	-4.39	2.89E-5	Heschl's gyrus morphology	
LAML	cis	1	rs115654617	chr2:203893999	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs115743514	chr22:51011933	CHKB-CPT1B	chr22:51007291-51021428:-	-0.62	-4.48	2.03E-5	Narcolepsy	
LAML	cis	1	rs115743514	chr22:51011933	CPT1B	chr22:51007291-51017096:-	-0.75	-4.53	1.68E-5	Narcolepsy	
LAML	cis	1	rs11579634	chr1:46466391	CCDC163P	chr1:45960581-45965646:-	0.6	4.9	3.69E-6	Body mass index	
LAML	cis	1	rs11579634	chr1:46466391	PIK3R3	chr1:46505813-46642160:-	-0.39	-4.69	8.89E-6	Body mass index	
LAML	cis	1	rs115810193	chr2:203943168	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs11589562	chr1:46466721	CCDC163P	chr1:45960581-45965646:-	0.6	5	2.53E-6	Body mass index	
LAML	cis	1	rs11589562	chr1:46466721	PIK3R3	chr1:46505813-46642160:-	-0.39	-4.65	1.05E-5	Body mass index	
LAML	cis	1	rs115953525	chr2:203744445	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs116101630	chr11:506826	RNH1	chr11:494512-507273:-	-0.46	-4.62	1.15E-5	Body mass index	
LAML	cis	1	rs11623413	chr14:75588824	EIF2B2	chr14:75469612-75476292:+	-0.44	-4.38	3.0E-5	Height	
LAML	cis	1	rs116382857	chr2:203751932	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs116678869	chr2:203819471	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs11674602	chr2:73723185	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs11674602	chr2:73723185	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs11681497	chr2:242344333	SEPT2	chr2:242254723-242293439:+	0.89	4.82	5.19E-6	Chronic lymphocytic leukemia	
LAML	cis	1	rs116876680	chr11:517473	RNH1	chr11:494512-507273:-	-0.45	-4.42	2.58E-5	Body mass index	
LAML	cis	1	rs11689392	chr2:73622026	ALMS1P	chr2:73872046-73912692:+	0.55	5.28	7.8E-7	Metabolite levels	
LAML	cis	1	rs11689392	chr2:73622026	NAT8	chr2:73867850-73869537:-	0.63	5.69	1.29E-7	Metabolite levels	
LAML	cis	1	rs11700	chr16:67232684	RLTPR	chr16:67679030-67691470:+	0.6	5.07	1.87E-6	HDL cholesterol	
LAML	cis	1	rs11704059	chr22:18449543	MICAL3	chr22:18270418-18507325:-	-0.42	-6.26	9.94E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs11704733	chr22:18446212	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs11704827	chr22:18450287	MICAL3	chr22:18270418-18507325:-	-0.42	-6.31	7.78E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs11705221	chr22:18443287	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs11706117	chr3:134212526	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	3.98E-7	Height	
LAML	cis	1	rs11708531	chr3:134224902	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs117339389	chr11:505025	RNH1	chr11:494512-507273:-	-0.49	-5.3	7.16E-7	Body mass index	
LAML	cis	1	rs11739344	chr5:56111087	C5orf35	chr5:56205103-56213010:+	0.88	7.67	1.19E-11	Type 2 diabetes	
LAML	cis	1	rs11739677	chr5:150294883	LOC134466	chr5:150310000-150326146:-	1.01	5.79	8.32E-8	Crohn's disease	
LAML	cis	1	rs11740172	chr5:150300278	LOC134466	chr5:150310000-150326146:-	0.94	5.2	1.07E-6	Crohn's disease	
LAML	cis	1	rs11741861	chr5:150277909	LOC134466	chr5:150310000-150326146:-	-1.05	-5.83	6.99E-8	Crohn's disease	
LAML	cis	1	rs11743488	chr5:150279218	LOC134466	chr5:150310000-150326146:-	0.96	5.17	1.22E-6	Crohn's disease	
LAML	cis	1	rs11746560	chr5:150185925	LOC134466	chr5:150310000-150326146:-	1.04	5.75	9.99E-8	Crohn's disease	
LAML	cis	1	rs11746807	chr5:150300419	LOC134466	chr5:150310000-150326146:-	0.94	5.2	1.07E-6	Crohn's disease	
LAML	cis	1	rs11747065	chr5:150295486	LOC134466	chr5:150310000-150326146:-	0.94	5.2	1.07E-6	Crohn's disease	
LAML	cis	1	rs11748553	chr5:150184553	LOC134466	chr5:150310000-150326146:-	1.04	5.75	9.99E-8	Crohn's disease	
LAML	cis	1	rs11758849	chr6:86708262	SNHG5	chr6:86386726-86388451:-	-0.58	-5.14	1.37E-6	Response to antipsychotic treatment	
LAML	cis	1	rs11759855	chr6:86610841	SNHG5	chr6:86386726-86388451:-	-0.58	-5.61	1.81E-7	Response to antipsychotic treatment	
LAML	cis	1	rs11761466	chr7:112911034	LOC401397	chr7:112756774-112758637:-	-0.36	-4.82	5.2E-6	Metabolite levels	
LAML	cis	1	rs11790388	chr9:129740283	RALGPS1	chr9:129677053-129985443:+	-0.55	-4.93	3.29E-6	Schizophrenia	
LAML	cis	1	rs117907570	chr6:86601283	SNHG5	chr6:86386726-86388451:-	-0.6	-5.93	4.42E-8	Response to antipsychotic treatment	
LAML	cis	1	rs11810993	chr1:46478793	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs11810993	chr1:46478793	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs118110670	chr10:81792242	LOC219347	chr10:81805991-81838949:-	1.41	9.3	3.6E-15	Chronic obstructive pulmonary disease-related biomarkers	
LAML	cis	1	rs11845639	chr14:75570293	EIF2B2	chr14:75469612-75476292:+	0.43	4.27	4.44E-5	Height	
LAML	cis	1	rs11858714	chr15:40717447	IVD	chr15:40697686-40713512:+	-0.47	-4.39	2.89E-5	Heschl's gyrus morphology	
LAML	cis	1	rs11867934	chr17:16933404	FLCN	chr17:17115529-17140502:-	0.44	4.31	3.92E-5	Diabetic retinopathy	
LAML	cis	1	rs11869714	chr17:48587307	MYCBPAP	chr17:48585745-48608861:+	-0.67	-5.3	7.17E-7	Visceral fat	
LAML	cis	1	rs11893881	chr2:73824373	ALMS1P	chr2:73872046-73912692:+	0.55	5.46	3.58E-7	Metabolite levels	
LAML	cis	1	rs11893881	chr2:73824373	NAT8	chr2:73867850-73869537:-	0.61	5.68	1.35E-7	Metabolite levels	
LAML	cis	1	rs11899576	chr2:86256193	LOC90784	chr2:86247339-86250991:-	-0.91	-5.66	1.48E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs11899576	chr2:86256193	POLR1A	chr2:86253453-86333278:-	-0.45	-4.27	4.55E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs11899740	chr2:73631212	ALMS1P	chr2:73872046-73912692:+	0.56	5.37	5.26E-7	Metabolite levels	
LAML	cis	1	rs11899740	chr2:73631212	NAT8	chr2:73867850-73869537:-	0.66	6.1	2.07E-8	Metabolite levels	
LAML	cis	1	rs11899902	chr2:73631564	ALMS1P	chr2:73872046-73912692:+	0.57	5.37	5.31E-7	Metabolite levels	
LAML	cis	1	rs11899902	chr2:73631564	NAT8	chr2:73867850-73869537:-	0.69	6.22	1.21E-8	Metabolite levels	
LAML	cis	1	rs11901272	chr2:73720444	ALMS1P	chr2:73872046-73912692:+	0.53	5.18	1.19E-6	Metabolite levels	
LAML	cis	1	rs11901272	chr2:73720444	NAT8	chr2:73867850-73869537:-	0.63	5.83	7.04E-8	Metabolite levels	
LAML	cis	1	rs11903916	chr2:73815328	ALMS1P	chr2:73872046-73912692:+	0.56	5.49	3.13E-7	Metabolite levels	
LAML	cis	1	rs11903916	chr2:73815328	NAT8	chr2:73867850-73869537:-	0.65	6.11	1.98E-8	Metabolite levels	
LAML	cis	1	rs11919350	chr3:134235970	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs11927068	chr3:134266321	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs11928499	chr3:134232350	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs11957134	chr5:150230950	LOC134466	chr5:150310000-150326146:-	-0.96	-5.16	1.29E-6	Crohn's disease	
LAML	cis	1	rs11965538	chr6:28239915	ZNF187	chr6:28234788-28245978:+	-0.37	-4.17	6.45E-5	Depression	
LAML	cis	1	rs11976020	chr7:72247800	TYW1B	chr7:72023729-72298813:-	0.62	7.02	2.82E-10	Educational attainment (years of education)	
LAML	cis	1	rs12021587	chr1:46472759	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs12021587	chr1:46472759	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs12049588	chr1:46472422	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs12049588	chr1:46472422	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs12051145	chr16:67239676	RLTPR	chr16:67679030-67691470:+	-0.62	-5.67	1.44E-7	HDL cholesterol	
LAML	cis	1	rs12051247	chr16:67241282	RLTPR	chr16:67679030-67691470:+	-0.62	-5.86	6.22E-8	HDL cholesterol	
LAML	cis	1	rs12051249	chr16:67241427	RLTPR	chr16:67679030-67691470:+	-0.52	-5.73	1.07E-7	HDL cholesterol	
LAML	cis	1	rs12095015	chr1:207456474	CD55	chr1:207494817-207534309:+	-0.48	-5.51	2.89E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs12125555	chr1:41707111	SCMH1	chr1:41492875-41707788:-	-0.34	-5.72	1.12E-7	Height	
LAML	cis	1	rs12129263	chr1:17723870	PADI6	chr1:17698741-17728195:+	-0.49	-5.26	8.34E-7	Basal cell carcinoma	
LAML	cis	1	rs12130219	chr1:152162106	FLG	chr1:152274651-152297679:-	0.51	4.4	2.78E-5	Inflammatory skin disease	
LAML	cis	1	rs12132197	chr1:17723964	PADI6	chr1:17698741-17728195:+	-0.5	-5.41	4.31E-7	Basal cell carcinoma	
LAML	cis	1	rs12132237	chr1:17724112	PADI6	chr1:17698741-17728195:+	-0.5	-5.41	4.31E-7	Basal cell carcinoma	
LAML	cis	1	rs12132919	chr1:156318141	CCT3	chr1:156278752-156308195:-	-0.33	-4.2	5.81E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LAML	cis	1	rs12134073	chr1:41689283	SCMH1	chr1:41492875-41707788:-	-0.34	-5.7	1.26E-7	Height	
LAML	cis	1	rs12134662	chr1:17724767	PADI6	chr1:17698741-17728195:+	-0.5	-5.41	4.31E-7	Basal cell carcinoma	
LAML	cis	1	rs12139630	chr1:46350935	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs12139630	chr1:46350935	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs12144263	chr1:46352446	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs12144263	chr1:46352446	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs12148786	chr15:76800362	SCAPER	chr15:76640529-77197744:-	-0.38	-5.67	1.39E-7	Blood metabolite levels	
LAML	cis	1	rs12154056	chr6:86634094	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs12158906	chr22:18437382	MICAL3	chr22:18270418-18507325:-	-0.4	-6.14	1.74E-8	Presence of antiphospholipid antibodies	
LAML	cis	1	rs12190598	chr6:86686074	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs12190604	chr6:86716215	SNHG5	chr6:86386726-86388451:-	-0.6	-5.8	7.94E-8	Response to antipsychotic treatment	
LAML	cis	1	rs12192992	chr6:86609915	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12196037	chr6:86694631	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12196411	chr6:86779762	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12196937	chr6:49382808	MUT	chr6:49398994-49431031:-	0.45	6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs12199516	chr6:86726221	SNHG5	chr6:86386726-86388451:-	-0.6	-5.78	8.82E-8	Response to antipsychotic treatment	
LAML	cis	1	rs12199784	chr6:86726808	SNHG5	chr6:86386726-86388451:-	-0.61	-5.9	5.08E-8	Response to antipsychotic treatment	
LAML	cis	1	rs12200330	chr6:86656653	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12201571	chr6:86609750	SNHG5	chr6:86386726-86388451:-	-0.58	-5.61	1.81E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12201735	chr6:86656939	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs12201741	chr6:86602619	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12201880	chr6:86627007	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs12202075	chr6:49427655	MUT	chr6:49398994-49431031:-	0.44	6.66	1.57E-9	Folate pathway vitamin levels	
LAML	cis	1	rs12203493	chr6:86758642	SNHG5	chr6:86386726-86388451:-	-0.56	-5.4	4.65E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12203924	chr6:86776412	SNHG5	chr6:86386726-86388451:-	-0.56	-5.4	4.65E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12204015	chr6:86598334	SNHG5	chr6:86386726-86388451:-	-0.59	-5.68	1.38E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12204365	chr6:86700532	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs12205336	chr6:86722367	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12205548	chr6:86759770	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12207305	chr6:86723502	SNHG5	chr6:86386726-86388451:-	-0.61	-5.9	5.08E-8	Response to antipsychotic treatment	
LAML	cis	1	rs12207610	chr6:86688016	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12208493	chr6:86662267	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12209127	chr6:86724427	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12212733	chr6:86726013	SNHG5	chr6:86386726-86388451:-	-0.58	-5.61	1.81E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12213149	chr6:86668644	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12213740	chr6:86656733	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12215037	chr6:86727631	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12215903	chr6:86675028	SNHG5	chr6:86386726-86388451:-	-0.59	-5.84	6.72E-8	Response to antipsychotic treatment	
LAML	cis	1	rs12216203	chr6:86675301	SNHG5	chr6:86386726-86388451:-	-0.58	-5.61	1.81E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12216328	chr6:86703418	SNHG5	chr6:86386726-86388451:-	-0.58	-5.61	1.81E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12220777	chr10:81788104	LOC219347	chr10:81805991-81838949:-	-1.32	-9.01	1.59E-14	Chronic obstructive pulmonary disease-related biomarkers	
LAML	cis	1	rs12328085	chr2:86262009	LOC90784	chr2:86247339-86250991:-	-0.91	-5.66	1.48E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs12328085	chr2:86262009	POLR1A	chr2:86253453-86333278:-	-0.45	-4.27	4.55E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs1233491	chr6:29461730	MOG	chr6:29624809-29640147:+	0.94	5.57	2.17E-7	Cutaneous lupus erythematosus	
LAML	cis	1	rs12363232	chr11:47623890	MTCH2	chr11:47638859-47664206:-	-0.39	-4.51	1.81E-5	Subjective well-being	
LAML	cis	1	rs12405451	chr1:46384326	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs12405451	chr1:46384326	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs12409773	chr1:46358831	CCDC163P	chr1:45960581-45965646:-	-0.6	-4.95	3.11E-6	Body mass index	
LAML	cis	1	rs12409773	chr1:46358831	PIK3R3	chr1:46505813-46642160:-	0.39	4.71	7.96E-6	Body mass index	
LAML	cis	1	rs12410060	chr1:75245848	CRYZ	chr1:75171175-75199092:-	-0.5	-4.9	3.78E-6	Resistin levels	
LAML	cis	1	rs12410071	chr1:46358886	CCDC163P	chr1:45960581-45965646:-	-0.6	-4.95	3.11E-6	Body mass index	
LAML	cis	1	rs12410071	chr1:46358886	PIK3R3	chr1:46505813-46642160:-	0.39	4.71	7.96E-6	Body mass index	
LAML	cis	1	rs12411269	chr1:46271052	CCDC163P	chr1:45960581-45965646:-	-0.6	-4.95	3.08E-6	Body mass index	
LAML	cis	1	rs12411269	chr1:46271052	PIK3R3	chr1:46505813-46642160:-	0.38	4.6	1.24E-5	Body mass index	
LAML	cis	1	rs12416687	chr10:104629011	AS3MT	chr10:104613967-104661653:+	-0.5	-4.55	1.54E-5	Arsenic metabolism	
LAML	cis	1	rs12416687	chr10:104629011	C10orf32	chr10:104613967-104624718:+	-0.71	-7.24	9.69E-11	Arsenic metabolism	
LAML	cis	1	rs12417570	chr11:462684	RNH1	chr11:494512-507273:-	-0.42	-4.39	2.86E-5	Body mass index	
LAML	cis	1	rs12418639	chr11:473300	RNH1	chr11:494512-507273:-	0.4	5.3	6.89E-7	Body mass index	
LAML	cis	1	rs12419692	chr11:47624714	MTCH2	chr11:47638859-47664206:-	0.39	4.59	1.3E-5	Subjective well-being	
LAML	cis	1	rs12419716	chr11:503385	RNH1	chr11:494512-507273:-	-0.49	-5.3	7.16E-7	Body mass index	
LAML	cis	1	rs12419766	chr11:503710	RNH1	chr11:494512-507273:-	-0.49	-5.3	7.16E-7	Body mass index	
LAML	cis	1	rs12421457	chr11:505780	RNH1	chr11:494512-507273:-	-0.46	-4.6	1.27E-5	Body mass index	
LAML	cis	1	rs1242229	chr11:117062370	TAGLN	chr11:117070040-117075507:+	0.5	4.38	2.91E-5	Protein quantitative trait loci	
LAML	cis	1	rs12433464	chr14:88824015	PTPN21	chr14:88932123-89021123:-	0.6	5.59	2.0E-7	Coronary artery calcification	
LAML	cis	1	rs12435391	chr14:75601737	EIF2B2	chr14:75469612-75476292:+	0.45	4.36	3.16E-5	Height	
LAML	cis	1	rs12441433	chr15:76816015	SCAPER	chr15:76640529-77197744:-	-0.41	-6.32	7.64E-9	Blood metabolite levels	
LAML	cis	1	rs12443137	chr15:76840832	SCAPER	chr15:76640529-77197744:-	-0.38	-5.68	1.37E-7	Blood metabolite levels	
LAML	cis	1	rs12446632	chr16:19935389	C16orf88	chr16:19717676-19729492:-	0.68	5.4	4.68E-7	Body mass index;Menarche (age at onset);Childhood body mass index;Obesity	
LAML	cis	1	rs12459222	chr19:46859301	PPP5C	chr19:46850294-46894103:+	-0.47	-6.52	3.01E-9	Crohn's disease;Inflammatory bowel disease	
LAML	cis	1	rs12490835	chr3:134223730	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs12506659	chr4:170259647	SH3RF1	chr4:170015407-170192249:-	-0.37	-6.14	1.72E-8	Night sleep phenotypes	
LAML	cis	1	rs12561806	chr1:46396776	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs12561806	chr1:46396776	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs12564541	chr1:46380237	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs12564541	chr1:46380237	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs12587386	chr14:88827764	PTPN21	chr14:88932123-89021123:-	0.63	5.86	6.1E-8	Coronary artery calcification	
LAML	cis	1	rs12588240	chr14:75612083	EIF2B2	chr14:75469612-75476292:+	0.44	4.38	3.0E-5	Height	
LAML	cis	1	rs12589376	chr14:75561152	EIF2B2	chr14:75469612-75476292:+	0.45	4.44	2.36E-5	Height	
LAML	cis	1	rs12589467	chr14:88823583	PTPN21	chr14:88932123-89021123:-	0.63	5.86	6.1E-8	Coronary artery calcification	
LAML	cis	1	rs12589480	chr14:88881270	PTPN21	chr14:88932123-89021123:-	0.63	5.44	3.82E-7	Coronary artery calcification	
LAML	cis	1	rs12589815	chr14:75544101	EIF2B2	chr14:75469612-75476292:+	0.43	4.31	3.86E-5	Height	
LAML	cis	1	rs12589876	chr14:75544189	EIF2B2	chr14:75469612-75476292:+	0.43	4.31	3.86E-5	Height	
LAML	cis	1	rs12590452	chr14:75548756	EIF2B2	chr14:75469612-75476292:+	0.44	4.31	3.87E-5	Height	
LAML	cis	1	rs12594212	chr15:76802014	SCAPER	chr15:76640529-77197744:-	-0.38	-5.63	1.72E-7	Blood metabolite levels	
LAML	cis	1	rs12594541	chr15:76834368	SCAPER	chr15:76640529-77197744:-	-0.38	-5.68	1.37E-7	Blood metabolite levels	
LAML	cis	1	rs12598978	chr16:30482540	LOC440354	chr16:29454226-29625038:-;chr16	-0.47	-5.41	4.35E-7	Ulcerative colitis;Inflammatory bowel disease	
LAML	cis	1	rs12598978	chr16:30482540	LOC595101	chr16:30278914-30346695:-	-0.53	-5.06	1.95E-6	Ulcerative colitis;Inflammatory bowel disease	
LAML	cis	1	rs12621280	chr2:232132984	ARMC9	chr2:232063342-232238606:+	0.35	4.2	5.85E-5	Food antigen IgG levels	
LAML	cis	1	rs12622009	chr2:86248325	LOC90784	chr2:86247339-86250991:-	-0.91	-5.66	1.48E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs12622009	chr2:86248325	POLR1A	chr2:86253453-86333278:-	-0.45	-4.27	4.55E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs12627787	chr22:51012381	CHKB-CPT1B	chr22:51007291-51021428:-	-0.62	-4.48	2.03E-5	Narcolepsy	
LAML	cis	1	rs12627787	chr22:51012381	CPT1B	chr22:51007291-51017096:-	-0.75	-4.53	1.68E-5	Narcolepsy	
LAML	cis	1	rs12637751	chr3:134266124	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs12652003	chr5:150231945	LOC134466	chr5:150310000-150326146:-	0.96	5.16	1.29E-6	Crohn's disease	
LAML	cis	1	rs12656538	chr5:150251380	LOC134466	chr5:150310000-150326146:-	0.96	5.17	1.22E-6	Crohn's disease	
LAML	cis	1	rs12656600	chr5:150311872	LOC134466	chr5:150310000-150326146:-	0.94	5.2	1.07E-6	Crohn's disease	
LAML	cis	1	rs12659118	chr5:150324622	LOC134466	chr5:150310000-150326146:-	1.08	5.99	3.44E-8	Crohn's disease	
LAML	cis	1	rs12661204	chr6:86678586	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12663651	chr6:86701655	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs12663690	chr6:86640162	SNHG5	chr6:86386726-86388451:-	0.59	5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12664335	chr6:86597774	SNHG5	chr6:86386726-86388451:-	0.59	5.68	1.38E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12665321	chr6:86769289	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs12691307	chr16:29939877	LOC440354	chr16:29454226-29625038:-;chr16	0.43	4.26	4.64E-5	Schizophrenia	
LAML	cis	1	rs12733173	chr1:152173972	FLG	chr1:152274651-152297679:-	0.51	4.4	2.78E-5	Inflammatory skin disease	
LAML	cis	1	rs12760175	chr1:46447840	CCDC163P	chr1:45960581-45965646:-	-0.57	-4.77	6.37E-6	Body mass index	
LAML	cis	1	rs12760175	chr1:46447840	PIK3R3	chr1:46505813-46642160:-	0.38	4.56	1.45E-5	Body mass index	
LAML	cis	1	rs12774378	chr10:91331621	FLJ37201	chr10:91451057-91457685:-	-0.52	-4.6	1.25E-5	Metabolic traits	
LAML	cis	1	rs12777243	chr10:91336117	FLJ37201	chr10:91451057-91457685:-	-0.53	-4.66	9.83E-6	Metabolic traits	
LAML	cis	1	rs12786555	chr11:506229	RNH1	chr11:494512-507273:-	-0.46	-4.6	1.27E-5	Body mass index	
LAML	cis	1	rs12788729	chr11:502371	RNH1	chr11:494512-507273:-	-0.5	-5.35	5.7E-7	Body mass index	
LAML	cis	1	rs12794284	chr11:477623	RNH1	chr11:494512-507273:-	-0.43	-4.91	3.62E-6	Body mass index	
LAML	cis	1	rs12801148	chr11:511707	RNH1	chr11:494512-507273:-	-0.46	-4.6	1.27E-5	Body mass index	
LAML	cis	1	rs12801271	chr11:508720	RNH1	chr11:494512-507273:-	-0.46	-4.6	1.27E-5	Body mass index	
LAML	cis	1	rs12828040	chr12:7326541	PEX5	chr12:7341759-7371167:+	0.47	5.13	1.46E-6	IgG glycosylation	
LAML	cis	1	rs12828421	chr12:7335217	PEX5	chr12:7341759-7371167:+	-0.46	-4.98	2.74E-6	IgG glycosylation	
LAML	cis	1	rs12879542	chr14:75507525	EIF2B2	chr14:75469612-75476292:+	0.46	4.64	1.07E-5	Height	
LAML	cis	1	rs12889309	chr14:75593902	EIF2B2	chr14:75469612-75476292:+	0.44	4.32	3.76E-5	Height	
LAML	cis	1	rs12889472	chr14:75543979	EIF2B2	chr14:75469612-75476292:+	0.45	4.48	2.04E-5	Height	
LAML	cis	1	rs12897094	chr14:75579416	EIF2B2	chr14:75469612-75476292:+	0.42	4.2	5.8E-5	Height	
LAML	cis	1	rs12898430	chr15:76874923	SCAPER	chr15:76640529-77197744:-	-0.4	-6.02	2.95E-8	Blood metabolite levels	
LAML	cis	1	rs12972121	chr19:53667295	ZNF665	chr19:53666552-53696619:-	-0.36	-4.46	2.14E-5	Yu-Zhi constitution type in type 2 diabetes	
LAML	cis	1	rs13008738	chr2:61078921	AHSA2	chr2:61404553-61414058:+	-0.37	-4.31	3.93E-5	Inflammatory skin disease	
LAML	cis	1	rs13053667	chr22:18443404	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs13057203	chr22:18446024	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs13059720	chr3:134242021	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs13071551	chr3:134310867	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.33	6.27E-7	Height	
LAML	cis	1	rs13081177	chr3:134289860	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.33	6.27E-7	Height	
LAML	cis	1	rs13081688	chr3:134259954	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs13087875	chr3:134261123	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs13089966	chr3:134279197	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs13090969	chr3:134307257	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.33	6.27E-7	Height	
LAML	cis	1	rs13096604	chr3:134250099	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs13099	chr14:75599155	EIF2B2	chr14:75469612-75476292:+	-0.45	-4.35	3.33E-5	Height	
LAML	cis	1	rs13130762	chr4:130022875	C4orf33	chr4:130014829-130033842:+	-0.55	-4.69	8.76E-6	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs1317149	chr11:47486885	MTCH2	chr11:47638859-47664206:-	-0.4	-4.56	1.48E-5	Subjective well-being	
LAML	cis	1	rs13182402	chr5:125918148	ALDH7A1	chr5:125878918-125931082:-	-0.62	-4.35	3.31E-5	Osteoporosis	
LAML	cis	1	rs13194429	chr6:86646705	SNHG5	chr6:86386726-86388451:-	-0.58	-5.61	1.81E-7	Response to antipsychotic treatment	
LAML	cis	1	rs13195401	chr6:26463574	BTN3A2	chr6:26365398-26378546:+	-1.05	-6.28	8.86E-9	Schizophrenia	
LAML	cis	1	rs13195402	chr6:26463575	BTN3A2	chr6:26365398-26378546:+	-1.05	-6.28	8.86E-9	Schizophrenia	
LAML	cis	1	rs13196930	chr6:86652245	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs13199006	chr6:86608708	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs13200462	chr6:28218199	ZNF187	chr6:28234788-28245978:+	-0.43	-4.45	2.22E-5	Depression	
LAML	cis	1	rs13217384	chr6:86720000	SNHG5	chr6:86386726-86388451:-	-0.6	-5.87	5.83E-8	Response to antipsychotic treatment	
LAML	cis	1	rs13220495	chr6:26441640	BTN3A2	chr6:26365398-26378546:+	-1.05	-6.28	8.86E-9	Schizophrenia	
LAML	cis	1	rs13228379	chr7:112921733	GPR85	chr7:112720468-112727833:-	-0.44	-4.24	5.03E-5	Metabolite levels	
LAML	cis	1	rs13228379	chr7:112921733	LOC401397	chr7:112756774-112758637:-	-0.35	-4.73	7.56E-6	Metabolite levels	
LAML	cis	1	rs13252719	chr8:71734569	XKR9	chr8:71581600-71648176:+	0.64	6.6	2.05E-9	Bone mineral density	
LAML	cis	1	rs13253842	chr8:71625503	XKR9	chr8:71581600-71648176:+	0.64	6.6	2.05E-9	Bone mineral density	
LAML	cis	1	rs13317532	chr3:183641669	ABCC5	chr3:183637726-183735727:-	-0.41	-4.51	1.78E-5	Anterior chamber depth	
LAML	cis	1	rs13322305	chr3:134310791	ANAPC13	chr3:134196547-134204865:-	0.37	4.97	2.83E-6	Height	
LAML	cis	1	rs13338688	chr16:67248831	RLTPR	chr16:67679030-67691470:+	-0.62	-5.86	6.22E-8	HDL cholesterol	
LAML	cis	1	rs13339140	chr16:67213923	RLTPR	chr16:67679030-67691470:+	-0.51	-4.27	4.54E-5	HDL cholesterol	
LAML	cis	1	rs1337844	chr6:86677273	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs1337850	chr6:86729103	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs13383871	chr2:73631779	ALMS1P	chr2:73872046-73912692:+	0.56	5.37	5.26E-7	Metabolite levels	
LAML	cis	1	rs13383871	chr2:73631779	NAT8	chr2:73867850-73869537:-	0.66	6.1	2.07E-8	Metabolite levels	
LAML	cis	1	rs13384952	chr2:73723959	ALMS1P	chr2:73872046-73912692:+	-0.55	-5.2	1.1E-6	Metabolite levels	
LAML	cis	1	rs13384952	chr2:73723959	NAT8	chr2:73867850-73869537:-	-0.69	-6.35	6.58E-9	Metabolite levels	
LAML	cis	1	rs13390702	chr2:86237935	LOC90784	chr2:86247339-86250991:-	-0.94	-5.62	1.73E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs13398075	chr2:202376269	PPIL3	chr2:201735680-201753999:-	0.97	4.55	1.55E-5	Rheumatoid arthritis	
LAML	cis	1	rs13398956	chr2:73720258	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs13398956	chr2:73720258	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs13408294	chr2:202171573	PPIL3	chr2:201735680-201753999:-	-0.89	-6.05	2.65E-8	Rheumatoid arthritis	
LAML	cis	1	rs13421462	chr2:73719875	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs13421462	chr2:73719875	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs13424612	chr2:240900121	NDUFA10	chr2:240900158-240964798:-	0.46	5.18	1.16E-6	Odorant perception (isobutyraldehyde)	
LAML	cis	1	rs13428235	chr2:73633430	ALMS1P	chr2:73872046-73912692:+	0.57	5.37	5.31E-7	Metabolite levels	
LAML	cis	1	rs13428235	chr2:73633430	NAT8	chr2:73867850-73869537:-	0.69	6.22	1.21E-8	Metabolite levels	
LAML	cis	1	rs13431267	chr2:73782200	ALMS1P	chr2:73872046-73912692:+	0.55	5.39	4.82E-7	Metabolite levels	
LAML	cis	1	rs13431267	chr2:73782200	NAT8	chr2:73867850-73869537:-	0.67	6.32	7.55E-9	Metabolite levels	
LAML	cis	1	rs13432605	chr2:73810981	ALMS1P	chr2:73872046-73912692:+	0.54	5.2	1.09E-6	Metabolite levels	
LAML	cis	1	rs13432605	chr2:73810981	NAT8	chr2:73867850-73869537:-	0.66	6	3.32E-8	Metabolite levels	
LAML	cis	1	rs1351452	chr11:116943354	TAGLN	chr11:117070040-117075507:+	-0.53	-4.99	2.6E-6	Protein quantitative trait loci	
LAML	cis	1	rs1357762	chr3:134264859	ANAPC13	chr3:134196547-134204865:-	0.39	5.27	8.01E-7	Height	
LAML	cis	1	rs1371135	chr15:90391270	AP3S2	chr15:90373832-90456222:-	-0.59	-5.08	1.81E-6	Type 2 diabetes	
LAML	cis	1	rs1374531	chr4:106523932	PPA2	chr4:106290235-106395227:-	-0.67	-4.28	4.29E-5	Post bronchodilator FEV1	
LAML	cis	1	rs1388527	chr11:6948441	OR10A2	chr11:6890986-6891897:+	-0.52	-4.53	1.64E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs1388527	chr11:6948441	OR10A4	chr11:6897879-6898825:+	-0.53	-4.59	1.31E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs1388527	chr11:6948441	OR2D3	chr11:6942233-6943224:+	-0.5	-4.58	1.38E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs1390006	chr17:56890663	RAD51C	chr17:56769963-56811690:+	-0.5	-6.09	2.12E-8	Cognitive test performance	
LAML	cis	1	rs1401999	chr3:183678342	ABCC5	chr3:183637726-183735727:-	-0.41	-4.32	3.72E-5	Anterior chamber depth	
LAML	cis	1	rs1402002	chr3:183642794	ABCC5	chr3:183637726-183735727:-	-0.41	-4.51	1.78E-5	Anterior chamber depth	
LAML	cis	1	rs1402003	chr3:183642879	ABCC5	chr3:183637726-183735727:-	-0.41	-4.51	1.78E-5	Anterior chamber depth	
LAML	cis	1	rs1403284	chr2:73726662	ALMS1P	chr2:73872046-73912692:+	-0.51	-4.76	6.56E-6	Metabolite levels	
LAML	cis	1	rs1403284	chr2:73726662	NAT8	chr2:73867850-73869537:-	-0.62	-5.59	2.04E-7	Metabolite levels	
LAML	cis	1	rs1412444	chr10:91002927	LIPA	chr10:90973328-91174382:-	0.39	4.97	2.81E-6	Fibrinogen levels	
LAML	cis	1	rs1412445	chr10:91002804	LIPA	chr10:90973328-91174382:-	0.41	5.11	1.54E-6	Fibrinogen levels	
LAML	cis	1	rs1415753	chr6:86753074	SNHG5	chr6:86386726-86388451:-	-0.56	-5.4	4.65E-7	Response to antipsychotic treatment	
LAML	cis	1	rs1419183	chr6:28242794	ZNF187	chr6:28234788-28245978:+	-0.37	-4.17	6.45E-5	Depression	
LAML	cis	1	rs1423620	chr5:56100996	C5orf35	chr5:56205103-56213010:+	0.84	7.37	5.16E-11	Type 2 diabetes	
LAML	cis	1	rs1423621	chr5:56101035	C5orf35	chr5:56205103-56213010:+	0.87	7.78	7.14E-12	Type 2 diabetes	
LAML	cis	1	rs1429906	chr1:207420327	CD55	chr1:207494817-207534309:+	0.39	4.55	1.5E-5	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs144447022	chr6:29244219	MOG	chr6:29624809-29640147:+	0.89	5.62	1.78E-7	Schizophrenia	
LAML	cis	1	rs144447022	chr6:29244219	ZFP57	chr6:29640171-29648887:-	1.02	4.77	6.36E-6	Schizophrenia	
LAML	cis	1	rs1451374	chr7:50622653	FIGNL1	chr7:50511834-50518088:-	-0.34	-4.59	1.3E-5	Malaria	
LAML	cis	1	rs1451375	chr7:50622712	FIGNL1	chr7:50511834-50518088:-	0.32	4.19	6.15E-5	Malaria	
LAML	cis	1	rs1465880	chr2:240932326	NDUFA10	chr2:240900158-240964798:-	0.46	5.05	1.98E-6	Odorant perception (isobutyraldehyde)	
LAML	cis	1	rs1466389	chr17:2096384	SRR	chr17:2207248-2228553:+	-0.58	-4.81	5.36E-6	Esophageal cancer (squamous cell)	
LAML	cis	1	rs1498718	chr3:134205920	ANAPC13	chr3:134196547-134204865:-	0.39	5.27	8.01E-7	Height	
LAML	cis	1	rs1507758	chr1:207507481	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs1507760	chr1:207509365	CD55	chr1:207494817-207534309:+	-0.44	-5.1	1.66E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs1507761	chr1:207509799	CD55	chr1:207494817-207534309:+	-0.44	-5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs151964	chr5:96123666	ERAP1	chr5:96096515-96149837:-	-0.65	-6.58	2.24E-9	Ankylosing spondylitis	
LAML	cis	1	rs1533684	chr3:183635815	ABCC5	chr3:183637726-183735727:-	-0.4	-4.37	3.02E-5	Anterior chamber depth	
LAML	cis	1	rs1534025	chr3:134313304	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.33	6.27E-7	Height	
LAML	cis	1	rs1534026	chr3:134284767	ANAPC13	chr3:134196547-134204865:-	0.39	5.33	6.09E-7	Height	
LAML	cis	1	rs1534471	chr2:73647508	ALMS1P	chr2:73872046-73912692:+	0.54	5.27	7.84E-7	Metabolite levels	
LAML	cis	1	rs1534471	chr2:73647508	NAT8	chr2:73867850-73869537:-	0.63	5.87	5.76E-8	Metabolite levels	
LAML	cis	1	rs1535500	chr6:39284050	KCNK17	chr6:39266778-39282237:-	-0.45	-4.94	3.14E-6	Type 2 diabetes	
LAML	cis	1	rs1541853	chr2:203835177	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs1552994	chr1:152171461	FLG	chr1:152274651-152297679:-	0.51	4.4	2.78E-5	Inflammatory skin disease	
LAML	cis	1	rs1555569	chr17:2149425	SRR	chr17:2207248-2228553:+	-0.63	-5.12	1.51E-6	Esophageal cancer (squamous cell)	
LAML	cis	1	rs1557503	chr22:51013072	CHKB-CPT1B	chr22:51007291-51021428:-	-0.71	-5.08	1.75E-6	Narcolepsy	
LAML	cis	1	rs1557503	chr22:51013072	CPT1B	chr22:51007291-51017096:-	-0.81	-4.88	4.12E-6	Narcolepsy	
LAML	cis	1	rs1559282	chr5:56099375	C5orf35	chr5:56205103-56213010:+	0.87	7.69	1.12E-11	Type 2 diabetes	
LAML	cis	1	rs1561328	chr2:86272758	LOC90784	chr2:86247339-86250991:-	-0.91	-5.66	1.48E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs1561328	chr2:86272758	POLR1A	chr2:86253453-86333278:-	-0.45	-4.27	4.55E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs156407	chr7:23315639	NUPL2	chr7:23221446-23240629:+	-0.36	-4.23	5.3E-5	Parkinson's disease	
LAML	cis	1	rs156421	chr7:23312487	NUPL2	chr7:23221446-23240629:+	-0.4	-4.46	2.13E-5	Parkinson's disease	
LAML	cis	1	rs15676	chr9:131572027	ENDOG	chr9:131580779-131584954:+	-0.43	-5.85	6.24E-8	Blood metabolite levels	
LAML	cis	1	rs1572275	chr1:207478980	CD55	chr1:207494817-207534309:+	-0.43	-5.05	2.04E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs1577917	chr6:86691940	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs1577919	chr6:86757296	SNHG5	chr6:86386726-86388451:-	-0.56	-5.4	4.65E-7	Response to antipsychotic treatment	
LAML	cis	1	rs1599932	chr12:58177943	FAM119B	chr12:58166383-58176323:+	0.63	8.36	4.13E-13	Multiple sclerosis	
LAML	cis	1	rs1609985	chr12:131320170	STX2	chr12:131274149-131323811:-	0.51	6	3.29E-8	Plasma plasminogen activator levels	
LAML	cis	1	rs1615767	chr19:35554767	LIN37	chr19:36239512-36245419:+	0.43	4.33	3.59E-5	Serum albumin level	
LAML	cis	1	rs1652333	chr1:207470460	CD55	chr1:207494817-207534309:+	-0.44	-5.09	1.72E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs1665982	chr3:47905079	ZNF589	chr3:48282596-48329113:+	-0.62	-5.04	2.1E-6	Educational attainment (years of education)	
LAML	cis	1	rs166663	chr7:23316742	NUPL2	chr7:23221446-23240629:+	-0.4	-4.46	2.14E-5	Parkinson's disease	
LAML	cis	1	rs1679732	chr6:28221264	ZNF187	chr6:28234788-28245978:+	0.41	4.25	4.86E-5	Depression	
LAML	cis	1	rs16837131	chr2:202173812	PPIL3	chr2:201735680-201753999:-	0.83	4.75	6.75E-6	Rheumatoid arthritis	
LAML	cis	1	rs16843245	chr2:242032709	MTERFD2	chr2:242034545-242041747:-	0.72	4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs16843267	chr2:242039589	MTERFD2	chr2:242034545-242041747:-	-0.69	-4.3	3.99E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs1684942	chr3:47900703	ZNF589	chr3:48282596-48329113:+	0.49	4.34	3.39E-5	Educational attainment (years of education)	
LAML	cis	1	rs16876529	chr6:86591202	SNHG5	chr6:86386726-86388451:-	-0.61	-5.9	5.08E-8	Response to antipsychotic treatment	
LAML	cis	1	rs16952009	chr17:2102437	SRR	chr17:2207248-2228553:+	-0.52	-4.29	4.15E-5	Esophageal cancer (squamous cell)	
LAML	cis	1	rs16960009	chr17:64681102	HELZ	chr17:65066555-65241319:-	-0.54	-4.85	4.56E-6	Food addiction	
LAML	cis	1	rs16960045	chr17:64688908	HELZ	chr17:65066555-65241319:-	0.53	4.79	5.95E-6	Food addiction	
LAML	cis	1	rs16984547	chr19:53682042	ZNF665	chr19:53666552-53696619:-	-0.59	-4.31	3.82E-5	Asthma	
LAML	cis	1	rs1699392	chr4:130022347	C4orf33	chr4:130014829-130033842:+	-0.55	-4.69	8.76E-6	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs1699394	chr4:130019312	C4orf33	chr4:130014829-130033842:+	-0.54	-4.29	4.24E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs17036821	chr3:12533148	TSEN2	chr3:12525931-12581122:+	-0.53	-4.58	1.35E-5	Prostate cancer (gene x gene interaction)	
LAML	cis	1	rs1707304	chr1:46598269	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.26	8.16E-7	Body mass index	
LAML	cis	1	rs1707304	chr1:46598269	PIK3R3	chr1:46505813-46642160:-	0.38	4.56	1.47E-5	Body mass index	
LAML	cis	1	rs1707321	chr1:46505309	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs1707321	chr1:46505309	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs1707335	chr1:46571921	CCDC163P	chr1:45960581-45965646:-	-0.6	-5.06	1.91E-6	Body mass index	
LAML	cis	1	rs1707335	chr1:46571921	PIK3R3	chr1:46505813-46642160:-	0.38	4.64	1.08E-5	Body mass index	
LAML	cis	1	rs1707336	chr1:46493460	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs1707336	chr1:46493460	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs1707340	chr1:46514942	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs1707340	chr1:46514942	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs17115100	chr10:104591393	SFXN2	chr10:104474298-104498946:+	-0.63	-5.3	7.15E-7	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LAML	cis	1	rs17121622	chr1:100377744	LRRC39	chr1:100614413-100643800:-	1.08	4.29	4.19E-5	Carotid intima media thickness	
LAML	cis	1	rs17121644	chr1:100385430	LRRC39	chr1:100614413-100643800:-	1.08	4.29	4.19E-5	Carotid intima media thickness	
LAML	cis	1	rs17121651	chr14:50097172	RPL36AL	chr14:50085407-50087349:-	0.34	4.26	4.71E-5	Carotid intima media thickness	
LAML	cis	1	rs17124700	chr14:88905629	PTPN21	chr14:88932123-89021123:-	0.69	6.15	1.64E-8	Coronary artery calcification	
LAML	cis	1	rs17183295	chr17:31078272	MYO1D	chr17:30819628-31203902:-	0.8	6.8	7.88E-10	Refractive error	
LAML	cis	1	rs17183600	chr17:31175079	MYO1D	chr17:30819628-31203902:-	0.81	7.29	7.84E-11	Refractive error	
LAML	cis	1	rs17183628	chr17:31184631	MYO1D	chr17:30819628-31203902:-	-0.81	-7.29	7.84E-11	Refractive error	
LAML	cis	1	rs17268570	chr2:56361582	CCDC85A	chr2:56411258-56613308:+	0.44	4.71	8.06E-6	HIV-1 control	
LAML	cis	1	rs17288338	chr19:46856421	PPP5C	chr19:46850294-46894103:+	-0.47	-6.57	2.31E-9	Crohn's disease;Inflammatory bowel disease	
LAML	cis	1	rs17433780	chr1:89474818	GBP3	chr1:89472367-89488549:-	0.66	8.81	4.19E-14	Carotid intima media thickness	
LAML	cis	1	rs174551	chr11:61573684	FADS2	chr11:61583728-61634825:+	0.5	5.65	1.56E-7	LDL cholesterol	
LAML	cis	1	rs17525350	chr1:169669815	C1orf112	chr1:169631245-169822227:+	-0.47	-5.33	6.12E-7	Amyotrophic lateral sclerosis	
LAML	cis	1	rs175425	chr14:75626131	EIF2B2	chr14:75469612-75476292:+	-0.43	-4.25	4.76E-5	Height	
LAML	cis	1	rs175426	chr14:75624134	EIF2B2	chr14:75469612-75476292:+	-0.43	-4.25	4.76E-5	Height	
LAML	cis	1	rs175436	chr14:75608683	EIF2B2	chr14:75469612-75476292:+	-0.45	-4.51	1.79E-5	Height	
LAML	cis	1	rs175442	chr14:75603564	EIF2B2	chr14:75469612-75476292:+	-0.43	-4.25	4.76E-5	Height	
LAML	cis	1	rs175443	chr14:75601963	EIF2B2	chr14:75469612-75476292:+	-0.45	-4.43	2.45E-5	Height	
LAML	cis	1	rs175449	chr14:75590846	EIF2B2	chr14:75469612-75476292:+	-0.43	-4.25	4.76E-5	Height	
LAML	cis	1	rs175492	chr14:75545220	EIF2B2	chr14:75469612-75476292:+	0.43	4.49	1.96E-5	Height	
LAML	cis	1	rs175512	chr14:75523382	EIF2B2	chr14:75469612-75476292:+	-0.49	-4.85	4.67E-6	Height	
LAML	cis	1	rs17571940	chr1:41566191	SCMH1	chr1:41492875-41707788:-	0.33	5.35	5.59E-7	Height	
LAML	cis	1	rs1757924	chr4:130019599	C4orf33	chr4:130014829-130033842:+	-0.56	-4.85	4.66E-6	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs1757925	chr4:130020791	C4orf33	chr4:130014829-130033842:+	0.54	4.64	1.07E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs1757927	chr4:130022069	C4orf33	chr4:130014829-130033842:+	-0.55	-4.69	8.76E-6	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs1757928	chr4:130022161	C4orf33	chr4:130014829-130033842:+	-0.55	-4.69	8.76E-6	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs1757930	chr4:130022356	C4orf33	chr4:130014829-130033842:+	-0.55	-4.35	3.33E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs1757935	chr4:130023759	C4orf33	chr4:130014829-130033842:+	-0.55	-4.69	8.76E-6	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs17608059	chr17:13910549	CDRT15P	chr17:13927815-13928915:+	-0.48	-4.91	3.54E-6	Temperament	
LAML	cis	1	rs17685	chr7:75616105	STYXL1	chr7:75625656-75677321:-	0.38	4.6	1.24E-5	Coffee consumption;Coffee consumption (cups per day)	
LAML	cis	1	rs1768803	chr1:46546208	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs1768803	chr1:46546208	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs1768816	chr1:46528599	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs1768816	chr1:46528599	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs17694011	chr3:134213981	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs17698817	chr14:88822976	PTPN21	chr14:88932123-89021123:-	0.63	5.86	6.1E-8	Coronary artery calcification	
LAML	cis	1	rs17714284	chr7:127147205	FSCN3	chr7:127231463-127241843:+	0.73	4.47	2.11E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs17727568	chr5:150244688	LOC134466	chr5:150310000-150326146:-	1.05	5.83	6.99E-8	Crohn's disease	
LAML	cis	1	rs17761723	chr17:2107090	SRR	chr17:2207248-2228553:+	0.59	4.78	6.16E-6	Esophageal cancer (squamous cell)	
LAML	cis	1	rs17761864	chr17:2171637	SRR	chr17:2207248-2228553:+	-0.63	-5.17	1.22E-6	Esophageal cancer (squamous cell)	
LAML	cis	1	rs17772064	chr14:88822871	PTPN21	chr14:88932123-89021123:-	0.63	5.86	6.1E-8	Coronary artery calcification	
LAML	cis	1	rs17772222	chr14:88826482	PTPN21	chr14:88932123-89021123:-	-0.68	-6.1	2.06E-8	Coronary artery calcification	
LAML	cis	1	rs17772288	chr14:88827366	PTPN21	chr14:88932123-89021123:-	0.63	5.86	6.1E-8	Coronary artery calcification	
LAML	cis	1	rs17780981	chr17:31119037	MYO1D	chr17:30819628-31203902:-	0.81	7.29	7.84E-11	Refractive error	
LAML	cis	1	rs17781136	chr17:31185042	MYO1D	chr17:30819628-31203902:-	0.81	7.29	7.84E-11	Refractive error	
LAML	cis	1	rs1778508	chr6:28229881	ZNF187	chr6:28234788-28245978:+	0.37	4.17	6.45E-5	Depression	
LAML	cis	1	rs17800886	chr5:150309539	LOC134466	chr5:150310000-150326146:-	0.87	4.82	5.28E-6	Crohn's disease	
LAML	cis	1	rs17800987	chr5:150323428	LOC134466	chr5:150310000-150326146:-	1	5.35	5.79E-7	Crohn's disease	
LAML	cis	1	rs17834627	chr17:2198892	SRR	chr17:2207248-2228553:+	-0.66	-5.36	5.41E-7	Esophageal cancer (squamous cell)	
LAML	cis	1	rs1783521	chr11:64106291	PPP2R5B	chr11:64692180-64701945:+	-0.4	-4.6	1.27E-5	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LAML	cis	1	rs17848459	chr22:51012311	CHKB-CPT1B	chr22:51007291-51021428:-	-0.62	-4.48	2.03E-5	Narcolepsy	
LAML	cis	1	rs17848459	chr22:51012311	CPT1B	chr22:51007291-51017096:-	-0.75	-4.53	1.68E-5	Narcolepsy	
LAML	cis	1	rs17878846	chr10:104630412	SFXN2	chr10:104474298-104498946:+	-0.62	-5.15	1.35E-6	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LAML	cis	1	rs1794693	chr6:167405670	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs1800615	chr1:15832281	CASP9	chr1:15817324-15851384:-	0.39	4.39	2.86E-5	Glomerular filtration rate (creatinine)	
LAML	cis	1	rs1814336	chr3:134200823	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs1814337	chr3:134200682	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs1815787	chr11:116921397	TAGLN	chr11:117070040-117075507:+	0.53	4.99	2.6E-6	Subjective well-being	
LAML	cis	1	rs1819333	chr6:167373547	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs1833896	chr5:56097669	C5orf35	chr5:56205103-56213010:+	0.87	7.69	1.12E-11	Type 2 diabetes	
LAML	cis	1	rs1835307	chr1:207426565	CD55	chr1:207494817-207534309:+	0.39	4.55	1.5E-5	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs1839622	chr12:7334534	PEX5	chr12:7341759-7371167:+	0.46	5	2.47E-6	IgG glycosylation	
LAML	cis	1	rs1857964	chr6:86635994	SNHG5	chr6:86386726-86388451:-	-0.58	-5.61	1.81E-7	Response to antipsychotic treatment	
LAML	cis	1	rs1857965	chr6:86630776	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs1858001	chr1:207488004	CD55	chr1:207494817-207534309:+	-0.46	-5.29	7.37E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs1862619	chr5:56098256	C5orf35	chr5:56205103-56213010:+	0.87	7.69	1.12E-11	Type 2 diabetes	
LAML	cis	1	rs1863913	chr3:134200205	ANAPC13	chr3:134196547-134204865:-	0.39	5.27	8.01E-7	Height	
LAML	cis	1	rs1874883	chr3:134205071	ANAPC13	chr3:134196547-134204865:-	0.39	5.52	2.69E-7	Height	
LAML	cis	1	rs1875124	chr12:58196802	FAM119B	chr12:58166383-58176323:+	0.63	8.36	4.13E-13	Multiple sclerosis	
LAML	cis	1	rs1880376	chr3:134270347	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs1880377	chr3:134270468	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs1881245	chr2:73649928	ALMS1P	chr2:73872046-73912692:+	0.53	5.29	7.34E-7	Metabolite levels	
LAML	cis	1	rs1881245	chr2:73649928	NAT8	chr2:73867850-73869537:-	0.62	5.82	7.25E-8	Metabolite levels	
LAML	cis	1	rs1885986	chr17:2203175	SRR	chr17:2207248-2228553:+	-0.66	-5.32	6.36E-7	Esophageal cancer (squamous cell)	
LAML	cis	1	rs190414	chr5:56116772	C5orf35	chr5:56205103-56213010:+	0.88	7.67	1.19E-11	Type 2 diabetes	
LAML	cis	1	rs1911552	chr6:86638024	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs1911553	chr6:86630892	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs1917130	chr3:134313773	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.23	9.58E-7	Height	
LAML	cis	1	rs1952012	chr14:50098896	RPL36AL	chr14:50085407-50087349:-	0.34	4.26	4.71E-5	Carotid intima media thickness	
LAML	cis	1	rs1955599	chr14:88825132	PTPN21	chr14:88932123-89021123:-	0.63	5.86	6.1E-8	Coronary artery calcification	
LAML	cis	1	rs1955600	chr14:88825384	PTPN21	chr14:88932123-89021123:-	0.63	5.86	6.1E-8	Coronary artery calcification	
LAML	cis	1	rs1957977	chr14:50090603	RPL36AL	chr14:50085407-50087349:-	0.38	4.55	1.52E-5	Carotid intima media thickness	
LAML	cis	1	rs1962716	chr6:86648436	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs1966839	chr7:50627101	FIGNL1	chr7:50511834-50518088:-	-0.34	-4.6	1.24E-5	Malaria	
LAML	cis	1	rs1970584	chr9:126110306	OR1L6	chr9:125512019-125513060:+	0.85	4.36	3.15E-5	Educational attainment	
LAML	cis	1	rs1978604	chr5:175949049	LMAN2	chr5:176758564-176778885:-	-0.34	-4.26	4.61E-5	Menopause (age at onset)	
LAML	cis	1	rs1978968	chr22:18448113	MICAL3	chr22:18270418-18507325:-	0.39	5.93	4.44E-8	Presence of antiphospholipid antibodies	
LAML	cis	1	rs1979	chr6:26377591	BTN3A2	chr6:26365398-26378546:+	-1.13	-8.32	4.85E-13	Schizophrenia	
LAML	cis	1	rs199347	chr7:23293746	NUPL2	chr7:23221446-23240629:+	-0.37	-4.35	3.26E-5	Parkinson's disease	
LAML	cis	1	rs199348	chr7:23293098	NUPL2	chr7:23221446-23240629:+	-0.4	-4.64	1.06E-5	Parkinson's disease	
LAML	cis	1	rs199351	chr7:23300049	NUPL2	chr7:23221446-23240629:+	-0.38	-4.4	2.77E-5	Parkinson's disease	
LAML	cis	1	rs1995688	chr6:86632319	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs1999852	chr6:86705738	SNHG5	chr6:86386726-86388451:-	-0.6	-5.78	8.82E-8	Response to antipsychotic treatment	
LAML	cis	1	rs2000614	chr11:116915742	TAGLN	chr11:117070040-117075507:+	0.53	4.99	2.6E-6	Protein quantitative trait loci	
LAML	cis	1	rs2000615	chr11:116915819	TAGLN	chr11:117070040-117075507:+	0.51	4.61	1.22E-5	Protein quantitative trait loci	
LAML	cis	1	rs2000616	chr11:116916529	TAGLN	chr11:117070040-117075507:+	0.53	4.99	2.6E-6	Protein quantitative trait loci	
LAML	cis	1	rs2001483	chr12:131318645	STX2	chr12:131274149-131323811:-	0.52	6.08	2.28E-8	Plasma plasminogen activator levels	
LAML	cis	1	rs2013815	chr6:167373812	RNASET2	chr6:167343008-167412795:-	0.71	9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs2017760	chr1:207455421	CD55	chr1:207494817-207534309:+	0.44	5.09	1.72E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs2019097	chr2:202193463	PPIL3	chr2:201735680-201753999:-	-0.89	-6.05	2.65E-8	Rheumatoid arthritis	
LAML	cis	1	rs2028299	chr15:90374257	AP3S2	chr15:90373832-90456222:-	-0.57	-4.77	6.24E-6	Type 2 diabetes	
LAML	cis	1	rs2056486	chr2:73717567	ALMS1P	chr2:73872046-73912692:+	0.54	5.26	8.42E-7	Metabolite levels	
LAML	cis	1	rs2056486	chr2:73717567	NAT8	chr2:73867850-73869537:-	0.65	6.04	2.75E-8	Metabolite levels	
LAML	cis	1	rs2056544	chr15:76826003	SCAPER	chr15:76640529-77197744:-	-0.38	-5.68	1.38E-7	Blood metabolite levels	
LAML	cis	1	rs2056603	chr3:134312749	ANAPC13	chr3:134196547-134204865:-	0.38	5.22	1.0E-6	Height	
LAML	cis	1	rs2056604	chr3:134312648	ANAPC13	chr3:134196547-134204865:-	0.37	4.97	2.83E-6	Height	
LAML	cis	1	rs2069502	chr12:58144665	FAM119B	chr12:58166383-58176323:+	-0.61	-7.87	4.58E-12	Multiple sclerosis	
LAML	cis	1	rs2072052	chr12:58146719	FAM119B	chr12:58166383-58176323:+	0.61	7.87	4.58E-12	Multiple sclerosis	
LAML	cis	1	rs2073604	chr22:51008925	CHKB-CPT1B	chr22:51007291-51021428:-	-0.7	-5.08	1.8E-6	Narcolepsy	
LAML	cis	1	rs2073604	chr22:51008925	CPT1B	chr22:51007291-51017096:-	-0.82	-4.92	3.5E-6	Narcolepsy	
LAML	cis	1	rs2073605	chr22:51008850	CHKB-CPT1B	chr22:51007291-51021428:-	-0.7	-4.95	3.08E-6	Narcolepsy	
LAML	cis	1	rs2073605	chr22:51008850	CPT1B	chr22:51007291-51017096:-	-0.8	-4.73	7.37E-6	Narcolepsy	
LAML	cis	1	rs2074038	chr11:44087989	ACCS	chr11:44087475-44105569:+	0.68	5.65	1.54E-7	IgA nephropathy	
LAML	cis	1	rs2074771	chr2:242350944	SEPT2	chr2:242254723-242293439:+	0.89	4.82	5.19E-6	Chronic lymphocytic leukemia	
LAML	cis	1	rs2074823	chr2:242051503	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs2077808	chr1:45988115	CCDC163P	chr1:45960581-45965646:-	-1.26	-14.53	2.71E-26	Homocysteine levels	
LAML	cis	1	rs2098297	chr14:75619118	EIF2B2	chr14:75469612-75476292:+	-0.45	-4.48	2.01E-5	Height	
LAML	cis	1	rs2099942	chr22:18438314	MICAL3	chr22:18270418-18507325:-	-0.4	-6.14	1.74E-8	Presence of antiphospholipid antibodies	
LAML	cis	1	rs2099943	chr22:18438559	MICAL3	chr22:18270418-18507325:-	-0.4	-6.14	1.74E-8	Presence of antiphospholipid antibodies	
LAML	cis	1	rs2099944	chr22:18438578	MICAL3	chr22:18270418-18507325:-	-0.4	-6.14	1.74E-8	Presence of antiphospholipid antibodies	
LAML	cis	1	rs2099945	chr22:18438642	MICAL3	chr22:18270418-18507325:-	-0.4	-6.17	1.52E-8	Presence of antiphospholipid antibodies	
LAML	cis	1	rs2113078	chr5:56087190	C5orf35	chr5:56205103-56213010:+	0.78	6.57	2.31E-9	Type 2 diabetes	
LAML	cis	1	rs2113079	chr5:56157951	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs2120107	chr15:76869789	SCAPER	chr15:76640529-77197744:-	-0.41	-6.04	2.66E-8	Blood metabolite levels	
LAML	cis	1	rs2127905	chr11:117026374	TAGLN	chr11:117070040-117075507:+	0.5	4.38	2.91E-5	Protein quantitative trait loci	
LAML	cis	1	rs2130392	chr4:185639169	MLF1IP	chr4:185615220-185655286:-	-0.39	-4.99	2.54E-6	Kawasaki disease	
LAML	cis	1	rs213733	chr1:41576989	SCMH1	chr1:41492875-41707788:-	0.33	5.35	5.59E-7	Height	
LAML	cis	1	rs213734	chr1:41575699	SCMH1	chr1:41492875-41707788:-	0.33	5.35	5.59E-7	Height	
LAML	cis	1	rs213742	chr1:41621127	SCMH1	chr1:41492875-41707788:-	0.33	5.5	2.93E-7	Height	
LAML	cis	1	rs213747	chr1:41628738	SCMH1	chr1:41492875-41707788:-	0.34	5.7	1.26E-7	Height	
LAML	cis	1	rs213748	chr1:41628730	SCMH1	chr1:41492875-41707788:-	0.34	5.7	1.26E-7	Height	
LAML	cis	1	rs213754	chr1:41598848	SCMH1	chr1:41492875-41707788:-	0.34	5.7	1.26E-7	Height	
LAML	cis	1	rs2140195	chr2:73702344	ALMS1P	chr2:73872046-73912692:+	0.53	5.29	7.34E-7	Metabolite levels	
LAML	cis	1	rs2140195	chr2:73702344	NAT8	chr2:73867850-73869537:-	0.62	5.82	7.25E-8	Metabolite levels	
LAML	cis	1	rs2140636	chr7:112920080	LOC401397	chr7:112756774-112758637:-	-0.36	-4.82	5.2E-6	Metabolite levels	
LAML	cis	1	rs2147712	chr14:50091684	RPL36AL	chr14:50085407-50087349:-	0.38	4.62	1.15E-5	Carotid intima media thickness	
LAML	cis	1	rs2149085	chr6:167371110	RNASET2	chr6:167343008-167412795:-	0.7	8.57	1.39E-13	Crohn's disease	
LAML	cis	1	rs2149090	chr6:167372764	RNASET2	chr6:167343008-167412795:-	0.71	9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs2149091	chr6:167372786	RNASET2	chr6:167343008-167412795:-	0.71	9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs2154536	chr21:38492147	PIGP	chr21:38437664-38445458:-	-0.45	-5.53	2.63E-7	Eye color traits	
LAML	cis	1	rs2155583	chr11:116915217	TAGLN	chr11:117070040-117075507:+	0.53	4.99	2.6E-6	Protein quantitative trait loci	
LAML	cis	1	rs2164879	chr2:86261579	LOC90784	chr2:86247339-86250991:-	-0.91	-5.66	1.48E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs2164879	chr2:86261579	POLR1A	chr2:86253453-86333278:-	-0.45	-4.27	4.55E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs2166663	chr6:86593896	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs2176824	chr3:183654029	ABCC5	chr3:183637726-183735727:-	-0.41	-4.51	1.78E-5	Anterior chamber depth	
LAML	cis	1	rs2177601	chr3:134245434	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs2184476	chr1:207504669	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs2224949	chr14:50096560	RPL36AL	chr14:50085407-50087349:-	-0.34	-4.26	4.71E-5	Carotid intima media thickness	
LAML	cis	1	rs2240539	chr2:242035544	MTERFD2	chr2:242034545-242041747:-	-0.69	-4.3	3.99E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs2240541	chr2:242065624	MTERFD2	chr2:242034545-242041747:-	-0.68	-5.15	1.34E-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs2240544	chr2:242066830	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs2246833	chr10:91005854	LIPA	chr10:90973328-91174382:-	0.39	5.02	2.24E-6	Fibrinogen levels	
LAML	cis	1	rs2246942	chr10:91004886	LIPA	chr10:90973328-91174382:-	0.38	4.75	6.82E-6	Fibrinogen levels	
LAML	cis	1	rs2250644	chr10:91008879	LIPA	chr10:90973328-91174382:-	0.38	4.88	4.11E-6	Fibrinogen levels	
LAML	cis	1	rs2268617	chr14:75608728	EIF2B2	chr14:75469612-75476292:+	0.43	4.27	4.44E-5	Height	
LAML	cis	1	rs2269381	chr22:51020069	CHKB-CPT1B	chr22:51007291-51021428:-	-0.7	-4.96	2.88E-6	Narcolepsy	
LAML	cis	1	rs2269381	chr22:51020069	CPT1B	chr22:51007291-51017096:-	-0.81	-4.78	6.15E-6	Narcolepsy	
LAML	cis	1	rs2269382	chr22:51018911	CHKB-CPT1B	chr22:51007291-51021428:-	-0.71	-5.06	1.94E-6	Narcolepsy	
LAML	cis	1	rs2269382	chr22:51018911	CPT1B	chr22:51007291-51017096:-	-0.81	-4.81	5.44E-6	Narcolepsy	
LAML	cis	1	rs2269384	chr22:51011115	CHKB-CPT1B	chr22:51007291-51021428:-	-0.62	-4.48	2.03E-5	Narcolepsy	
LAML	cis	1	rs2269384	chr22:51011115	CPT1B	chr22:51007291-51017096:-	-0.75	-4.53	1.68E-5	Narcolepsy	
LAML	cis	1	rs2269385	chr22:51010939	CHKB-CPT1B	chr22:51007291-51021428:-	-0.62	-4.48	2.03E-5	Narcolepsy	
LAML	cis	1	rs2269385	chr22:51010939	CPT1B	chr22:51007291-51017096:-	-0.75	-4.53	1.68E-5	Narcolepsy	
LAML	cis	1	rs2270044	chr2:242056924	MTERFD2	chr2:242034545-242041747:-	-0.69	-4.33	3.62E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs2275426	chr1:46487552	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs2275426	chr1:46487552	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs2277862	chr20:34152782	CPNE1	chr20:34213968-34262539:-	-0.64	-4.37	3.04E-5	Cholesterol, total	
LAML	cis	1	rs2292239	chr12:56482180	RPS26	chr12:56435686-56438005:+	0.7	6.75	9.93E-10	Cognitive function	
LAML	cis	1	rs2295135	chr14:88894210	PTPN21	chr14:88932123-89021123:-	0.68	6.1	2.06E-8	Coronary artery calcification	
LAML	cis	1	rs2300601	chr14:75639571	EIF2B2	chr14:75469612-75476292:+	0.46	4.53	1.63E-5	Height	
LAML	cis	1	rs2302045	chr2:242021216	MTERFD2	chr2:242034545-242041747:-	-0.69	-4.3	3.99E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs2302048	chr2:242062117	MTERFD2	chr2:242034545-242041747:-	-0.69	-4.33	3.62E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs2302051	chr2:242062410	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs2302052	chr2:242063448	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs2304668	chr2:239168448	LOC151174	chr2:239133754-239140318:-	0.85	4.76	6.54E-6	Irritable bowel syndrome	
LAML	cis	1	rs2305746	chr19:35556300	LIN37	chr19:36239512-36245419:+	0.52	4.98	2.67E-6	Serum albumin level	
LAML	cis	1	rs2313217	chr3:183635997	ABCC5	chr3:183637726-183735727:-	-0.41	-4.51	1.78E-5	Anterior chamber depth	
LAML	cis	1	rs2324843	chr6:86617501	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs2329340	chr7:50620229	FIGNL1	chr7:50511834-50518088:-	-0.34	-4.59	1.3E-5	Malaria	
LAML	cis	1	rs2329341	chr7:50620275	FIGNL1	chr7:50511834-50518088:-	-0.34	-4.59	1.3E-5	Malaria	
LAML	cis	1	rs2329342	chr7:50624971	FIGNL1	chr7:50511834-50518088:-	0.34	4.59	1.3E-5	Malaria	
LAML	cis	1	rs2346676	chr16:67223803	RLTPR	chr16:67679030-67691470:+	-0.56	-5.91	4.86E-8	HDL cholesterol	
LAML	cis	1	rs2348114	chr2:201582193	PPIL3	chr2:201735680-201753999:-	0.78	4.91	3.56E-6	Intelligence	
LAML	cis	1	rs2351706	chr15:90384115	AP3S2	chr15:90373832-90456222:-	-0.59	-5.08	1.78E-6	Type 2 diabetes	
LAML	cis	1	rs2351707	chr15:90384045	AP3S2	chr15:90373832-90456222:-	-0.59	-5.08	1.78E-6	Type 2 diabetes	
LAML	cis	1	rs2356559	chr1:45981512	CCDC163P	chr1:45960581-45965646:-	-1.24	-13.7	1.39E-24	Homocysteine levels	
LAML	cis	1	rs2356561	chr1:45980862	CCDC163P	chr1:45960581-45965646:-	-1.09	-10.84	1.65E-18	Homocysteine levels	
LAML	cis	1	rs2363803	chr1:41637529	SCMH1	chr1:41492875-41707788:-	-0.34	-5.7	1.26E-7	Height	
LAML	cis	1	rs236918	chr11:117091609	TAGLN	chr11:117070040-117075507:+	-0.52	-4.7	8.45E-6	Protein quantitative trait loci	
LAML	cis	1	rs2370578	chr3:134199612	ANAPC13	chr3:134196547-134204865:-	0.39	5.41	4.32E-7	Height	
LAML	cis	1	rs2370641	chr3:134222161	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs2370642	chr3:134222136	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs2373865	chr3:134291556	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.33	6.27E-7	Height	
LAML	cis	1	rs239935	chr6:167411788	RNASET2	chr6:167343008-167412795:-	-0.7	-8.54	1.68E-13	Crohn's disease	
LAML	cis	1	rs2404602	chr15:77030792	SCAPER	chr15:76640529-77197744:-	-0.4	-5.97	3.73E-8	Blood metabolite levels	
LAML	cis	1	rs2404740	chr15:76852143	SCAPER	chr15:76640529-77197744:-	-0.4	-6.06	2.42E-8	Blood metabolite levels	
LAML	cis	1	rs2404741	chr15:76851735	SCAPER	chr15:76640529-77197744:-	-0.4	-6.06	2.42E-8	Blood metabolite levels	
LAML	cis	1	rs2421555	chr2:73816955	ALMS1P	chr2:73872046-73912692:+	0.54	5.25	8.75E-7	Metabolite levels	
LAML	cis	1	rs2421555	chr2:73816955	NAT8	chr2:73867850-73869537:-	0.63	5.74	1.06E-7	Metabolite levels	
LAML	cis	1	rs2432195	chr5:56120413	C5orf35	chr5:56205103-56213010:+	0.89	7.79	6.68E-12	Type 2 diabetes	
LAML	cis	1	rs2448707	chr6:49446951	MUT	chr6:49398994-49431031:-	-0.45	-6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs244899	chr5:167911040	FBLL1	chr5:167956582-167957638:+	0.47	4.23	5.19E-5	Response to platinum-based chemotherapy (carboplatin)	
LAML	cis	1	rs246454	chr5:96123264	ERAP1	chr5:96096515-96149837:-	-0.64	-6.57	2.39E-9	Ankylosing spondylitis	
LAML	cis	1	rs2471884	chr11:117010320	TAGLN	chr11:117070040-117075507:+	0.51	4.43	2.48E-5	Protein quantitative trait loci	
LAML	cis	1	rs2486447	chr1:46545724	CCDC163P	chr1:45960581-45965646:-	-0.6	-5.06	1.91E-6	Body mass index	
LAML	cis	1	rs2486447	chr1:46545724	PIK3R3	chr1:46505813-46642160:-	0.38	4.64	1.08E-5	Body mass index	
LAML	cis	1	rs2501962	chr6:49453636	MUT	chr6:49398994-49431031:-	-0.44	-6.66	1.57E-9	Folate pathway vitamin levels	
LAML	cis	1	rs2501963	chr6:49454281	MUT	chr6:49398994-49431031:-	-0.44	-6.66	1.57E-9	Folate pathway vitamin levels	
LAML	cis	1	rs2513093	chr11:116806687	TAGLN	chr11:117070040-117075507:+	0.52	4.81	5.42E-6	Protein quantitative trait loci	
LAML	cis	1	rs2513095	chr11:116806269	TAGLN	chr11:117070040-117075507:+	0.49	4.44	2.35E-5	Protein quantitative trait loci	
LAML	cis	1	rs2524005	chr6:29899677	MOG	chr6:29624809-29640147:+	0.45	4.47	2.05E-5	Bipolar disorder and schizophrenia	
LAML	cis	1	rs2524005	chr6:29899677	ZFP57	chr6:29640171-29648887:-	0.75	6.14	1.75E-8	Bipolar disorder and schizophrenia	
LAML	cis	1	rs2526828	chr1:17729903	PADI6	chr1:17698741-17728195:+	-0.52	-5.61	1.87E-7	Basal cell carcinoma	
LAML	cis	1	rs2526829	chr1:17728231	PADI6	chr1:17698741-17728195:+	-0.53	-5.77	8.97E-8	Basal cell carcinoma	
LAML	cis	1	rs252887	chr5:56166188	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs252898	chr5:56188931	C5orf35	chr5:56205103-56213010:+	0.96	8.74	6.12E-14	Type 2 diabetes	
LAML	cis	1	rs252902	chr5:56116085	C5orf35	chr5:56205103-56213010:+	0.88	7.67	1.19E-11	Type 2 diabetes	
LAML	cis	1	rs252904	chr5:56118733	C5orf35	chr5:56205103-56213010:+	0.88	7.67	1.19E-11	Type 2 diabetes	
LAML	cis	1	rs252909	chr5:56121131	C5orf35	chr5:56205103-56213010:+	0.88	7.67	1.19E-11	Type 2 diabetes	
LAML	cis	1	rs252910	chr5:56192983	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs252915	chr5:56121754	C5orf35	chr5:56205103-56213010:+	-0.88	-7.67	1.19E-11	Type 2 diabetes	
LAML	cis	1	rs252916	chr5:56121788	C5orf35	chr5:56205103-56213010:+	0.89	7.79	6.68E-12	Type 2 diabetes	
LAML	cis	1	rs252919	chr5:56124111	C5orf35	chr5:56205103-56213010:+	0.88	7.67	1.19E-11	Type 2 diabetes	
LAML	cis	1	rs252921	chr5:56137787	C5orf35	chr5:56205103-56213010:+	0.96	8.74	6.12E-14	Type 2 diabetes	
LAML	cis	1	rs252922	chr5:56136343	C5orf35	chr5:56205103-56213010:+	0.96	8.74	6.2E-14	Type 2 diabetes	
LAML	cis	1	rs2548664	chr5:56133555	C5orf35	chr5:56205103-56213010:+	0.95	8.59	1.26E-13	Type 2 diabetes	
LAML	cis	1	rs2548665	chr5:56131805	C5orf35	chr5:56205103-56213010:+	0.95	8.59	1.26E-13	Type 2 diabetes	
LAML	cis	1	rs256438	chr5:79366249	THBS4	chr5:79330991-79379105:+	-0.57	-5.83	6.94E-8	Serum thyroid-stimulating hormone levels	
LAML	cis	1	rs2564974	chr1:207483445	CD55	chr1:207494817-207534309:+	-0.44	-5.09	1.72E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs2564978	chr1:207494416	CD55	chr1:207494817-207534309:+	0.48	5.51	2.89E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs2576692	chr2:55516723	PRDXDD1P	chr2:55509455-55511605:+	-0.71	-4.43	2.42E-5	Height	
LAML	cis	1	rs2576699	chr2:55528257	PRDXDD1P	chr2:55509455-55511605:+	-0.76	-4.99	2.57E-6	Height	
LAML	cis	1	rs2589060	chr2:55509853	PRDXDD1P	chr2:55509455-55511605:+	-0.61	-4.2	5.79E-5	Height	
LAML	cis	1	rs2589061	chr2:55509805	PRDXDD1P	chr2:55509455-55511605:+	-0.75	-4.8	5.59E-6	Height	
LAML	cis	1	rs2589063	chr2:55509485	PRDXDD1P	chr2:55509455-55511605:+	-0.64	-4.35	3.35E-5	Height	
LAML	cis	1	rs2589113	chr2:55516323	PRDXDD1P	chr2:55509455-55511605:+	-0.65	-4.43	2.43E-5	Height	
LAML	cis	1	rs2589114	chr2:55525012	PRDXDD1P	chr2:55509455-55511605:+	-0.76	-4.99	2.57E-6	Height	
LAML	cis	1	rs2589117	chr2:55528514	PRDXDD1P	chr2:55509455-55511605:+	-0.62	-4.4	2.74E-5	Height	
LAML	cis	1	rs2595500	chr11:6963165	OR10A2	chr11:6890986-6891897:+	0.52	4.52	1.69E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2595500	chr11:6963165	OR10A4	chr11:6897879-6898825:+	0.52	4.47	2.11E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2595500	chr11:6963165	OR2D3	chr11:6942233-6943224:+	0.51	4.62	1.17E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2595501	chr11:6955340	OR10A2	chr11:6890986-6891897:+	-0.52	-4.48	2.02E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2595501	chr11:6955340	OR10A4	chr11:6897879-6898825:+	-0.53	-4.53	1.65E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2595501	chr11:6955340	OR2D3	chr11:6942233-6943224:+	-0.51	-4.6	1.25E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2638090	chr11:6955142	OR10A2	chr11:6890986-6891897:+	-0.52	-4.48	2.02E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2638090	chr11:6955142	OR10A4	chr11:6897879-6898825:+	-0.53	-4.53	1.65E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2638090	chr11:6955142	OR2D3	chr11:6942233-6943224:+	-0.51	-4.6	1.25E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2638092	chr11:6961746	OR10A2	chr11:6890986-6891897:+	-0.52	-4.53	1.64E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2638092	chr11:6961746	OR10A4	chr11:6897879-6898825:+	-0.53	-4.59	1.31E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2638092	chr11:6961746	OR2D3	chr11:6942233-6943224:+	-0.5	-4.58	1.38E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs26510	chr5:96125910	ERAP1	chr5:96096515-96149837:-	-0.65	-6.63	1.75E-9	Ankylosing spondylitis	
LAML	cis	1	rs2655310	chr4:130017919	C4orf33	chr4:130014829-130033842:+	-0.54	-4.64	1.07E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs2665826	chr17:61944924	SMARCD2	chr17:61909441-61920351:-	0.35	4.45	2.23E-5	Body mass index	
LAML	cis	1	rs2694917	chr12:56912864	SPRYD4	chr12:56862301-56864765:+	0.43	5.3	7.17E-7	Blood metabolite ratios	
LAML	cis	1	rs2739330	chr22:24295286	DDT	chr22:24237099-24322019:-	0.49	6.38	5.79E-9	Liver enzyme levels (gamma-glutamyl transferase)	
LAML	cis	1	rs2739330	chr22:24295286	GSTT1	chr22:24376141-24384284:-	0.67	7.8	6.52E-12	Liver enzyme levels (gamma-glutamyl transferase)	
LAML	cis	1	rs2739330	chr22:24295286	LOC391322	chr22:24373117-24374043:+	0.67	6.54	2.69E-9	Liver enzyme levels (gamma-glutamyl transferase)	
LAML	cis	1	rs2749418	chr1:41509674	SCMH1	chr1:41492875-41707788:-	0.32	5.16	1.25E-6	Height	
LAML	cis	1	rs27529	chr5:96126308	ERAP1	chr5:96096515-96149837:-	-0.62	-6.28	8.94E-9	Ankylosing spondylitis	
LAML	cis	1	rs2757042	chr6:167371234	RNASET2	chr6:167343008-167412795:-	0.7	8.38	3.66E-13	Crohn's disease	
LAML	cis	1	rs2757047	chr6:167374489	RNASET2	chr6:167343008-167412795:-	0.71	9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs2766690	chr14:100682154	CCNK	chr14:99947739-99977851:+	0.44	5.02	2.27E-6	Electroencephalographic traits in alcoholism	
LAML	cis	1	rs2766692	chr14:100684192	CCNK	chr14:99947739-99977851:+	-0.44	-5.03	2.24E-6	Electroencephalographic traits in alcoholism	
LAML	cis	1	rs2769347	chr6:167371737	RNASET2	chr6:167343008-167412795:-	0.71	8.9	2.8E-14	Crohn's disease	
LAML	cis	1	rs2769352	chr6:167378619	RNASET2	chr6:167343008-167412795:-	0.71	9.05	1.3E-14	Crohn's disease	
LAML	cis	1	rs2769354	chr6:167379771	RNASET2	chr6:167343008-167412795:-	0.71	9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs27710	chr5:96126197	ERAP1	chr5:96096515-96149837:-	0.62	6.28	8.94E-9	Ankylosing spondylitis	
LAML	cis	1	rs2782828	chr1:207496999	CD55	chr1:207494817-207534309:+	0.48	5.51	2.89E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs2799077	chr6:28234597	ZNF187	chr6:28234788-28245978:+	-0.37	-4.17	6.45E-5	Depression	
LAML	cis	1	rs2802217	chr1:207482970	CD55	chr1:207494817-207534309:+	0.48	5.51	2.89E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs2802233	chr1:207471224	CD55	chr1:207494817-207534309:+	-0.44	-5.09	1.72E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs2802234	chr1:207471589	CD55	chr1:207494817-207534309:+	0.44	5.09	1.72E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs2802236	chr1:207472189	CD55	chr1:207494817-207534309:+	-0.48	-5.51	2.89E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs2802238	chr1:207476141	CD55	chr1:207494817-207534309:+	0.48	5.51	2.89E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs280604	chr4:129921170	C4orf33	chr4:130014829-130033842:+	-0.54	-4.22	5.5E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs2812972	chr6:86669880	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs2816815	chr6:86691656	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs2816821	chr6:86657084	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs2832259	chr21:30584698	CCT8	chr21:30428650-30446010:-	0.71	5.69	1.31E-7	Response to mTOR inhibitor (everolimus)	
LAML	cis	1	rs2832267	chr21:30591662	CCT8	chr21:30428650-30446010:-	0.7	5.4	4.59E-7	Response to mTOR inhibitor (everolimus)	
LAML	cis	1	rs2832270	chr21:30594532	CCT8	chr21:30428650-30446010:-	0.6	5.32	6.48E-7	Response to mTOR inhibitor (everolimus)	
LAML	cis	1	rs2832272	chr21:30597403	CCT8	chr21:30428650-30446010:-	0.69	5.69	1.29E-7	Response to mTOR inhibitor (everolimus)	
LAML	cis	1	rs2835607	chr21:38491973	PIGP	chr21:38437664-38445458:-	-0.45	-5.53	2.63E-7	Eye color traits	
LAML	cis	1	rs2835608	chr21:38493455	PIGP	chr21:38437664-38445458:-	-0.45	-5.53	2.63E-7	Eye color traits	
LAML	cis	1	rs28409322	chr3:134252385	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs28434757	chr22:18451554	MICAL3	chr22:18270418-18507325:-	-0.43	-6.49	3.46E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs2854219	chr17:61942682	SMARCD2	chr17:61909441-61920351:-	0.34	4.21	5.73E-5	Body mass index	
LAML	cis	1	rs2857891	chr11:6962957	OR10A2	chr11:6890986-6891897:+	-0.53	-4.65	1.04E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2857891	chr11:6962957	OR10A4	chr11:6897879-6898825:+	-0.53	-4.55	1.55E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2857891	chr11:6962957	OR2D3	chr11:6942233-6943224:+	-0.51	-4.69	8.74E-6	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs2857891	chr11:6962957	ZNF215	chr11:6947654-7005861:+	-0.5	-4.23	5.3E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs28626045	chr14:75589195	EIF2B2	chr14:75469612-75476292:+	0.44	4.38	3.0E-5	Height	
LAML	cis	1	rs2872249	chr3:183636273	ABCC5	chr3:183637726-183735727:-	-0.41	-4.51	1.78E-5	Anterior chamber depth	
LAML	cis	1	rs2887797	chr3:134202506	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs2896954	chr15:76851692	C15orf27	chr15:76352299-76521461:+	0.39	4.25	4.77E-5	Blood metabolite levels	
LAML	cis	1	rs2896954	chr15:76851692	SCAPER	chr15:76640529-77197744:-	-0.42	-6.44	4.25E-9	Blood metabolite levels	
LAML	cis	1	rs2901438	chr2:73665656	ALMS1P	chr2:73872046-73912692:+	0.54	5.27	7.84E-7	Metabolite levels	
LAML	cis	1	rs2901438	chr2:73665656	NAT8	chr2:73867850-73869537:-	0.63	5.87	5.76E-8	Metabolite levels	
LAML	cis	1	rs2914937	chr1:207488768	CD55	chr1:207494817-207534309:+	0.49	5.53	2.59E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs2917781	chr2:55510569	PRDXDD1P	chr2:55509455-55511605:+	-0.61	-4.2	5.79E-5	Height	
LAML	cis	1	rs2920959	chr2:55510572	PRDXDD1P	chr2:55509455-55511605:+	-0.61	-4.2	5.79E-5	Height	
LAML	cis	1	rs2966465	chr2:55510627	PRDXDD1P	chr2:55509455-55511605:+	-0.71	-4.43	2.42E-5	Height	
LAML	cis	1	rs2977993	chr9:131608786	ENDOG	chr9:131580779-131584954:+	0.45	5.9	5.02E-8	Schizophrenia	
LAML	cis	1	rs2978894	chr8:6693629	XKR5	chr8:6666043-6693037:-	-0.42	-4.89	3.94E-6	IgA nephropathy	
LAML	cis	1	rs2985684	chr14:50101682	RPL36AL	chr14:50085407-50087349:-	0.34	4.17	6.45E-5	Carotid intima media thickness	
LAML	cis	1	rs2985687	chr14:50100386	RPL36AL	chr14:50085407-50087349:-	0.34	4.26	4.71E-5	Carotid intima media thickness	
LAML	cis	1	rs2985696	chr14:50094913	RPL36AL	chr14:50085407-50087349:-	0.38	4.62	1.15E-5	Carotid intima media thickness	
LAML	cis	1	rs2985697	chr14:50092902	RPL36AL	chr14:50085407-50087349:-	0.38	4.62	1.15E-5	Carotid intima media thickness	
LAML	cis	1	rs2993259	chr1:46001550	CCDC163P	chr1:45960581-45965646:-	-1.26	-14.53	2.71E-26	Homocysteine levels	
LAML	cis	1	rs3007030	chr14:50086563	RPL36AL	chr14:50085407-50087349:-	0.37	4.38	2.91E-5	Carotid intima media thickness	
LAML	cis	1	rs3007031	chr14:50102269	RPL36AL	chr14:50085407-50087349:-	0.34	4.26	4.71E-5	Carotid intima media thickness	
LAML	cis	1	rs30187	chr5:96124330	ERAP1	chr5:96096515-96149837:-	-0.65	-6.63	1.75E-9	Ankylosing spondylitis	
LAML	cis	1	rs30378	chr5:96121994	ERAP1	chr5:96096515-96149837:-	-0.63	-6.08	2.27E-8	Ankylosing spondylitis	
LAML	cis	1	rs30379	chr5:96122260	ERAP1	chr5:96096515-96149837:-	-0.64	-6.57	2.39E-9	Ankylosing spondylitis	
LAML	cis	1	rs30380	chr5:96122281	ERAP1	chr5:96096515-96149837:-	-0.64	-6.57	2.39E-9	Ankylosing spondylitis	
LAML	cis	1	rs3091242	chr1:25674785	RHD	chr1:25598981-25656935:+	-0.67	-8.88	3.05E-14	Erythrocyte sedimentation rate	
LAML	cis	1	rs3099459	chr5:56137170	C5orf35	chr5:56205103-56213010:+	0.95	8.59	1.26E-13	Type 2 diabetes	
LAML	cis	1	rs3099899	chr4:129917368	C4orf33	chr4:130014829-130033842:+	-0.54	-4.22	5.5E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs3105369	chr4:130022448	C4orf33	chr4:130014829-130033842:+	-0.55	-4.69	8.76E-6	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs3180872	chr22:51017394	CHKB-CPT1B	chr22:51007291-51021428:-	-0.71	-5.08	1.75E-6	Narcolepsy	
LAML	cis	1	rs3180872	chr22:51017394	CPT1B	chr22:51007291-51017096:-	-0.81	-4.88	4.12E-6	Narcolepsy	
LAML	cis	1	rs319680	chr3:47898307	ZNF589	chr3:48282596-48329113:+	0.49	4.22	5.45E-5	Educational attainment (years of education)	
LAML	cis	1	rs319690	chr3:47927484	ZNF589	chr3:48282596-48329113:+	0.48	4.3	3.96E-5	Blood pressure	
LAML	cis	1	rs3204270	chr17:79682051	ARL16	chr17:79648234-79650954:-	-1.05	-8.21	8.52E-13	Dental caries	
LAML	cis	1	rs3213445	chr22:51015838	CHKB-CPT1B	chr22:51007291-51021428:-	-0.71	-5.08	1.75E-6	Narcolepsy	
LAML	cis	1	rs3213445	chr22:51015838	CPT1B	chr22:51007291-51017096:-	-0.81	-4.88	4.12E-6	Narcolepsy	
LAML	cis	1	rs3213446	chr22:51015674	CHKB-CPT1B	chr22:51007291-51021428:-	-0.62	-4.48	2.03E-5	Narcolepsy	
LAML	cis	1	rs3213446	chr22:51015674	CPT1B	chr22:51007291-51017096:-	-0.75	-4.53	1.68E-5	Narcolepsy	
LAML	cis	1	rs33322	chr5:56175226	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs33325	chr5:56142547	C5orf35	chr5:56205103-56213010:+	0.96	8.74	6.12E-14	Type 2 diabetes	
LAML	cis	1	rs33326	chr5:56142601	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs33955793	chr3:12544829	TSEN2	chr3:12525931-12581122:+	0.53	4.58	1.35E-5	Prostate cancer (gene x gene interaction)	
LAML	cis	1	rs34102169	chr1:46424864	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs34102169	chr1:46424864	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs34106666	chr6:86676258	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs34281561	chr6:86701872	SNHG5	chr6:86386726-86388451:-	-0.58	-5.61	1.81E-7	Response to antipsychotic treatment	
LAML	cis	1	rs34428306	chr1:152184316	FLG	chr1:152274651-152297679:-	0.5	4.53	1.62E-5	Inflammatory skin disease	
LAML	cis	1	rs34453673	chr5:434722	EXOC3	chr5:443334-467407:+	-0.36	-5.5	2.99E-7	Cystic fibrosis severity	
LAML	cis	1	rs34454389	chr1:41663236	SCMH1	chr1:41492875-41707788:-	-0.34	-5.7	1.26E-7	Height	
LAML	cis	1	rs34581302	chr6:86705948	SNHG5	chr6:86386726-86388451:-	-0.58	-5.61	1.81E-7	Response to antipsychotic treatment	
LAML	cis	1	rs34622557	chr6:86630852	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs34680851	chr14:100723154	CCNK	chr14:99947739-99977851:+	-0.4	-4.25	4.87E-5	Electroencephalographic traits in alcoholism	
LAML	cis	1	rs34777851	chr2:242047530	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs34847072	chr5:437862	EXOC3	chr5:443334-467407:+	-0.36	-5.5	2.99E-7	Cystic fibrosis severity	
LAML	cis	1	rs34849118	chr2:240919912	NDUFA10	chr2:240900158-240964798:-	0.47	5.22	9.97E-7	Odorant perception (isobutyraldehyde)	
LAML	cis	1	rs34852683	chr6:86702330	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs35006492	chr4:129878342	C4orf33	chr4:130014829-130033842:+	0.56	4.42	2.51E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs35068485	chr11:466032	RNH1	chr11:494512-507273:-	-0.45	-5.08	1.77E-6	Body mass index	
LAML	cis	1	rs35115612	chr5:125926839	ALDH7A1	chr5:125878918-125931082:-	0.62	4.18	6.36E-5	Osteoporosis	
LAML	cis	1	rs35212307	chr2:203765756	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs35231079	chr11:515224	RNH1	chr11:494512-507273:-	-0.45	-4.42	2.58E-5	Body mass index	
LAML	cis	1	rs35255804	chr11:492617	RNH1	chr11:494512-507273:-	-0.5	-5.24	9.06E-7	Body mass index	
LAML	cis	1	rs35385043	chr6:86648546	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs35419329	chr6:86702291	SNHG5	chr6:86386726-86388451:-	-0.58	-5.61	1.81E-7	Response to antipsychotic treatment	
LAML	cis	1	rs35454259	chr6:27254475	BTN3A2	chr6:26365398-26378546:+	-0.66	-5.26	8.36E-7	Schizophrenia	
LAML	cis	1	rs35624992	chr11:47615798	MTCH2	chr11:47638859-47664206:-	-0.39	-4.42	2.51E-5	Subjective well-being	
LAML	cis	1	rs35648651	chr2:239133843	LOC151174	chr2:239133754-239140318:-	0.77	4.3	4.07E-5	Irritable bowel syndrome	
LAML	cis	1	rs35649392	chr7:112907635	LOC401397	chr7:112756774-112758637:-	-0.36	-4.82	5.2E-6	Metabolite levels	
LAML	cis	1	rs35718987	chr3:134272783	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs35760725	chr6:86648985	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs35761942	chr6:86629504	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs35797755	chr6:86706554	SNHG5	chr6:86386726-86388451:-	-0.6	-5.78	8.82E-8	Response to antipsychotic treatment	
LAML	cis	1	rs35811812	chr11:498442	RNH1	chr11:494512-507273:-	-0.48	-5.15	1.3E-6	Body mass index	
LAML	cis	1	rs35874808	chr11:506442	RNH1	chr11:494512-507273:-	-0.46	-4.6	1.27E-5	Body mass index	
LAML	cis	1	rs35898083	chr11:484469	RNH1	chr11:494512-507273:-	-0.43	-4.91	3.62E-6	Body mass index	
LAML	cis	1	rs35923643	chr11:123355391	GRAMD1B	chr11:123396528-123493518:+	0.44	4.9	3.68E-6	Follicular lymphoma;Chronic lymphocytic leukemia	
LAML	cis	1	rs35996687	chr11:458595	RNH1	chr11:494512-507273:-	-0.43	-4.4	2.71E-5	Body mass index	
LAML	cis	1	rs36096931	chr6:86693134	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs36123022	chr3:12552980	TSEN2	chr3:12525931-12581122:+	0.54	4.55	1.55E-5	Prostate cancer (gene x gene interaction)	
LAML	cis	1	rs364283	chr6:167383750	RNASET2	chr6:167343008-167412795:-	-0.71	-8.86	3.41E-14	Crohn's disease	
LAML	cis	1	rs364451	chr6:167384756	RNASET2	chr6:167343008-167412795:-	-0.71	-9.05	1.3E-14	Crohn's disease	
LAML	cis	1	rs365189	chr6:167384545	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs3729639	chr16:67225501	RLTPR	chr16:67679030-67691470:+	-0.48	-5.66	1.48E-7	HDL cholesterol	
LAML	cis	1	rs3730399	chr16:67229019	RLTPR	chr16:67679030-67691470:+	-0.62	-5.7	1.23E-7	HDL cholesterol	
LAML	cis	1	rs3732276	chr2:242343404	SEPT2	chr2:242254723-242293439:+	0.89	4.82	5.19E-6	Chronic lymphocytic leukemia	
LAML	cis	1	rs3738848	chr2:73761881	ALMS1P	chr2:73872046-73912692:+	0.54	5.25	8.85E-7	Metabolite levels	
LAML	cis	1	rs3738848	chr2:73761881	NAT8	chr2:73867850-73869537:-	0.63	5.87	5.76E-8	Metabolite levels	
LAML	cis	1	rs3742773	chr14:75579643	EIF2B2	chr14:75469612-75476292:+	0.43	4.27	4.44E-5	Height	
LAML	cis	1	rs3742778	chr14:75538217	EIF2B2	chr14:75469612-75476292:+	-0.42	-4.24	5.03E-5	Height	
LAML	cis	1	rs3742780	chr14:75505008	EIF2B2	chr14:75469612-75476292:+	0.45	4.46	2.13E-5	Height	
LAML	cis	1	rs3743714	chr16:66583705	TK2	chr16:66543352-66584315:-	0.66	4.41	2.65E-5	3-hydroxypropylmercapturic acid levels in smokers	
LAML	cis	1	rs376551	chr6:167384923	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs376574	chr6:167389956	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs3770066	chr2:86392350	POLR1A	chr2:86253453-86333278:-	-0.56	-4.23	5.3E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs3770087	chr2:86267068	LOC90784	chr2:86247339-86250991:-	-0.91	-5.66	1.48E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs3770087	chr2:86267068	POLR1A	chr2:86253453-86333278:-	-0.45	-4.27	4.55E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs3770090	chr2:86263288	LOC90784	chr2:86247339-86250991:-	-0.91	-5.66	1.48E-7	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs3770090	chr2:86263288	POLR1A	chr2:86253453-86333278:-	-0.45	-4.27	4.55E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LAML	cis	1	rs3771355	chr2:242054143	MTERFD2	chr2:242034545-242041747:-	-0.7	-4.43	2.44E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs3782130	chr12:58161898	FAM119B	chr12:58166383-58176323:+	0.64	8.36	4.12E-13	Multiple sclerosis	
LAML	cis	1	rs3796093	chr2:242039198	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs3796689	chr4:185649866	MLF1IP	chr4:185615220-185655286:-	-0.4	-4.87	4.15E-6	Kawasaki disease	
LAML	cis	1	rs3805108	chr3:183691650	ABCC5	chr3:183637726-183735727:-	-0.42	-4.45	2.23E-5	Anterior chamber depth	
LAML	cis	1	rs3806988	chr6:49431569	MUT	chr6:49398994-49431031:-	0.44	6.66	1.57E-9	Folate pathway vitamin levels	
LAML	cis	1	rs3813227	chr2:73651967	ALMS1P	chr2:73872046-73912692:+	-0.54	-5.27	7.84E-7	Metabolite levels	
LAML	cis	1	rs3813227	chr2:73651967	NAT8	chr2:73867850-73869537:-	-0.63	-5.87	5.76E-8	Metabolite levels	
LAML	cis	1	rs3814855	chr14:88933360	PTPN21	chr14:88932123-89021123:-	0.66	5.86	6.04E-8	Coronary artery calcification	
LAML	cis	1	rs3815292	chr2:242032762	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs3815304	chr2:242050761	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs3815505	chr19:46892118	PPP5C	chr19:46850294-46894103:+	-0.38	-5.19	1.1E-6	Crohn's disease;Inflammatory bowel disease	
LAML	cis	1	rs3823114	chr6:49431720	MUT	chr6:49398994-49431031:-	0.44	6.66	1.57E-9	Folate pathway vitamin levels	
LAML	cis	1	rs3824754	chr10:104614350	SFXN2	chr10:104474298-104498946:+	-0.63	-5.3	6.96E-7	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LAML	cis	1	rs3824755	chr10:104595849	SFXN2	chr10:104474298-104498946:+	-0.63	-5.28	7.52E-7	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LAML	cis	1	rs3825079	chr12:58203354	FAM119B	chr12:58166383-58176323:+	0.63	8.36	4.13E-13	Multiple sclerosis	
LAML	cis	1	rs3846055	chr3:134203973	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs3846056	chr3:134227292	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs385113	chr6:167403971	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs3856807	chr3:12527600	TSEN2	chr3:12525931-12581122:+	0.59	5.14	1.39E-6	Prostate cancer (gene x gene interaction)	
LAML	cis	1	rs385863	chr6:167386615	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs386548	chr6:167385533	RNASET2	chr6:167343008-167412795:-	0.71	9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs389946	chr6:167407268	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs389956	chr6:167407254	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs391396	chr4:130037653	C4orf33	chr4:130014829-130033842:+	-0.51	-4.34	3.51E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs3915499	chr16:15910743	KIAA0430	chr16:15688245-15737009:-	-0.33	-4.26	4.65E-5	Resting heart rate	
LAML	cis	1	rs3931020	chr1:75235317	CRYZ	chr1:75171175-75199092:-	-0.47	-4.62	1.16E-5	Resistin levels	
LAML	cis	1	rs3932818	chr3:134206069	ANAPC13	chr3:134196547-134204865:-	0.39	5.27	8.01E-7	Height	
LAML	cis	1	rs393558	chr6:167397750	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs393727	chr6:167398632	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs394522	chr6:167398071	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs3960018	chr15:90383307	AP3S2	chr15:90373832-90456222:-	-0.59	-5.08	1.78E-6	Type 2 diabetes	
LAML	cis	1	rs397713	chr6:167386714	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs398278	chr6:167388169	RNASET2	chr6:167343008-167412795:-	-0.67	-8.01	2.25E-12	Crohn's disease	
LAML	cis	1	rs39841	chr5:96120170	ERAP1	chr5:96096515-96149837:-	-0.56	-5.14	1.36E-6	Inflammatory skin disease	
LAML	cis	1	rs400063	chr6:167386592	RNASET2	chr6:167343008-167412795:-	-0.71	-9.12	8.99E-15	Crohn's disease	
LAML	cis	1	rs400176	chr6:167406238	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs400837	chr6:167411008	RNASET2	chr6:167343008-167412795:-	-0.7	-9.02	1.47E-14	Crohn's disease	
LAML	cis	1	rs402749	chr6:167386104	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs404222	chr6:167402150	RNASET2	chr6:167343008-167412795:-	-0.71	-8.84	3.61E-14	Crohn's disease	
LAML	cis	1	rs405553	chr6:167395058	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs406095	chr6:167409087	RNASET2	chr6:167343008-167412795:-	-0.7	-9.02	1.47E-14	Crohn's disease	
LAML	cis	1	rs4073846	chr1:46462881	CCDC163P	chr1:45960581-45965646:-	0.6	5	2.53E-6	Body mass index	
LAML	cis	1	rs4073846	chr1:46462881	PIK3R3	chr1:46505813-46642160:-	-0.39	-4.65	1.05E-5	Body mass index	
LAML	cis	1	rs407515	chr6:167407544	RNASET2	chr6:167343008-167412795:-	-0.7	-9.02	1.47E-14	Crohn's disease	
LAML	cis	1	rs4076006	chr1:46438076	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs4076006	chr1:46438076	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs408040	chr6:167398903	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs408080	chr6:167392522	RNASET2	chr6:167343008-167412795:-	-0.71	-8.84	3.61E-14	Crohn's disease	
LAML	cis	1	rs408087	chr6:167398952	RNASET2	chr6:167343008-167412795:-	-0.71	-9.12	8.99E-15	Crohn's disease	
LAML	cis	1	rs408918	chr6:167399282	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs409356	chr6:167405226	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs41266839	chr6:26409890	BTN3A2	chr6:26365398-26378546:+	-1.05	-6.28	8.86E-9	Schizophrenia	
LAML	cis	1	rs41275764	chr19:46857257	PPP5C	chr19:46850294-46894103:+	-0.47	-6.52	3.01E-9	Crohn's disease;Inflammatory bowel disease	
LAML	cis	1	rs413232	chr6:167400972	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs4134386	chr1:46395089	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs4134386	chr1:46395089	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs4148571	chr3:183720576	ABCC5	chr3:183637726-183735727:-	-0.4	-4.28	4.27E-5	Anterior chamber depth	
LAML	cis	1	rs4148575	chr3:183702275	ABCC5	chr3:183637726-183735727:-	-0.42	-4.45	2.28E-5	Anterior chamber depth	
LAML	cis	1	rs4149547	chr2:240933308	NDUFA10	chr2:240900158-240964798:-	0.46	5.18	1.16E-6	Odorant perception (isobutyraldehyde)	
LAML	cis	1	rs4149551	chr2:240921463	NDUFA10	chr2:240900158-240964798:-	0.47	5.22	9.97E-7	Odorant perception (isobutyraldehyde)	
LAML	cis	1	rs4149556	chr2:240915307	NDUFA10	chr2:240900158-240964798:-	0.46	5.16	1.3E-6	Odorant perception (isobutyraldehyde)	
LAML	cis	1	rs415842	chr6:167406681	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs415890	chr6:167406633	RNASET2	chr6:167343008-167412795:-	0.71	9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs416131	chr6:167406544	RNASET2	chr6:167343008-167412795:-	0.73	9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs420259	chr16:23634026	DCTN5	chr16:23652807-23681182:+	-0.67	-6.39	5.4E-9	Bipolar disorder	
LAML	cis	1	rs421214	chr6:167396629	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs422094	chr6:167397033	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs422562	chr6:167406318	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs422694	chr6:167406074	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs422780	chr6:167406209	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs4246215	chr11:61564299	FADS2	chr11:61583728-61634825:+	0.48	5.71	1.19E-7	Phospholipid levels (plasma);Platelet count;Red blood cell fatty acid levels;Trans fatty acid levels;Inflammatory bowel disease	
LAML	cis	1	rs4267943	chr6:49439805	MUT	chr6:49398994-49431031:-	-0.45	-6.56	2.52E-9	Folate pathway vitamin levels	
LAML	cis	1	rs429083	chr6:167383972	RNASET2	chr6:167343008-167412795:-	-0.71	-8.86	3.41E-14	Crohn's disease	
LAML	cis	1	rs4299518	chr3:45809273	SACM1L	chr3:45730754-45786900:+	-0.38	-4.38	2.93E-5	Hirschsprung disease	
LAML	cis	1	rs430097	chr6:167405073	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs430293	chr6:167404958	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs430477	chr6:167389851	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs4309773	chr3:134277301	ANAPC13	chr3:134196547-134204865:-	0.41	5.6	1.89E-7	Height	
LAML	cis	1	rs43184	chr5:56141777	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs4322591	chr14:75600697	EIF2B2	chr14:75469612-75476292:+	0.44	4.38	3.0E-5	Height	
LAML	cis	1	rs4324798	chr6:28776117	MOG	chr6:29624809-29640147:+	0.75	4.9	3.75E-6	Lung adenocarcinoma	
LAML	cis	1	rs4324798	chr6:28776117	ZFP57	chr6:29640171-29648887:-	0.95	4.72	7.64E-6	Lung adenocarcinoma	
LAML	cis	1	rs4334685	chr3:134304335	ANAPC13	chr3:134196547-134204865:-	0.37	4.97	2.83E-6	Height	
LAML	cis	1	rs436707	chr6:167388843	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs4367113	chr3:134287975	ANAPC13	chr3:134196547-134204865:-	0.39	5.33	6.09E-7	Height	
LAML	cis	1	rs4368544	chr3:134300014	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.33	6.27E-7	Height	
LAML	cis	1	rs4376778	chr1:46288846	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs4376778	chr1:46288846	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs439237	chr6:167391392	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs4394010	chr4:129894649	C4orf33	chr4:130014829-130033842:+	0.54	4.22	5.5E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs439553	chr6:167391212	RNASET2	chr6:167343008-167412795:-	-0.71	-9.12	8.99E-15	Crohn's disease	
LAML	cis	1	rs4409766	chr10:104616663	SFXN2	chr10:104474298-104498946:+	-0.58	-5.04	2.09E-6	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LAML	cis	1	rs4410378	chr22:18451391	MICAL3	chr22:18270418-18507325:-	-0.43	-6.5	3.29E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs4417907	chr3:134291363	ANAPC13	chr3:134196547-134204865:-	0.4	5.57	2.15E-7	Height	
LAML	cis	1	rs4423809	chr3:134300107	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.23	9.58E-7	Height	
LAML	cis	1	rs444988	chr6:167389674	RNASET2	chr6:167343008-167412795:-	-0.71	-8.84	3.61E-14	Crohn's disease	
LAML	cis	1	rs4452748	chr7:50625056	FIGNL1	chr7:50511834-50518088:-	0.34	4.59	1.3E-5	Malaria	
LAML	cis	1	rs4466058	chr4:129923879	C4orf33	chr4:130014829-130033842:+	-0.55	-4.26	4.64E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs4469291	chr6:49440614	MUT	chr6:49398994-49431031:-	0.45	6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs448060	chr6:167382622	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs4498009	chr3:134198008	ANAPC13	chr3:134196547-134204865:-	0.39	5.41	4.32E-7	Height	
LAML	cis	1	rs4510208	chr2:203734866	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs4535272	chr3:134299916	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.14	1.37E-6	Height	
LAML	cis	1	rs4535301	chr4:170263443	SH3RF1	chr4:170015407-170192249:-	-0.34	-5.43	4.05E-7	Night sleep phenotypes	
LAML	cis	1	rs4545281	chr1:46360054	CCDC163P	chr1:45960581-45965646:-	-0.66	-5.36	5.41E-7	Body mass index	
LAML	cis	1	rs4545281	chr1:46360054	PIK3R3	chr1:46505813-46642160:-	0.39	4.49	1.96E-5	Body mass index	
LAML	cis	1	rs45587933	chr19:46886234	PPP5C	chr19:46850294-46894103:+	-0.38	-5.19	1.14E-6	Crohn's disease;Inflammatory bowel disease	
LAML	cis	1	rs4572812	chr3:134291177	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.33	6.27E-7	Height	
LAML	cis	1	rs4579080	chr4:170261499	SH3RF1	chr4:170015407-170192249:-	-0.37	-6.12	1.9E-8	Night sleep phenotypes	
LAML	cis	1	rs4579248	chr5:150268151	LOC134466	chr5:150310000-150326146:-	0.95	5.15	1.33E-6	Crohn's disease	
LAML	cis	1	rs4604928	chr11:117044203	TAGLN	chr11:117070040-117075507:+	0.5	4.38	2.91E-5	Protein quantitative trait loci	
LAML	cis	1	rs4606360	chr1:173699007	ANKRD45	chr1:173577475-173639001:-	0.47	4.19	6.07E-5	Subjective well-being	
LAML	cis	1	rs4619189	chr12:131313797	STX2	chr12:131274149-131323811:-	0.48	5.63	1.71E-7	Plasma plasminogen activator levels	
LAML	cis	1	rs4646536	chr12:58157988	FAM119B	chr12:58166383-58176323:+	0.63	8.55	1.58E-13	Multiple sclerosis	
LAML	cis	1	rs4647934	chr4:1016279	DGKQ	chr4:952676-967344:-	-0.4	-4.38	2.96E-5	Bone mineral density	
LAML	cis	1	rs4660306	chr1:45978675	CCDC163P	chr1:45960581-45965646:-	1.28	14.94	4.18E-27	Homocysteine levels	
LAML	cis	1	rs4660317	chr1:46326226	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs4660317	chr1:46326226	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs4660319	chr1:46341623	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs4660319	chr1:46341623	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs4660321	chr1:46366760	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs4660321	chr1:46366760	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs4660870	chr1:45995231	CCDC163P	chr1:45960581-45965646:-	-1.09	-10.66	3.91E-18	Homocysteine levels	
LAML	cis	1	rs4660898	chr1:46402171	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs4660898	chr1:46402171	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs4660910	chr1:46548402	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs4660910	chr1:46548402	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs4663865	chr2:239145960	LOC151174	chr2:239133754-239140318:-	-0.77	-4.41	2.61E-5	Irritable bowel syndrome	
LAML	cis	1	rs4663866	chr2:239150815	LOC151174	chr2:239133754-239140318:-	0.76	4.17	6.43E-5	Irritable bowel syndrome	
LAML	cis	1	rs4675310	chr2:203880834	ALS2CR8	chr2:203776978-203851060:+	0.49	4.36	3.18E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs4684106	chr3:12550199	TSEN2	chr3:12525931-12581122:+	-0.53	-4.69	8.66E-6	Prostate cancer (gene x gene interaction)	
LAML	cis	1	rs469758	chr5:96121715	ERAP1	chr5:96096515-96149837:-	-0.64	-6.57	2.39E-9	Ankylosing spondylitis	
LAML	cis	1	rs4700775	chr5:178426150	ZNF879	chr5:178450776-178461387:+	-0.51	-4.75	6.99E-6	Pubertal anthropometrics	
LAML	cis	1	rs4706254	chr6:86602813	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs4707239	chr6:86610717	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs4710147	chr6:167374239	RNASET2	chr6:167343008-167412795:-	0.71	9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs4713039	chr6:10906256	ELOVL2	chr6:10980995-11044624:-	0.5	4.43	2.41E-5	Allergic rhinitis	
LAML	cis	1	rs4713039	chr6:10906256	SYCP2L	chr6:10747995-10974539:+	0.55	4.94	3.2E-6	Allergic rhinitis	
LAML	cis	1	rs4715129	chr6:49415043	MUT	chr6:49398994-49431031:-	0.45	6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs4715130	chr6:49416825	MUT	chr6:49398994-49431031:-	0.43	6.35	6.54E-9	Folate pathway vitamin levels	
LAML	cis	1	rs4719220	chr7:71680703	CALN1	chr7:71244477-71912136:-	-0.48	-4.18	6.26E-5	Amyotrophic lateral sclerosis (sporadic)	
LAML	cis	1	rs473188	chr11:116812029	TAGLN	chr11:117070040-117075507:+	0.52	4.88	4.06E-6	Protein quantitative trait loci	
LAML	cis	1	rs4752856	chr11:47648042	MTCH2	chr11:47638859-47664206:-	-0.39	-4.52	1.75E-5	Subjective well-being	
LAML	cis	1	rs4752857	chr11:47655752	MTCH2	chr11:47638859-47664206:-	-0.39	-4.42	2.51E-5	Subjective well-being	
LAML	cis	1	rs4759229	chr12:56474480	RPS26	chr12:56435686-56438005:+	-0.7	-6.45	4.05E-9	Cognitive function	
LAML	cis	1	rs4759523	chr12:131315412	STX2	chr12:131274149-131323811:-	0.52	5.97	3.79E-8	Plasma plasminogen activator levels	
LAML	cis	1	rs4759524	chr12:131315610	STX2	chr12:131274149-131323811:-	0.52	5.97	3.79E-8	Plasma plasminogen activator levels	
LAML	cis	1	rs4759787	chr12:131290180	STX2	chr12:131274149-131323811:-	0.52	5.97	3.79E-8	Plasma plasminogen activator levels	
LAML	cis	1	rs4759793	chr12:131297238	STX2	chr12:131274149-131323811:-	0.52	5.97	3.79E-8	Plasma plasminogen activator levels	
LAML	cis	1	rs4789693	chr17:80421870	HEXDC	chr17:80376252-80400515:+	0.29	4.62	1.17E-5	Glucocorticoid-induced osteonecrosis	
LAML	cis	1	rs4794048	chr17:45763073	LOC100272146	chr17:45500843-45504056:+	-0.34	-4.36	3.15E-5	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LAML	cis	1	rs479493	chr1:41567202	SCMH1	chr1:41492875-41707788:-	0.33	5.35	5.59E-7	Height	
LAML	cis	1	rs4802307	chr19:46849806	PPP5C	chr19:46850294-46894103:+	-0.47	-6.58	2.3E-9	Crohn's disease;Inflammatory bowel disease	
LAML	cis	1	rs4806073	chr19:35555190	LIN37	chr19:36239512-36245419:+	-0.43	-4.33	3.59E-5	Serum albumin level	
LAML	cis	1	rs4844591	chr1:207500293	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs4844592	chr1:207501211	CD55	chr1:207494817-207534309:+	0.47	5.39	4.69E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs4854058	chr2:240923677	NDUFA10	chr2:240900158-240964798:-	0.45	5.04	2.14E-6	Odorant perception (isobutyraldehyde)	
LAML	cis	1	rs4862406	chr4:185629339	MLF1IP	chr4:185615220-185655286:-	0.39	5.1	1.65E-6	Kawasaki disease	
LAML	cis	1	rs4869313	chr5:96223880	ERAP2	chr5:96211644-96255398:+	-1	-13.39	6.09E-24	Pediatric autoimmune diseases	
LAML	cis	1	rs4886818	chr15:76880939	SCAPER	chr15:76640529-77197744:-	-0.4	-6.02	2.95E-8	Blood metabolite levels	
LAML	cis	1	rs4899544	chr14:75546556	EIF2B2	chr14:75469612-75476292:+	0.43	4.31	3.86E-5	Height	
LAML	cis	1	rs4899546	chr14:75594946	EIF2B2	chr14:75469612-75476292:+	0.44	4.38	3.0E-5	Height	
LAML	cis	1	rs4903275	chr14:75512509	EIF2B2	chr14:75469612-75476292:+	0.46	4.64	1.07E-5	Height	
LAML	cis	1	rs4903279	chr14:75546583	EIF2B2	chr14:75469612-75476292:+	0.43	4.31	3.86E-5	Height	
LAML	cis	1	rs4903281	chr14:75554361	EIF2B2	chr14:75469612-75476292:+	0.43	4.27	4.44E-5	Height	
LAML	cis	1	rs4903284	chr14:75592483	EIF2B2	chr14:75469612-75476292:+	0.45	4.44	2.34E-5	Height	
LAML	cis	1	rs4903289	chr14:75623988	EIF2B2	chr14:75469612-75476292:+	-0.45	-4.44	2.34E-5	Height	
LAML	cis	1	rs4905941	chr14:100725438	CCNK	chr14:99947739-99977851:+	-0.42	-4.7	8.29E-6	Electroencephalographic traits in alcoholism	
LAML	cis	1	rs4919690	chr10:104616500	AS3MT	chr10:104613967-104661653:+	0.49	4.51	1.75E-5	Arsenic metabolism	
LAML	cis	1	rs4919690	chr10:104616500	C10orf32	chr10:104613967-104624718:+	0.71	7.33	6.19E-11	Arsenic metabolism	
LAML	cis	1	rs4920603	chr1:17727379	PADI6	chr1:17698741-17728195:+	0.55	6.19	1.37E-8	Basal cell carcinoma	
LAML	cis	1	rs4932148	chr15:90394356	AP3S2	chr15:90373832-90456222:-	-0.55	-4.8	5.54E-6	Type 2 diabetes	
LAML	cis	1	rs4955485	chr3:134295843	ANAPC13	chr3:134196547-134204865:-	0.37	4.92	3.47E-6	Height	
LAML	cis	1	rs4955555	chr3:134286427	ANAPC13	chr3:134196547-134204865:-	0.39	5.33	6.09E-7	Height	
LAML	cis	1	rs4958422	chr5:150186734	LOC134466	chr5:150310000-150326146:-	1.03	5.73	1.1E-7	Crohn's disease	
LAML	cis	1	rs4958426	chr5:150278346	LOC134466	chr5:150310000-150326146:-	1.05	5.83	6.99E-8	Crohn's disease	
LAML	cis	1	rs4958842	chr5:150224877	LOC134466	chr5:150310000-150326146:-	0.96	5.16	1.29E-6	Crohn's disease	
LAML	cis	1	rs4958852	chr5:150330631	LOC134466	chr5:150310000-150326146:-	0.92	4.21	5.62E-5	Crohn's disease	
LAML	cis	1	rs4974483	chr3:134219001	ANAPC13	chr3:134196547-134204865:-	0.39	5.27	8.01E-7	Height	
LAML	cis	1	rs4974484	chr3:134219019	ANAPC13	chr3:134196547-134204865:-	0.39	5.41	4.32E-7	Height	
LAML	cis	1	rs4974493	chr3:134219993	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs4987280	chr1:169679553	C1orf112	chr1:169631245-169822227:+	-0.47	-5.37	5.21E-7	Amyotrophic lateral sclerosis	
LAML	cis	1	rs4987845	chr18:60795188	TNFRSF11A	chr18:59992548-60053502:+	-0.65	-4.22	5.38E-5	Chronic lymphocytic leukemia	
LAML	cis	1	rs4987855	chr18:60793549	TNFRSF11A	chr18:59992548-60053502:+	-0.65	-4.22	5.38E-5	Chronic lymphocytic leukemia	
LAML	cis	1	rs4987856	chr18:60793494	TNFRSF11A	chr18:59992548-60053502:+	0.65	4.22	5.38E-5	Chronic lymphocytic leukemia	
LAML	cis	1	rs5013012	chr22:18450149	MICAL3	chr22:18270418-18507325:-	-0.42	-6.31	7.78E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs5013014	chr22:18449927	MICAL3	chr22:18270418-18507325:-	-0.42	-6.26	9.94E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs510988	chr11:116813804	TAGLN	chr11:117070040-117075507:+	0.5	4.51	1.81E-5	Protein quantitative trait loci	
LAML	cis	1	rs511676	chr11:116824884	TAGLN	chr11:117070040-117075507:+	0.5	4.51	1.81E-5	Protein quantitative trait loci	
LAML	cis	1	rs542508	chr1:100370833	LRRC39	chr1:100614413-100643800:-	1.08	4.29	4.19E-5	Carotid intima media thickness	
LAML	cis	1	rs55639339	chr4:1009917	DGKQ	chr4:952676-967344:-	-0.41	-4.2	5.76E-5	Bone mineral density	
LAML	cis	1	rs55722539	chr14:88878035	PTPN21	chr14:88932123-89021123:-	0.67	6	3.19E-8	Coronary artery calcification	
LAML	cis	1	rs55748686	chr7:127148595	FSCN3	chr7:127231463-127241843:+	0.72	4.43	2.48E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs55842567	chr5:437586	EXOC3	chr5:443334-467407:+	-0.36	-5.5	2.99E-7	Cystic fibrosis severity	
LAML	cis	1	rs55913793	chr3:134285968	ANAPC13	chr3:134196547-134204865:-	0.39	5.33	6.09E-7	Height	
LAML	cis	1	rs55921267	chr7:127148361	FSCN3	chr7:127231463-127241843:+	0.72	4.43	2.48E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs55938551	chr2:242033593	MTERFD2	chr2:242034545-242041747:-	-0.69	-4.34	3.49E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs56013339	chr3:12543198	TSEN2	chr3:12525931-12581122:+	0.53	4.58	1.35E-5	Prostate cancer (gene x gene interaction)	
LAML	cis	1	rs56040780	chr16:28861881	TUFM	chr16:28853732-28857729:-	0.22	5.58	2.12E-7	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LAML	cis	1	rs56040865	chr7:127152442	FSCN3	chr7:127231463-127241843:+	0.72	4.43	2.48E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs56042615	chr5:437667	EXOC3	chr5:443334-467407:+	-0.36	-5.5	2.99E-7	Cystic fibrosis severity	
LAML	cis	1	rs56043407	chr17:2166078	SRR	chr17:2207248-2228553:+	-0.63	-5.12	1.5E-6	Esophageal cancer (squamous cell)	
LAML	cis	1	rs56060721	chr7:127148448	FSCN3	chr7:127231463-127241843:+	0.72	4.43	2.48E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs56098064	chr14:50105849	RPL36AL	chr14:50085407-50087349:-	0.34	4.26	4.71E-5	Carotid intima media thickness	
LAML	cis	1	rs56104584	chr5:437542	EXOC3	chr5:443334-467407:+	-0.36	-5.5	2.99E-7	Cystic fibrosis severity	
LAML	cis	1	rs56145559	chr2:73623439	ALMS1P	chr2:73872046-73912692:+	0.56	5.05	2.04E-6	Schizophrenia	
LAML	cis	1	rs56145559	chr2:73623439	NAT8	chr2:73867850-73869537:-	0.69	5.95	4.01E-8	Schizophrenia	
LAML	cis	1	rs56154726	chr2:73721767	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs56154726	chr2:73721767	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs562179	chr11:116805204	TAGLN	chr11:117070040-117075507:+	0.51	4.66	9.79E-6	Protein quantitative trait loci	
LAML	cis	1	rs56234712	chr16:67241754	RLTPR	chr16:67679030-67691470:+	-0.52	-5.73	1.07E-7	HDL cholesterol	
LAML	cis	1	rs56384645	chr1:17722952	PADI6	chr1:17698741-17728195:+	-0.49	-5.26	8.34E-7	Basal cell carcinoma	
LAML	cis	1	rs56672945	chr2:73622663	ALMS1P	chr2:73872046-73912692:+	0.57	5.37	5.31E-7	Metabolite levels	
LAML	cis	1	rs56672945	chr2:73622663	NAT8	chr2:73867850-73869537:-	0.69	6.22	1.21E-8	Metabolite levels	
LAML	cis	1	rs568617	chr11:65653242	CTSW	chr11:65647284-65651212:+	-0.59	-8.47	2.33E-13	Crohn's disease	
LAML	cis	1	rs56987357	chr14:88824363	PTPN21	chr14:88932123-89021123:-	0.62	5.75	1.01E-7	Coronary artery calcification	
LAML	cis	1	rs57117519	chr2:242033696	MTERFD2	chr2:242034545-242041747:-	-0.69	-4.3	3.99E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs57406211	chr5:150170966	LOC134466	chr5:150310000-150326146:-	0.93	5.18	1.18E-6	Crohn's disease	
LAML	cis	1	rs5758511	chr22:42336172	CYP2D6	chr22:42522502-42526883:-	0.44	4.61	1.19E-5	Birth weight	
LAML	cis	1	rs5770911	chr22:51011241	CHKB-CPT1B	chr22:51007291-51021428:-	-0.71	-5.06	1.94E-6	Narcolepsy	
LAML	cis	1	rs5770911	chr22:51011241	CPT1B	chr22:51007291-51017096:-	-0.81	-4.81	5.44E-6	Narcolepsy	
LAML	cis	1	rs5770917	chr22:51017353	CHKB-CPT1B	chr22:51007291-51021428:-	-0.71	-5.06	1.94E-6	Narcolepsy	
LAML	cis	1	rs5770917	chr22:51017353	CPT1B	chr22:51007291-51017096:-	-0.81	-4.81	5.44E-6	Narcolepsy	
LAML	cis	1	rs5770922	chr22:51023408	CHKB-CPT1B	chr22:51007291-51021428:-	-0.7	-4.96	2.88E-6	Narcolepsy	
LAML	cis	1	rs5770922	chr22:51023408	CPT1B	chr22:51007291-51017096:-	-0.81	-4.78	6.15E-6	Narcolepsy	
LAML	cis	1	rs5770924	chr22:51024542	CHKB-CPT1B	chr22:51007291-51021428:-	-0.7	-4.96	2.88E-6	Narcolepsy	
LAML	cis	1	rs5770924	chr22:51024542	CPT1B	chr22:51007291-51017096:-	-0.81	-4.78	6.15E-6	Narcolepsy	
LAML	cis	1	rs579890	chr11:116798963	TAGLN	chr11:117070040-117075507:+	0.51	4.67	9.53E-6	Protein quantitative trait loci	
LAML	cis	1	rs583583	chr1:147083114	ACP6	chr1:147119168-147142634:-	0.4	4.34	3.5E-5	Schizophrenia (negative symptoms)	
LAML	cis	1	rs58603761	chr2:73726605	ALMS1P	chr2:73872046-73912692:+	0.53	5.18	1.19E-6	Metabolite levels	
LAML	cis	1	rs58603761	chr2:73726605	NAT8	chr2:73867850-73869537:-	0.63	5.83	7.04E-8	Metabolite levels	
LAML	cis	1	rs58717741	chr5:150284936	LOC134466	chr5:150310000-150326146:-	0.99	5.48	3.29E-7	Crohn's disease	
LAML	cis	1	rs588918	chr11:116856642	TAGLN	chr11:117070040-117075507:+	0.52	5	2.52E-6	Protein quantitative trait loci	
LAML	cis	1	rs59321715	chr5:150313480	LOC134466	chr5:150310000-150326146:-	1.04	5.64	1.62E-7	Crohn's disease	
LAML	cis	1	rs59531858	chr5:150247063	LOC134466	chr5:150310000-150326146:-	0.96	5.17	1.22E-6	Crohn's disease	
LAML	cis	1	rs59715748	chr5:150189287	LOC134466	chr5:150310000-150326146:-	1.04	5.75	9.99E-8	Crohn's disease	
LAML	cis	1	rs5992135	chr22:18447114	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs5992917	chr22:18443699	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs5992919	chr22:18443855	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs5992921	chr22:18445263	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs5992922	chr22:18445287	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs5992926	chr22:18449876	MICAL3	chr22:18270418-18507325:-	-0.42	-6.26	9.94E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs5992928	chr22:18451438	MICAL3	chr22:18270418-18507325:-	-0.44	-6.49	3.5E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs6003958	chr22:24264089	DDT	chr22:24237099-24322019:-	-0.59	-6.25	1.04E-8	S-phenylmercapturic acid levels in smokers	
LAML	cis	1	rs6003958	chr22:24264089	GSTT1	chr22:24376141-24384284:-	-0.6	-5.03	2.21E-6	S-phenylmercapturic acid levels in smokers	
LAML	cis	1	rs6003958	chr22:24264089	LOC391322	chr22:24373117-24374043:+	-0.65	-4.75	6.95E-6	S-phenylmercapturic acid levels in smokers	
LAML	cis	1	rs60310240	chr14:88822709	PTPN21	chr14:88932123-89021123:-	0.63	5.86	6.1E-8	Coronary artery calcification	
LAML	cis	1	rs60844734	chr2:73623205	ALMS1P	chr2:73872046-73912692:+	0.57	5.37	5.31E-7	Metabolite levels	
LAML	cis	1	rs60844734	chr2:73623205	NAT8	chr2:73867850-73869537:-	0.69	6.22	1.21E-8	Metabolite levels	
LAML	cis	1	rs60982898	chr6:49385806	MUT	chr6:49398994-49431031:-	0.45	6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs61102033	chr1:46382441	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs61102033	chr1:46382441	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs6120974	chr20:34126827	CPNE1	chr20:34213968-34262539:-	-0.63	-4.31	3.86E-5	Triglycerides	
LAML	cis	1	rs613089	chr1:147081187	ACP6	chr1:147119168-147142634:-	-0.41	-4.35	3.34E-5	Schizophrenia (negative symptoms)	
LAML	cis	1	rs61524473	chr15:45646283	GATM	chr15:45653324-45670980:-	-0.64	-5.6	1.89E-7	Metabolite levels (small molecules and protein measures)	
LAML	cis	1	rs61530785	chr5:150261364	LOC134466	chr5:150310000-150326146:-	0.93	5.01	2.43E-6	Crohn's disease	
LAML	cis	1	rs61783200	chr1:46297403	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs61783200	chr1:46297403	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs61783220	chr1:46335312	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs61783220	chr1:46335312	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs61876323	chr11:462855	RNH1	chr11:494512-507273:-	-0.45	-5.08	1.77E-6	Body mass index	
LAML	cis	1	rs61876326	chr11:467368	RNH1	chr11:494512-507273:-	-0.45	-5.08	1.77E-6	Body mass index	
LAML	cis	1	rs61876332	chr11:487101	RNH1	chr11:494512-507273:-	-0.43	-4.91	3.62E-6	Body mass index	
LAML	cis	1	rs61876333	chr11:487136	RNH1	chr11:494512-507273:-	-0.4	-4.25	4.84E-5	Body mass index	
LAML	cis	1	rs61876334	chr11:487201	RNH1	chr11:494512-507273:-	-0.43	-4.91	3.62E-6	Body mass index	
LAML	cis	1	rs61876335	chr11:488878	RNH1	chr11:494512-507273:-	-0.42	-4.79	5.81E-6	Body mass index	
LAML	cis	1	rs61876336	chr11:489537	RNH1	chr11:494512-507273:-	-0.43	-4.93	3.37E-6	Body mass index	
LAML	cis	1	rs61876339	chr11:495283	RNH1	chr11:494512-507273:-	-0.51	-5.37	5.19E-7	Body mass index	
LAML	cis	1	rs61876340	chr11:495699	RNH1	chr11:494512-507273:-	-0.51	-5.3	6.94E-7	Body mass index	
LAML	cis	1	rs61876341	chr11:495892	RNH1	chr11:494512-507273:-	-0.51	-5.3	6.94E-7	Body mass index	
LAML	cis	1	rs61876342	chr11:496193	RNH1	chr11:494512-507273:-	-0.5	-5.34	5.84E-7	Body mass index	
LAML	cis	1	rs61877760	chr11:506596	RNH1	chr11:494512-507273:-	-0.46	-4.6	1.27E-5	Body mass index	
LAML	cis	1	rs61877775	chr11:521462	RNH1	chr11:494512-507273:-	-0.46	-4.4	2.69E-5	Body mass index	
LAML	cis	1	rs61977049	chr14:88827000	PTPN21	chr14:88932123-89021123:-	0.63	5.86	6.1E-8	Coronary artery calcification	
LAML	cis	1	rs61977058	chr14:88881915	PTPN21	chr14:88932123-89021123:-	0.68	6.1	2.06E-8	Coronary artery calcification	
LAML	cis	1	rs62070164	chr17:31086433	MYO1D	chr17:30819628-31203902:-	0.81	7.29	7.84E-11	Refractive error	
LAML	cis	1	rs62070187	chr17:31190724	MYO1D	chr17:30819628-31203902:-	0.81	7.29	7.84E-11	Refractive error	
LAML	cis	1	rs62136099	chr19:46847901	PPP5C	chr19:46850294-46894103:+	-0.47	-6.76	9.52E-10	Crohn's disease;Inflammatory bowel disease	
LAML	cis	1	rs62136101	chr19:46854055	PPP5C	chr19:46850294-46894103:+	-0.5	-7.23	1.02E-10	Crohn's disease;Inflammatory bowel disease	
LAML	cis	1	rs62136669	chr19:46882834	PPP5C	chr19:46850294-46894103:+	-0.38	-5.19	1.14E-6	Crohn's disease;Inflammatory bowel disease	
LAML	cis	1	rs62151652	chr2:73700131	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs62151652	chr2:73700131	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs62269547	chr3:134214042	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs62271513	chr3:134298412	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.23	9.58E-7	Height	
LAML	cis	1	rs62271514	chr3:134298554	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.23	9.58E-7	Height	
LAML	cis	1	rs62271515	chr3:134300507	ANAPC13	chr3:134196547-134204865:-	0.37	4.97	2.83E-6	Height	
LAML	cis	1	rs62436127	chr6:153320618	MTRF1L	chr6:153308401-153323925:-	-0.7	-4.23	5.17E-5	Morning vs. evening chronotype	
LAML	cis	1	rs641018	chr11:65655393	CTSW	chr11:65647284-65651212:+	-0.59	-8.47	2.33E-13	Crohn's disease	
LAML	cis	1	rs6429567	chr1:45956700	CCDC163P	chr1:45960581-45965646:-	-1.26	-14.53	2.71E-26	Homocysteine levels	
LAML	cis	1	rs6429569	chr1:46001330	CCDC163P	chr1:45960581-45965646:-	-1.09	-10.84	1.65E-18	Homocysteine levels	
LAML	cis	1	rs6429582	chr1:46321843	CCDC163P	chr1:45960581-45965646:-	0.57	4.24	5.12E-5	Body mass index	
LAML	cis	1	rs6435169	chr2:203753016	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs6439484	chr3:134249899	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs6439487	chr3:134260860	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs6443924	chr3:183679532	ABCC5	chr3:183637726-183735727:-	-0.41	-4.32	3.72E-5	Anterior chamber depth	
LAML	cis	1	rs6443926	chr3:183706630	ABCC5	chr3:183637726-183735727:-	-0.42	-4.45	2.28E-5	Anterior chamber depth	
LAML	cis	1	rs6443927	chr3:183718864	ABCC5	chr3:183637726-183735727:-	-0.42	-4.41	2.64E-5	Anterior chamber depth	
LAML	cis	1	rs6450408	chr5:56098146	C5orf35	chr5:56205103-56213010:+	0.88	7.67	1.19E-11	Type 2 diabetes	
LAML	cis	1	rs6450409	chr5:56101399	C5orf35	chr5:56205103-56213010:+	0.87	7.78	7.14E-12	Type 2 diabetes	
LAML	cis	1	rs6454513	chr6:86720049	SNHG5	chr6:86386726-86388451:-	0.6	5.86	6.0E-8	Response to antipsychotic treatment	
LAML	cis	1	rs6458690	chr6:49411619	MUT	chr6:49398994-49431031:-	0.44	6.66	1.57E-9	Folate pathway vitamin levels	
LAML	cis	1	rs6458694	chr6:49445306	MUT	chr6:49398994-49431031:-	0.45	6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs646153	chr11:64089588	PPP2R5B	chr11:64692180-64701945:+	-0.39	-4.4	2.72E-5	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LAML	cis	1	rs646867	chr1:25709258	RHD	chr1:25598981-25656935:+	-0.69	-8.9	2.69E-14	Erythrocyte sedimentation rate	
LAML	cis	1	rs6495206	chr15:76870963	SCAPER	chr15:76640529-77197744:-	-0.41	-6.33	7.21E-9	Blood metabolite levels	
LAML	cis	1	rs6496609	chr15:90379632	AP3S2	chr15:90373832-90456222:-	-0.57	-4.78	6.07E-6	Type 2 diabetes	
LAML	cis	1	rs6499118	chr16:67265360	RLTPR	chr16:67679030-67691470:+	-0.49	-5.82	7.17E-8	HDL cholesterol	
LAML	cis	1	rs6499121	chr16:67284840	RLTPR	chr16:67679030-67691470:+	-0.53	-6.13	1.82E-8	HDL cholesterol	
LAML	cis	1	rs6503877	chr17:56841948	RAD51C	chr17:56769963-56811690:+	0.51	6.16	1.58E-8	Cognitive test performance	
LAML	cis	1	rs6503882	chr17:56915761	RAD51C	chr17:56769963-56811690:+	0.5	6.09	2.12E-8	Cognitive test performance	
LAML	cis	1	rs6504661	chr17:48580126	MYCBPAP	chr17:48585745-48608861:+	0.67	5.66	1.48E-7	Visceral fat	
LAML	cis	1	rs6540896	chr1:207440851	CD55	chr1:207494817-207534309:+	0.39	4.55	1.5E-5	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs6545484	chr2:55510745	PRDXDD1P	chr2:55509455-55511605:+	-0.76	-4.99	2.57E-6	Height	
LAML	cis	1	rs6546835	chr2:73664715	ALMS1P	chr2:73872046-73912692:+	0.54	5.27	7.84E-7	Metabolite levels	
LAML	cis	1	rs6546835	chr2:73664715	NAT8	chr2:73867850-73869537:-	0.63	5.87	5.76E-8	Metabolite levels	
LAML	cis	1	rs6546836	chr2:73677833	ALMS1P	chr2:73872046-73912692:+	0.53	5.18	1.19E-6	Metabolite levels	
LAML	cis	1	rs6546836	chr2:73677833	NAT8	chr2:73867850-73869537:-	0.63	5.83	7.04E-8	Metabolite levels	
LAML	cis	1	rs6546837	chr2:73677898	ALMS1P	chr2:73872046-73912692:+	0.53	5.18	1.19E-6	Metabolite levels	
LAML	cis	1	rs6546837	chr2:73677898	NAT8	chr2:73867850-73869537:-	0.63	5.83	7.04E-8	Metabolite levels	
LAML	cis	1	rs6546838	chr2:73679280	ALMS1P	chr2:73872046-73912692:+	0.53	5.18	1.19E-6	Metabolite levels	
LAML	cis	1	rs6546838	chr2:73679280	NAT8	chr2:73867850-73869537:-	0.63	5.83	7.04E-8	Metabolite levels	
LAML	cis	1	rs6546839	chr2:73680508	ALMS1P	chr2:73872046-73912692:+	0.53	5.18	1.19E-6	Metabolite levels	
LAML	cis	1	rs6546839	chr2:73680508	NAT8	chr2:73867850-73869537:-	0.63	5.83	7.04E-8	Metabolite levels	
LAML	cis	1	rs656917	chr1:41569708	SCMH1	chr1:41492875-41707788:-	0.33	5.35	5.59E-7	Height	
LAML	cis	1	rs656980	chr11:65656282	CTSW	chr11:65647284-65651212:+	-0.59	-8.47	2.33E-13	Crohn's disease	
LAML	cis	1	rs6577145	chr1:100374441	LRRC39	chr1:100614413-100643800:-	1.12	4.51	1.8E-5	Carotid intima media thickness	
LAML	cis	1	rs6579245	chr20:34125271	CPNE1	chr20:34213968-34262539:-	-0.64	-4.32	3.72E-5	Cholesterol, total	
LAML	cis	1	rs6581155	chr12:58178162	FAM119B	chr12:58166383-58176323:+	0.64	8.56	1.46E-13	Multiple sclerosis	
LAML	cis	1	rs6589589	chr11:116932428	TAGLN	chr11:117070040-117075507:+	0.51	4.61	1.22E-5	Protein quantitative trait loci	
LAML	cis	1	rs6599388	chr4:939087	DGKQ	chr4:952676-967344:-	-0.39	-4.36	3.23E-5	Parkinson's disease	
LAML	cis	1	rs6600365	chr1:41556253	SCMH1	chr1:41492875-41707788:-	0.33	5.35	5.59E-7	Height	
LAML	cis	1	rs66534347	chr2:240899346	NDUFA10	chr2:240900158-240964798:-	0.43	4.62	1.15E-5	Odorant perception (isobutyraldehyde)	
LAML	cis	1	rs6656992	chr1:46333068	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs6656992	chr1:46333068	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs6661910	chr1:46290632	CCDC163P	chr1:45960581-45965646:-	-0.59	-4.8	5.54E-6	Body mass index	
LAML	cis	1	rs6661910	chr1:46290632	PIK3R3	chr1:46505813-46642160:-	0.39	4.66	1.0E-5	Body mass index	
LAML	cis	1	rs6662070	chr1:207505709	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs6662641	chr1:46571509	CCDC163P	chr1:45960581-45965646:-	-0.6	-5.06	1.91E-6	Body mass index	
LAML	cis	1	rs6662641	chr1:46571509	PIK3R3	chr1:46505813-46642160:-	0.38	4.64	1.08E-5	Body mass index	
LAML	cis	1	rs6663565	chr1:41563688	SCMH1	chr1:41492875-41707788:-	0.33	5.35	5.59E-7	Height	
LAML	cis	1	rs6664815	chr1:207415563	CD55	chr1:207494817-207534309:+	0.39	4.55	1.5E-5	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs6665958	chr1:100381815	LRRC39	chr1:100614413-100643800:-	1.08	4.29	4.19E-5	Carotid intima media thickness	
LAML	cis	1	rs6667191	chr1:45982844	CCDC163P	chr1:45960581-45965646:-	-1.26	-14.53	2.71E-26	Homocysteine levels	
LAML	cis	1	rs6668284	chr1:46354510	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs6668284	chr1:46354510	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs6669522	chr1:46397941	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs6669522	chr1:46397941	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs6672898	chr1:46290588	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs6672898	chr1:46290588	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs6675726	chr1:46560643	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs6675726	chr1:46560643	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs6675946	chr1:46371774	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs6675946	chr1:46371774	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs6677007	chr1:46400590	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs6677007	chr1:46400590	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs6680380	chr1:46300189	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs6680380	chr1:46300189	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs6686842	chr1:41530871	SCMH1	chr1:41492875-41707788:-	-0.33	-5.35	5.59E-7	Height	
LAML	cis	1	rs6695809	chr1:46285461	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs6695809	chr1:46285461	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs6700079	chr1:207501872	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs6700168	chr1:207502534	CD55	chr1:207494817-207534309:+	-0.44	-5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs6700597	chr1:46284246	CCDC163P	chr1:45960581-45965646:-	-0.6	-4.95	3.08E-6	Body mass index	
LAML	cis	1	rs6700597	chr1:46284246	PIK3R3	chr1:46505813-46642160:-	0.38	4.6	1.24E-5	Body mass index	
LAML	cis	1	rs6701614	chr1:46309420	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs6701614	chr1:46309420	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs6702997	chr1:207502347	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs6703002	chr1:207502372	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs6703857	chr1:207443553	CD55	chr1:207494817-207534309:+	0.39	4.5	1.82E-5	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs6705489	chr2:73648811	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs6705489	chr2:73648811	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs6707722	chr2:73654363	ALMS1P	chr2:73872046-73912692:+	0.55	5.41	4.38E-7	Metabolite levels	
LAML	cis	1	rs6707722	chr2:73654363	NAT8	chr2:73867850-73869537:-	0.67	6.27	9.39E-9	Metabolite levels	
LAML	cis	1	rs6710438	chr2:73820108	ALMS1P	chr2:73872046-73912692:+	-0.55	-5.24	9.13E-7	Metabolite levels	
LAML	cis	1	rs6710438	chr2:73820108	NAT8	chr2:73867850-73869537:-	-0.65	-5.9	5.13E-8	Metabolite levels	
LAML	cis	1	rs6711033	chr2:73746643	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs6711033	chr2:73746643	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs6711941	chr2:202178130	PPIL3	chr2:201735680-201753999:-	-0.83	-4.75	6.75E-6	Rheumatoid arthritis	
LAML	cis	1	rs6715284	chr2:202154397	PPIL3	chr2:201735680-201753999:-	-0.89	-6.05	2.65E-8	Rheumatoid arthritis	
LAML	cis	1	rs6715819	chr2:73772309	ALMS1P	chr2:73872046-73912692:+	0.52	5	2.5E-6	Metabolite levels	
LAML	cis	1	rs6715819	chr2:73772309	NAT8	chr2:73867850-73869537:-	0.64	5.89	5.41E-8	Metabolite levels	
LAML	cis	1	rs6720763	chr2:167992286	XIRP2	chr2:167744997-168116259:+	0.42	4.31	3.91E-5	Atopic dermatitis	
LAML	cis	1	rs6722332	chr2:203745327	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs6723704	chr2:203738664	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs6724782	chr2:73679990	ALMS1P	chr2:73872046-73912692:+	0.53	5.18	1.19E-6	Metabolite levels	
LAML	cis	1	rs6724782	chr2:73679990	NAT8	chr2:73867850-73869537:-	0.63	5.83	7.04E-8	Metabolite levels	
LAML	cis	1	rs6725887	chr2:203745885	ALS2CR8	chr2:203776978-203851060:+	0.5	4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs6732666	chr2:242055918	MTERFD2	chr2:242034545-242041747:-	-0.69	-4.33	3.62E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs6734408	chr2:239137481	LOC151174	chr2:239133754-239140318:-	0.76	4.26	4.58E-5	Irritable bowel syndrome	
LAML	cis	1	rs6736866	chr2:73661986	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs6736866	chr2:73661986	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs6738618	chr2:203749439	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs6740223	chr2:73653332	ALMS1P	chr2:73872046-73912692:+	0.55	5.41	4.38E-7	Metabolite levels	
LAML	cis	1	rs6740223	chr2:73653332	NAT8	chr2:73867850-73869537:-	0.67	6.27	9.39E-9	Metabolite levels	
LAML	cis	1	rs6745368	chr2:73809974	ALMS1P	chr2:73872046-73912692:+	0.55	5.39	4.82E-7	Metabolite levels	
LAML	cis	1	rs6745368	chr2:73809974	NAT8	chr2:73867850-73869537:-	0.67	6.32	7.55E-9	Metabolite levels	
LAML	cis	1	rs6751715	chr2:56363377	CCDC85A	chr2:56411258-56613308:+	0.44	4.71	8.06E-6	HIV-1 control	
LAML	cis	1	rs6753344	chr2:73653138	ALMS1P	chr2:73872046-73912692:+	-0.54	-5.31	6.79E-7	Metabolite levels	
LAML	cis	1	rs6753344	chr2:73653138	NAT8	chr2:73867850-73869537:-	-0.65	-6.04	2.71E-8	Metabolite levels	
LAML	cis	1	rs6755217	chr2:73641285	ALMS1P	chr2:73872046-73912692:+	0.56	5.37	5.26E-7	Metabolite levels	
LAML	cis	1	rs6755217	chr2:73641285	NAT8	chr2:73867850-73869537:-	0.66	6.1	2.07E-8	Metabolite levels	
LAML	cis	1	rs6755241	chr2:73641364	ALMS1P	chr2:73872046-73912692:+	0.56	5.37	5.26E-7	Metabolite levels	
LAML	cis	1	rs6755241	chr2:73641364	NAT8	chr2:73867850-73869537:-	0.66	6.1	2.07E-8	Metabolite levels	
LAML	cis	1	rs6756987	chr2:73687077	ALMS1P	chr2:73872046-73912692:+	0.53	5.18	1.19E-6	Metabolite levels	
LAML	cis	1	rs6756987	chr2:73687077	NAT8	chr2:73867850-73869537:-	0.63	5.83	7.04E-8	Metabolite levels	
LAML	cis	1	rs6759004	chr2:202004676	PPIL3	chr2:201735680-201753999:-	-1.06	-7.91	3.76E-12	Triptolide cytotoxicity	
LAML	cis	1	rs6763088	chr3:134254989	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs6763093	chr3:134254995	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs6765505	chr3:134208132	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs6766510	chr3:12551807	TSEN2	chr3:12525931-12581122:+	0.59	5.14	1.39E-6	Prostate cancer (gene x gene interaction)	
LAML	cis	1	rs6766818	chr3:134226159	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs6766897	chr3:134191303	ANAPC13	chr3:134196547-134204865:-	0.37	5.12	1.51E-6	Height	
LAML	cis	1	rs6767013	chr3:183680102	ABCC5	chr3:183637726-183735727:-	-0.41	-4.32	3.72E-5	Anterior chamber depth	
LAML	cis	1	rs6769885	chr3:134286913	ANAPC13	chr3:134196547-134204865:-	0.39	5.33	6.09E-7	Height	
LAML	cis	1	rs6772896	chr3:134203347	ANAPC13	chr3:134196547-134204865:-	0.39	5.41	4.32E-7	Height	
LAML	cis	1	rs67766926	chr2:61163581	AHSA2	chr2:61404553-61414058:+	-0.37	-4.4	2.75E-5	Inflammatory skin disease	
LAML	cis	1	rs677977	chr1:147083744	ACP6	chr1:147119168-147142634:-	-0.4	-4.31	3.81E-5	Schizophrenia (negative symptoms)	
LAML	cis	1	rs6782563	chr3:134295959	ANAPC13	chr3:134196547-134204865:-	-0.37	-4.92	3.47E-6	Height	
LAML	cis	1	rs6785027	chr3:134211649	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.43	4.04E-7	Height	
LAML	cis	1	rs6787371	chr3:134254991	ANAPC13	chr3:134196547-134204865:-	0.39	5.44	3.78E-7	Height	
LAML	cis	1	rs6790466	chr3:134197740	ANAPC13	chr3:134196547-134204865:-	0.39	5.41	4.32E-7	Height	
LAML	cis	1	rs67912009	chr11:495057	RNH1	chr11:494512-507273:-	-0.49	-5.08	1.76E-6	Body mass index	
LAML	cis	1	rs6793487	chr3:134299426	ANAPC13	chr3:134196547-134204865:-	-0.37	-4.92	3.47E-6	Height	
LAML	cis	1	rs6800217	chr3:183685893	ABCC5	chr3:183637726-183735727:-	-0.41	-4.32	3.72E-5	Anterior chamber depth	
LAML	cis	1	rs6800862	chr3:134228628	ANAPC13	chr3:134196547-134204865:-	0.39	5.27	8.01E-7	Height	
LAML	cis	1	rs6801596	chr3:134252114	ANAPC13	chr3:134196547-134204865:-	0.39	5.27	8.01E-7	Height	
LAML	cis	1	rs6802654	chr3:134217072	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs6802849	chr3:183698943	ABCC5	chr3:183637726-183735727:-	-0.41	-4.32	3.72E-5	Anterior chamber depth	
LAML	cis	1	rs6804242	chr3:183659463	ABCC5	chr3:183637726-183735727:-	-0.41	-4.38	2.9E-5	Anterior chamber depth	
LAML	cis	1	rs6804770	chr3:134230234	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs6805913	chr3:183662924	ABCC5	chr3:183637726-183735727:-	-0.41	-4.38	2.9E-5	Anterior chamber depth	
LAML	cis	1	rs6806417	chr3:134211446	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.43	4.04E-7	Height	
LAML	cis	1	rs68141011	chr6:28217797	ZNF187	chr6:28234788-28245978:+	-0.43	-4.45	2.22E-5	Depression	
LAML	cis	1	rs68171315	chr6:86707400	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs6874560	chr5:150182713	LOC134466	chr5:150310000-150326146:-	1.04	5.75	9.99E-8	Crohn's disease	
LAML	cis	1	rs6875011	chr5:150182710	LOC134466	chr5:150310000-150326146:-	0.94	5.09	1.69E-6	Crohn's disease	
LAML	cis	1	rs687672	chr11:65649984	CTSW	chr11:65647284-65651212:+	0.59	8.47	2.33E-13	Crohn's disease	
LAML	cis	1	rs6885541	chr5:56110857	C5orf35	chr5:56205103-56213010:+	0.88	7.67	1.19E-11	Type 2 diabetes	
LAML	cis	1	rs6901575	chr6:28250984	ZNF187	chr6:28234788-28245978:+	-0.37	-4.17	6.45E-5	Depression	
LAML	cis	1	rs6914463	chr6:86653415	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs6923124	chr6:49419864	MUT	chr6:49398994-49431031:-	0.44	6.66	1.57E-9	Folate pathway vitamin levels	
LAML	cis	1	rs6923148	chr6:86767786	SNHG5	chr6:86386726-86388451:-	0.59	5.74	1.03E-7	Response to antipsychotic treatment	
LAML	cis	1	rs6933377	chr6:86705255	SNHG5	chr6:86386726-86388451:-	0.47	4.42	2.54E-5	Response to antipsychotic treatment	
LAML	cis	1	rs6936048	chr6:86702608	SNHG5	chr6:86386726-86388451:-	-0.58	-5.62	1.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs693824	chr11:65654783	CTSW	chr11:65647284-65651212:+	-0.59	-8.47	2.33E-13	Crohn's disease	
LAML	cis	1	rs6940458	chr6:86644992	SNHG5	chr6:86386726-86388451:-	-0.59	-5.76	9.36E-8	Response to antipsychotic treatment	
LAML	cis	1	rs694739	chr11:64097233	PPP2R5B	chr11:64692180-64701945:+	-0.41	-4.54	1.56E-5	Crohn's disease;Alopecia areata;Psoriasis vulgaris	
LAML	cis	1	rs6949897	chr7:50621920	FIGNL1	chr7:50511834-50518088:-	-0.35	-4.71	8.23E-6	Malaria	
LAML	cis	1	rs694994	chr11:65653309	CTSW	chr11:65647284-65651212:+	-0.59	-8.47	2.33E-13	Crohn's disease	
LAML	cis	1	rs6961380	chr7:127148072	FSCN3	chr7:127231463-127241843:+	0.72	4.43	2.48E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs6962032	chr7:127151489	FSCN3	chr7:127231463-127241843:+	0.72	4.41	2.66E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs7007450	chr8:71640269	XKR9	chr8:71581600-71648176:+	0.64	6.6	2.05E-9	Bone mineral density	
LAML	cis	1	rs7017914	chr8:71591203	XKR9	chr8:71581600-71648176:+	0.64	6.6	2.05E-9	Bone mineral density	
LAML	cis	1	rs703842	chr12:58162739	FAM119B	chr12:58166383-58176323:+	-0.64	-8.68	8.18E-14	Multiple sclerosis	
LAML	cis	1	rs705696	chr12:56480648	RPS26	chr12:56435686-56438005:+	0.63	5.54	2.47E-7	Cognitive function	
LAML	cis	1	rs7072216	chr10:100156853	PYROXD2	chr10:100143323-100174978:-	0.45	5.1	1.63E-6	Metabolite levels	
LAML	cis	1	rs7098825	chr10:104628234	SFXN2	chr10:104474298-104498946:+	-0.63	-5.3	6.96E-7	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LAML	cis	1	rs7111	chr15:90373873	AP3S2	chr15:90373832-90456222:-	-0.57	-4.77	6.24E-6	Type 2 diabetes	
LAML	cis	1	rs7112513	chr11:117037361	TAGLN	chr11:117070040-117075507:+	0.52	4.68	8.96E-6	Protein quantitative trait loci	
LAML	cis	1	rs7114963	chr11:116875983	TAGLN	chr11:117070040-117075507:+	0.53	4.82	5.28E-6	Protein quantitative trait loci	
LAML	cis	1	rs7121347	chr11:116867209	TAGLN	chr11:117070040-117075507:+	0.5	4.56	1.49E-5	Protein quantitative trait loci	
LAML	cis	1	rs7122944	chr11:117034619	TAGLN	chr11:117070040-117075507:+	0.5	4.38	2.91E-5	Protein quantitative trait loci	
LAML	cis	1	rs7123517	chr11:117027755	TAGLN	chr11:117070040-117075507:+	0.5	4.38	2.91E-5	Protein quantitative trait loci	
LAML	cis	1	rs7124741	chr11:116752219	TAGLN	chr11:117070040-117075507:+	0.47	4.27	4.49E-5	Protein quantitative trait loci	
LAML	cis	1	rs7142235	chr14:75559963	EIF2B2	chr14:75469612-75476292:+	0.46	4.54	1.61E-5	Height	
LAML	cis	1	rs7142457	chr14:50097862	RPL36AL	chr14:50085407-50087349:-	0.34	4.26	4.71E-5	Carotid intima media thickness	
LAML	cis	1	rs71426508	chr2:239137767	LOC151174	chr2:239133754-239140318:-	0.86	4.91	3.67E-6	Irritable bowel syndrome	
LAML	cis	1	rs7145159	chr14:75583268	EIF2B2	chr14:75469612-75476292:+	0.43	4.27	4.44E-5	Height	
LAML	cis	1	rs7145588	chr14:88826796	PTPN21	chr14:88932123-89021123:-	0.63	5.86	6.1E-8	Coronary artery calcification	
LAML	cis	1	rs7147118	chr14:75610170	EIF2B2	chr14:75469612-75476292:+	0.44	4.32	3.76E-5	Height	
LAML	cis	1	rs71487292	chr11:486076	RNH1	chr11:494512-507273:-	-0.4	-4.25	4.84E-5	Body mass index	
LAML	cis	1	rs71487296	chr11:500282	RNH1	chr11:494512-507273:-	-0.51	-5.3	6.94E-7	Body mass index	
LAML	cis	1	rs715219	chr17:64691666	HELZ	chr17:65066555-65241319:-	0.52	4.65	1.01E-5	Food addiction	
LAML	cis	1	rs7156105	chr14:75541954	EIF2B2	chr14:75469612-75476292:+	0.42	4.24	5.03E-5	Height	
LAML	cis	1	rs7156328	chr14:75532941	EIF2B2	chr14:75469612-75476292:+	0.45	4.46	2.13E-5	Height	
LAML	cis	1	rs7166991	chr15:40671957	IVD	chr15:40697686-40713512:+	-0.47	-4.39	2.89E-5	Heschl's gyrus morphology	
LAML	cis	1	rs7218362	chr17:56888299	RAD51C	chr17:56769963-56811690:+	0.5	6.09	2.12E-8	Cognitive test performance	
LAML	cis	1	rs7226599	chr18:74491132	ZNF236	chr18:74536116-74682680:+	-0.35	-4.44	2.33E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)	
LAML	cis	1	rs72644211	chr10:81781695	LOC219347	chr10:81805991-81838949:-	1.19	7.54	2.28E-11	Chronic obstructive pulmonary disease-related biomarkers	
LAML	cis	1	rs72644212	chr10:81782514	LOC219347	chr10:81805991-81838949:-	1.25	8.78	4.92E-14	Chronic obstructive pulmonary disease-related biomarkers	
LAML	cis	1	rs72644213	chr10:81783660	LOC219347	chr10:81805991-81838949:-	1.24	8.84	3.68E-14	Chronic obstructive pulmonary disease-related biomarkers	
LAML	cis	1	rs72800847	chr16:31022639	STX4	chr16:31044416-31051484:+	0.28	4.23	5.16E-5	Response to metformin (IC50)	
LAML	cis	1	rs72819593	chr17:2199489	SRR	chr17:2207248-2228553:+	-0.66	-5.36	5.41E-7	Esophageal cancer (squamous cell)	
LAML	cis	1	rs72843784	chr6:26498758	BTN3A2	chr6:26365398-26378546:+	-1.05	-6.28	8.86E-9	Schizophrenia	
LAML	cis	1	rs72845397	chr11:6950903	OR10A2	chr11:6890986-6891897:+	-0.52	-4.53	1.64E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs72845397	chr11:6950903	OR10A4	chr11:6897879-6898825:+	-0.53	-4.59	1.31E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs72845397	chr11:6950903	OR2D3	chr11:6942233-6943224:+	-0.5	-4.58	1.38E-5	Response to cytadine analogues (cytosine arabinoside)	
LAML	cis	1	rs7285566	chr22:18445288	MICAL3	chr22:18270418-18507325:-	-0.4	-5.88	5.53E-8	Presence of antiphospholipid antibodies	
LAML	cis	1	rs7286219	chr22:18445709	MICAL3	chr22:18270418-18507325:-	-0.41	-6.26	9.87E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs7286607	chr22:18444657	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs7291169	chr22:18449038	MICAL3	chr22:18270418-18507325:-	-0.41	-6.3	8.45E-9	Presence of antiphospholipid antibodies	
LAML	cis	1	rs72926767	chr2:203796814	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926769	chr2:203798318	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926771	chr2:203801226	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926772	chr2:203804289	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926779	chr2:203805929	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926781	chr2:203808835	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926782	chr2:203811628	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926783	chr2:203815740	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926786	chr2:203816494	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926787	chr2:203818299	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926791	chr2:203822891	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926793	chr2:203826396	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926794	chr2:203827432	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926796	chr2:203827480	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72926802	chr2:203830228	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72928605	chr2:203832120	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72928608	chr2:203836507	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72928609	chr2:203837573	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72928613	chr2:203839628	ALS2CR8	chr2:203776978-203851060:+	-0.53	-4.53	1.65E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72928620	chr2:203840973	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932553	chr2:203842661	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932554	chr2:203845828	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932557	chr2:203846817	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932558	chr2:203847325	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932561	chr2:203848402	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932566	chr2:203855342	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932572	chr2:203859391	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932573	chr2:203861113	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932574	chr2:203866336	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932588	chr2:203883193	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932590	chr2:203884308	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932780	chr2:203695826	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932781	chr2:203697278	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932784	chr2:203698470	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932786	chr2:203698737	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932789	chr2:203699379	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932791	chr2:203700870	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72932793	chr2:203701004	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934505	chr2:203916487	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934510	chr2:203925360	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934512	chr2:203926271	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934513	chr2:203927587	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934514	chr2:203933339	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934518	chr2:203937908	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934519	chr2:203939640	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934537	chr2:203969504	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934545	chr2:203975958	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934554	chr2:203987806	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934556	chr2:203990789	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934563	chr2:203995405	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934573	chr2:204005072	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934704	chr2:203706433	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934706	chr2:203707752	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.7E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934707	chr2:203707878	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.7E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934710	chr2:203709776	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934711	chr2:203709997	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934714	chr2:203711581	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934715	chr2:203713280	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934729	chr2:203737770	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934732	chr2:203739856	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934735	chr2:203740010	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934737	chr2:203740798	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934738	chr2:203740861	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934740	chr2:203741362	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.37	3.02E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934745	chr2:203744454	ALS2CR8	chr2:203776978-203851060:+	-0.49	-4.25	4.76E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934749	chr2:203746816	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934751	chr2:203747522	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934753	chr2:203750272	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934763	chr2:203758396	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934764	chr2:203758521	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934765	chr2:203758551	ALS2CR8	chr2:203776978-203851060:+	-0.57	-5.13	1.42E-6	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934767	chr2:203766563	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72934944	chr2:202190610	PPIL3	chr2:201735680-201753999:-	-0.85	-4.47	2.07E-5	Rheumatoid arthritis	
LAML	cis	1	rs72936304	chr2:204036357	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936309	chr2:204040296	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936323	chr2:204050474	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936326	chr2:204054141	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936332	chr2:204056678	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936348	chr2:204064839	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936353	chr2:204070956	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936830	chr2:203769803	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936834	chr2:203771260	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936838	chr2:203772984	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936842	chr2:203773686	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936846	chr2:203774734	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936847	chr2:203774748	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936852	chr2:203775475	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936856	chr2:203775712	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936862	chr2:203786812	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936869	chr2:203788950	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936870	chr2:203789679	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936872	chr2:203790889	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936873	chr2:203791333	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936881	chr2:203794262	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs72936882	chr2:203794439	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs7301826	chr12:131291101	STX2	chr12:131274149-131323811:-	0.52	5.97	3.79E-8	Plasma plasminogen activator levels	
LAML	cis	1	rs7303	chr14:75520065	EIF2B2	chr14:75469612-75476292:+	0.45	4.46	2.13E-5	Height	
LAML	cis	1	rs73070422	chr4:1016645	DGKQ	chr4:952676-967344:-	-0.43	-4.51	1.8E-5	Bone mineral density	
LAML	cis	1	rs73116394	chr2:242367915	SEPT2	chr2:242254723-242293439:+	0.89	4.82	5.19E-6	Chronic lymphocytic leukemia	
LAML	cis	1	rs73116396	chr2:242368693	SEPT2	chr2:242254723-242293439:+	0.89	4.82	5.19E-6	Chronic lymphocytic leukemia	
LAML	cis	1	rs73193868	chr21:30600224	CCT8	chr21:30428650-30446010:-	0.76	5.84	6.71E-8	Response to mTOR inhibitor (everolimus)	
LAML	cis	1	rs73282209	chr5:150174959	LOC134466	chr5:150310000-150326146:-	0.84	4.58	1.33E-5	Crohn's disease	
LAML	cis	1	rs73282234	chr5:150195924	LOC134466	chr5:150310000-150326146:-	0.94	5.09	1.69E-6	Crohn's disease	
LAML	cis	1	rs73342417	chr21:30586627	CCT8	chr21:30428650-30446010:-	0.59	5.23	9.36E-7	Response to mTOR inhibitor (everolimus)	
LAML	cis	1	rs7356093	chr3:134238753	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs735665	chr11:123361397	GRAMD1B	chr11:123396528-123493518:+	0.45	5.01	2.37E-6	Follicular lymphoma;Chronic lymphocytic leukemia	
LAML	cis	1	rs73586989	chr16:67234741	RLTPR	chr16:67679030-67691470:+	-0.62	-5.67	1.44E-7	HDL cholesterol	
LAML	cis	1	rs7371896	chr3:134249769	ANAPC13	chr3:134196547-134204865:-	0.39	5.36	5.49E-7	Height	
LAML	cis	1	rs7374158	chr3:134270156	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs7374325	chr3:134275601	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs74000358	chr2:242020779	MTERFD2	chr2:242034545-242041747:-	-0.69	-4.3	3.99E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs74000379	chr2:242034103	MTERFD2	chr2:242034545-242041747:-	-0.69	-4.3	3.99E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs740393	chr2:242065498	MTERFD2	chr2:242034545-242041747:-	-0.58	-4.31	3.8E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs74071851	chr14:88882202	PTPN21	chr14:88932123-89021123:-	0.6	4.92	3.46E-6	Coronary artery calcification	
LAML	cis	1	rs741233	chr19:46894786	PPP5C	chr19:46850294-46894103:+	-0.38	-5.19	1.1E-6	Crohn's disease;Inflammatory bowel disease	
LAML	cis	1	rs7426847	chr3:134267519	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs7427492	chr3:134261654	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs7428326	chr3:134251184	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs7429866	chr3:134236306	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs7429990	chr3:47901803	ZNF589	chr3:48282596-48329113:+	0.53	4.53	1.62E-5	Educational attainment (years of education)	
LAML	cis	1	rs7432268	chr3:134242051	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs7433663	chr3:134235790	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs7433991	chr3:134312292	ANAPC13	chr3:134196547-134204865:-	0.37	4.97	2.83E-6	Height	
LAML	cis	1	rs74372131	chr10:81787214	LOC219347	chr10:81805991-81838949:-	1.32	8.98	1.82E-14	Chronic obstructive pulmonary disease-related biomarkers	
LAML	cis	1	rs74421437	chr2:203831252	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs74680618	chr2:242026270	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs747692	chr6:33737436	LEMD2	chr6:33738991-33756906:-	0.28	4.24	5.05E-5	Body mass index	
LAML	cis	1	rs74890219	chr2:242051224	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs74902201	chr17:64711563	HELZ	chr17:65066555-65241319:-	0.54	4.81	5.48E-6	Food addiction	
LAML	cis	1	rs74955473	chr5:150174558	LOC134466	chr5:150310000-150326146:-	0.93	5.18	1.18E-6	Crohn's disease	
LAML	cis	1	rs74973123	chr5:150169883	LOC134466	chr5:150310000-150326146:-	0.86	4.29	4.16E-5	Crohn's disease	
LAML	cis	1	rs7512422	chr1:207508950	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs7515491	chr1:46355079	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs7515491	chr1:46355079	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs75166090	chr2:203692760	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs7522601	chr1:46419021	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs7522601	chr1:46419021	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs7522701	chr1:207410965	CD55	chr1:207494817-207534309:+	0.39	4.55	1.5E-5	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs7522705	chr1:45992300	CCDC163P	chr1:45960581-45965646:-	1.09	10.84	1.65E-18	Homocysteine levels	
LAML	cis	1	rs7524495	chr1:46266932	CCDC163P	chr1:45960581-45965646:-	-0.6	-4.95	3.08E-6	Body mass index	
LAML	cis	1	rs7524495	chr1:46266932	PIK3R3	chr1:46505813-46642160:-	0.38	4.6	1.24E-5	Body mass index	
LAML	cis	1	rs75294883	chr5:150196503	LOC134466	chr5:150310000-150326146:-	1.03	5.52	2.77E-7	Crohn's disease	
LAML	cis	1	rs75306531	chr7:127151869	FSCN3	chr7:127231463-127241843:+	0.72	4.43	2.48E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs75324925	chr2:203698300	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs7534467	chr1:45988691	CCDC163P	chr1:45960581-45965646:-	-1.26	-14.53	2.71E-26	Homocysteine levels	
LAML	cis	1	rs7536557	chr1:45992114	CCDC163P	chr1:45960581-45965646:-	-1.09	-10.84	1.65E-18	Homocysteine levels	
LAML	cis	1	rs7538876	chr1:17722363	PADI6	chr1:17698741-17728195:+	-0.5	-5.47	3.4E-7	Basal cell carcinoma	
LAML	cis	1	rs7539932	chr1:46292354	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs7539932	chr1:46292354	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs7540325	chr1:46338217	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs7540325	chr1:46338217	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs7543250	chr1:207425043	CD55	chr1:207494817-207534309:+	-0.39	-4.55	1.5E-5	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs7545115	chr1:17724331	PADI6	chr1:17698741-17728195:+	-0.51	-5.52	2.68E-7	Basal cell carcinoma	
LAML	cis	1	rs7545125	chr1:207424727	CD55	chr1:207494817-207534309:+	0.48	5.51	2.89E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs7548463	chr1:207502891	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs7550746	chr1:46351719	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs7550746	chr1:46351719	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs7555030	chr1:207508730	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs7556436	chr1:46363880	CCDC163P	chr1:45960581-45965646:-	0.6	5	2.53E-6	Body mass index	
LAML	cis	1	rs7556436	chr1:46363880	PIK3R3	chr1:46505813-46642160:-	-0.39	-4.65	1.05E-5	Body mass index	
LAML	cis	1	rs7556615	chr1:46461369	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs7556615	chr1:46461369	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs7558944	chr2:73810909	ALMS1P	chr2:73872046-73912692:+	0.54	5.2	1.09E-6	Metabolite levels	
LAML	cis	1	rs7558944	chr2:73810909	NAT8	chr2:73867850-73869537:-	0.66	6	3.32E-8	Metabolite levels	
LAML	cis	1	rs7560547	chr2:203757916	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs75639658	chr17:48585734	MYCBPAP	chr17:48585745-48608861:+	-0.68	-5.74	1.02E-7	Visceral fat	
LAML	cis	1	rs7564890	chr2:73641853	ALMS1P	chr2:73872046-73912692:+	0.55	5.25	8.75E-7	Metabolite levels	
LAML	cis	1	rs7564890	chr2:73641853	NAT8	chr2:73867850-73869537:-	0.68	6.24	1.1E-8	Metabolite levels	
LAML	cis	1	rs7569147	chr2:167989691	XIRP2	chr2:167744997-168116259:+	-0.42	-4.41	2.67E-5	Atopic dermatitis	
LAML	cis	1	rs7572722	chr2:73724675	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs7572722	chr2:73724675	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs7576245	chr2:73829678	ALMS1P	chr2:73872046-73912692:+	0.57	5.63	1.68E-7	Metabolite levels	
LAML	cis	1	rs7576245	chr2:73829678	NAT8	chr2:73867850-73869537:-	0.65	6.03	2.81E-8	Metabolite levels	
LAML	cis	1	rs757978	chr2:242371101	SEPT2	chr2:242254723-242293439:+	0.89	4.82	5.19E-6	Chronic lymphocytic leukemia	
LAML	cis	1	rs7580558	chr2:242060296	MTERFD2	chr2:242034545-242041747:-	-0.73	-4.79	5.93E-6	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs7580825	chr2:73635148	ALMS1P	chr2:73872046-73912692:+	0.56	5.37	5.26E-7	Metabolite levels	
LAML	cis	1	rs7580825	chr2:73635148	NAT8	chr2:73867850-73869537:-	0.66	6.1	2.07E-8	Metabolite levels	
LAML	cis	1	rs75811104	chr2:242052338	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs7581224	chr2:84709215	DNAH6	chr2:84743579-85046711:+	0.7	7.73	9.09E-12	Coronary artery calcification	
LAML	cis	1	rs7582606	chr2:73813945	ALMS1P	chr2:73872046-73912692:+	0.54	5.2	1.09E-6	Metabolite levels	
LAML	cis	1	rs7582606	chr2:73813945	NAT8	chr2:73867850-73869537:-	0.66	6	3.32E-8	Metabolite levels	
LAML	cis	1	rs7582720	chr2:203753072	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs7583255	chr2:73797996	ALMS1P	chr2:73872046-73912692:+	0.55	5.39	4.82E-7	Metabolite levels	
LAML	cis	1	rs7583255	chr2:73797996	NAT8	chr2:73867850-73869537:-	0.67	6.32	7.55E-9	Metabolite levels	
LAML	cis	1	rs7584575	chr2:73666402	ALMS1P	chr2:73872046-73912692:+	0.53	5.32	6.34E-7	Metabolite levels	
LAML	cis	1	rs7584575	chr2:73666402	NAT8	chr2:73867850-73869537:-	0.61	5.79	8.16E-8	Metabolite levels	
LAML	cis	1	rs7585004	chr2:73666645	ALMS1P	chr2:73872046-73912692:+	0.56	4.91	3.59E-6	Metabolite levels	
LAML	cis	1	rs7585004	chr2:73666645	NAT8	chr2:73867850-73869537:-	0.68	5.73	1.1E-7	Metabolite levels	
LAML	cis	1	rs7586463	chr2:73798476	ALMS1P	chr2:73872046-73912692:+	0.55	5.39	4.82E-7	Metabolite levels	
LAML	cis	1	rs7586463	chr2:73798476	NAT8	chr2:73867850-73869537:-	0.67	6.32	7.55E-9	Metabolite levels	
LAML	cis	1	rs75869289	chr2:203806724	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs7590071	chr2:240900947	NDUFA10	chr2:240900158-240964798:-	0.48	5.28	7.69E-7	Odorant perception (isobutyraldehyde)	
LAML	cis	1	rs75913297	chr10:81789845	LOC219347	chr10:81805991-81838949:-	1.3	9.19	6.54E-15	Chronic obstructive pulmonary disease-related biomarkers	
LAML	cis	1	rs7591472	chr2:201889751	PPIL3	chr2:201735680-201753999:-	-1	-9.24	4.93E-15	Triptolide cytotoxicity	
LAML	cis	1	rs7594511	chr2:73681639	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs7594511	chr2:73681639	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs7598396	chr2:73652628	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs7598396	chr2:73652628	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs7598419	chr2:73798223	ALMS1P	chr2:73872046-73912692:+	0.55	5.39	4.82E-7	Metabolite levels	
LAML	cis	1	rs7598419	chr2:73798223	NAT8	chr2:73867850-73869537:-	0.67	6.32	7.55E-9	Metabolite levels	
LAML	cis	1	rs7601738	chr2:242375813	SEPT2	chr2:242254723-242293439:+	-0.89	-4.82	5.19E-6	Chronic lymphocytic leukemia	
LAML	cis	1	rs7604682	chr2:73788026	ALMS1P	chr2:73872046-73912692:+	0.54	5.25	8.85E-7	Metabolite levels	
LAML	cis	1	rs7604682	chr2:73788026	NAT8	chr2:73867850-73869537:-	0.63	5.87	5.76E-8	Metabolite levels	
LAML	cis	1	rs7605484	chr2:203724495	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs7607014	chr2:73730174	ALMS1P	chr2:73872046-73912692:+	-0.55	-5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs7607014	chr2:73730174	NAT8	chr2:73867850-73869537:-	-0.67	-6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs7611611	chr3:134307877	ANAPC13	chr3:134196547-134204865:-	0.37	4.97	2.83E-6	Height	
LAML	cis	1	rs7611828	chr3:134250325	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs7619451	chr3:134233238	ANAPC13	chr3:134196547-134204865:-	0.39	5.41	4.32E-7	Height	
LAML	cis	1	rs7620350	chr3:183710053	ABCC5	chr3:183637726-183735727:-	-0.41	-4.31	3.79E-5	Anterior chamber depth	
LAML	cis	1	rs762676	chr22:51017794	CHKB-CPT1B	chr22:51007291-51021428:-	-0.62	-4.48	2.03E-5	Narcolepsy	
LAML	cis	1	rs762676	chr22:51017794	CPT1B	chr22:51007291-51017096:-	-0.75	-4.53	1.68E-5	Narcolepsy	
LAML	cis	1	rs762677	chr22:51017713	CHKB-CPT1B	chr22:51007291-51021428:-	-0.62	-4.48	2.03E-5	Narcolepsy	
LAML	cis	1	rs762677	chr22:51017713	CPT1B	chr22:51007291-51017096:-	-0.75	-4.53	1.68E-5	Narcolepsy	
LAML	cis	1	rs76298043	chr2:203814694	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs763014	chr16:675680	WFIKKN1	chr16:679239-684116:+	0.37	4.22	5.39E-5	Height	
LAML	cis	1	rs7630874	chr3:134293291	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.33	6.27E-7	Height	
LAML	cis	1	rs7632670	chr3:183713877	ABCC5	chr3:183637726-183735727:-	-0.42	-4.42	2.49E-5	Anterior chamber depth	
LAML	cis	1	rs7637227	chr3:134244155	ANAPC13	chr3:134196547-134204865:-	0.39	5.44	3.88E-7	Height	
LAML	cis	1	rs76433514	chr5:150306532	LOC134466	chr5:150310000-150326146:-	1.01	5.79	8.32E-8	Crohn's disease	
LAML	cis	1	rs7645295	chr3:134307734	ANAPC13	chr3:134196547-134204865:-	0.36	4.67	9.32E-6	Height	
LAML	cis	1	rs76461893	chr2:203865515	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs7648990	chr3:134244390	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs7655841	chr4:129890790	C4orf33	chr4:130014829-130033842:+	0.54	4.22	5.5E-5	Chronic obstructive pulmonary disease (moderate to severe)	
LAML	cis	1	rs76767593	chr5:150169843	LOC134466	chr5:150310000-150326146:-	0.86	4.29	4.16E-5	Crohn's disease	
LAML	cis	1	rs76872831	chr5:150171559	LOC134466	chr5:150310000-150326146:-	0.93	5.18	1.18E-6	Crohn's disease	
LAML	cis	1	rs76890136	chr2:203850011	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs76935404	chr19:41419294	CYP2B7P1	chr19:41430170-41456563:+	-0.52	-5.25	8.85E-7	nicotine metabolite ratio in current smokers	
LAML	cis	1	rs76994419	chr15:40714150	IVD	chr15:40697686-40713512:+	-0.47	-4.39	2.89E-5	Heschl's gyrus morphology	
LAML	cis	1	rs77230711	chr2:203805552	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs7724558	chr5:150328866	LOC134466	chr5:150310000-150326146:-	0.93	4.24	5.12E-5	Crohn's disease	
LAML	cis	1	rs77268589	chr2:203751981	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs773125	chr12:56394954	RPS26	chr12:56435686-56438005:+	0.75	9.53	1.17E-15	Rheumatoid arthritis	
LAML	cis	1	rs773125	chr12:56394954	SUOX	chr12:56391043-56399307:+	-0.28	-4.34	3.5E-5	Rheumatoid arthritis	
LAML	cis	1	rs77335224	chr10:104636276	SFXN2	chr10:104474298-104498946:+	-0.63	-4.44	2.33E-5	Hypertension;Systolic blood pressure;Diastolic blood pressure	
LAML	cis	1	rs7740487	chr6:28216486	ZNF187	chr6:28234788-28245978:+	-0.43	-4.45	2.22E-5	Depression	
LAML	cis	1	rs7747824	chr6:86647106	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs7750918	chr6:49430082	MUT	chr6:49398994-49431031:-	0.44	6.46	3.88E-9	Folate pathway vitamin levels	
LAML	cis	1	rs7756203	chr6:86627707	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs7760207	chr6:86721700	SNHG5	chr6:86386726-86388451:-	-0.61	-5.9	5.08E-8	Response to antipsychotic treatment	
LAML	cis	1	rs7766645	chr6:86622238	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs7771342	chr6:86631936	SNHG5	chr6:86386726-86388451:-	-0.6	-5.75	9.78E-8	Response to antipsychotic treatment	
LAML	cis	1	rs7773987	chr6:135707486	AHI1	chr6:135605112-135818903:-	0.53	5.63	1.7E-7	Selective IgA deficiency	
LAML	cis	1	rs7787274	chr7:2275993	FTSJ2	chr7:2273928-2281833:-	0.33	4.23	5.16E-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	
LAML	cis	1	rs7789577	chr7:127150498	FSCN3	chr7:127231463-127241843:+	0.72	4.43	2.48E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs7789737	chr7:127150683	FSCN3	chr7:127231463-127241843:+	0.72	4.43	2.48E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs77931721	chr2:203763076	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs7799006	chr7:2278226	FTSJ2	chr7:2273928-2281833:-	0.35	4.41	2.58E-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	
LAML	cis	1	rs7810970	chr7:2276385	FTSJ2	chr7:2273928-2281833:-	0.33	4.22	5.39E-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	
LAML	cis	1	rs78520676	chr11:517173	RNH1	chr11:494512-507273:-	-0.45	-4.42	2.58E-5	Body mass index	
LAML	cis	1	rs785464	chr1:46523089	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs785464	chr1:46523089	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs785471	chr1:46518677	CCDC163P	chr1:45960581-45965646:-	-0.6	-5.06	1.91E-6	Body mass index	
LAML	cis	1	rs785471	chr1:46518677	PIK3R3	chr1:46505813-46642160:-	0.38	4.64	1.08E-5	Body mass index	
LAML	cis	1	rs785479	chr1:46492144	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs785479	chr1:46492144	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs785481	chr1:46554518	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs785481	chr1:46554518	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs785485	chr1:46574424	CCDC163P	chr1:45960581-45965646:-	-0.61	-5.06	1.96E-6	Body mass index	
LAML	cis	1	rs785485	chr1:46574424	PIK3R3	chr1:46505813-46642160:-	0.38	4.57	1.41E-5	Body mass index	
LAML	cis	1	rs785488	chr1:46576095	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs785488	chr1:46576095	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs785489	chr1:46576390	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs785489	chr1:46576390	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs785491	chr1:46583418	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs785491	chr1:46583418	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs785492	chr1:46583607	CCDC163P	chr1:45960581-45965646:-	-0.6	-5.06	1.91E-6	Body mass index	
LAML	cis	1	rs785492	chr1:46583607	PIK3R3	chr1:46505813-46642160:-	0.38	4.64	1.08E-5	Body mass index	
LAML	cis	1	rs785494	chr1:46586626	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs785494	chr1:46586626	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs785495	chr1:46587887	CCDC163P	chr1:45960581-45965646:-	-0.6	-5.06	1.91E-6	Body mass index	
LAML	cis	1	rs785495	chr1:46587887	PIK3R3	chr1:46505813-46642160:-	0.38	4.64	1.08E-5	Body mass index	
LAML	cis	1	rs785503	chr1:46595868	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs785503	chr1:46595868	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs785520	chr1:46568836	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs785520	chr1:46568836	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs786425	chr12:124085502	DDX55	chr12:124086672-124105483:+	0.4	4.35	3.33E-5	Pubertal anthropometrics	
LAML	cis	1	rs78797111	chr2:242056048	MTERFD2	chr2:242034545-242041747:-	-0.72	-4.31	3.88E-5	Pharmacokinetics of antipsychotic drugs in severe mental disorder (concentration drug ratio)	
LAML	cis	1	rs78907692	chr2:203932176	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs79045902	chr7:127147127	FSCN3	chr7:127231463-127241843:+	0.72	4.43	2.48E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs79074652	chr17:64695738	HELZ	chr17:65066555-65241319:-	0.47	4.22	5.34E-5	Food addiction	
LAML	cis	1	rs791856	chr6:86681841	SNHG5	chr6:86386726-86388451:-	0.59	5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs7940310	chr11:117024481	TAGLN	chr11:117070040-117075507:+	0.52	4.68	8.96E-6	Protein quantitative trait loci	
LAML	cis	1	rs79440439	chr11:478147	RNH1	chr11:494512-507273:-	-0.4	-4.25	4.84E-5	Body mass index	
LAML	cis	1	rs79442859	chr5:150171210	LOC134466	chr5:150310000-150326146:-	0.93	5.18	1.18E-6	Crohn's disease	
LAML	cis	1	rs7950364	chr11:116898886	TAGLN	chr11:117070040-117075507:+	0.51	4.61	1.22E-5	Protein quantitative trait loci	
LAML	cis	1	rs79539678	chr2:203740938	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs7954638	chr12:96314795	AMDHD1	chr12:96337071-96362369:+	0.55	5.84	6.55E-8	Metabolite levels (small molecules and protein measures)	
LAML	cis	1	rs79579293	chr14:88822068	PTPN21	chr14:88932123-89021123:-	0.63	5.79	8.24E-8	Coronary artery calcification	
LAML	cis	1	rs79642273	chr2:203830851	ALS2CR8	chr2:203776978-203851060:+	-0.5	-4.32	3.72E-5	Coronary artery disease or large artery stroke;Coronary artery disease or ischemic stroke	
LAML	cis	1	rs7973719	chr12:7334813	PEX5	chr12:7341759-7371167:+	0.46	5	2.47E-6	IgG glycosylation	
LAML	cis	1	rs79780973	chr5:150174810	LOC134466	chr5:150310000-150326146:-	0.93	5.18	1.18E-6	Crohn's disease	
LAML	cis	1	rs79808876	chr11:465763	RNH1	chr11:494512-507273:-	-0.45	-5.08	1.77E-6	Body mass index	
LAML	cis	1	rs8003506	chr14:75586288	EIF2B2	chr14:75469612-75476292:+	-0.47	-4.57	1.39E-5	Height	
LAML	cis	1	rs80085676	chr2:242347907	SEPT2	chr2:242254723-242293439:+	0.89	4.82	5.19E-6	Chronic lymphocytic leukemia	
LAML	cis	1	rs8014170	chr14:50071694	RPL36AL	chr14:50085407-50087349:-	0.36	4.35	3.31E-5	Carotid intima media thickness	
LAML	cis	1	rs8017642	chr14:75590822	EIF2B2	chr14:75469612-75476292:+	0.45	4.44	2.34E-5	Height	
LAML	cis	1	rs8028182	chr15:75718669	MAN2C1	chr15:75648135-75660941:-	0.37	4.77	6.37E-6	Sudden cardiac arrest	
LAML	cis	1	rs80308641	chr7:127147638	FSCN3	chr7:127231463-127241843:+	0.72	4.43	2.48E-5	Medication adherence in chronic diseases	
LAML	cis	1	rs8033938	chr15:40703114	IVD	chr15:40697686-40713512:+	-0.47	-4.39	2.89E-5	Heschl's gyrus morphology	
LAML	cis	1	rs8049173	chr16:11436882	C16orf75	chr16:11343506-11445617:+	0.44	5.31	6.78E-7	Vein graft stenosis in coronary artery bypass grafting	
LAML	cis	1	rs8049439	chr16:28837515	TUFM	chr16:28853732-28857729:-	0.24	6.35	6.49E-9	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LAML	cis	1	rs8054842	chr16:672799	WFIKKN1	chr16:679239-684116:+	0.37	4.21	5.55E-5	Height	
LAML	cis	1	rs8055427	chr16:11436883	C16orf75	chr16:11343506-11445617:+	0.44	5.31	6.78E-7	Vein graft stenosis in coronary artery bypass grafting	
LAML	cis	1	rs809775	chr1:46538040	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs809775	chr1:46538040	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs8137478	chr22:51017296	CHKB-CPT1B	chr22:51007291-51021428:-	-0.62	-4.48	2.03E-5	Narcolepsy	
LAML	cis	1	rs8137478	chr22:51017296	CPT1B	chr22:51007291-51017096:-	-0.75	-4.53	1.68E-5	Narcolepsy	
LAML	cis	1	rs8181644	chr12:58173466	FAM119B	chr12:58166383-58176323:+	0.63	8.36	4.13E-13	Multiple sclerosis	
LAML	cis	1	rs832551	chr5:56180112	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs832553	chr5:56114786	C5orf35	chr5:56205103-56213010:+	0.89	7.89	4.1E-12	Type 2 diabetes	
LAML	cis	1	rs832554	chr5:56115036	C5orf35	chr5:56205103-56213010:+	0.89	7.89	4.1E-12	Type 2 diabetes	
LAML	cis	1	rs832565	chr5:56150803	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs832568	chr5:56153776	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs832569	chr5:56154584	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs832578	chr5:56164223	C5orf35	chr5:56205103-56213010:+	0.96	8.74	6.12E-14	Type 2 diabetes	
LAML	cis	1	rs832582	chr5:56177743	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs832583	chr5:56178217	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs832584	chr5:56179212	C5orf35	chr5:56205103-56213010:+	-0.95	-8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs834575	chr1:100368382	LRRC39	chr1:100614413-100643800:-	1.08	4.29	4.19E-5	Carotid intima media thickness	
LAML	cis	1	rs836788	chr5:79912044	MSH3	chr5:79950294-80172633:+	0.37	4.57	1.39E-5	Glomerular filtration rate (creatinine)	
LAML	cis	1	rs860580	chr5:56149429	C5orf35	chr5:56205103-56213010:+	-0.97	-8.87	3.17E-14	Type 2 diabetes	
LAML	cis	1	rs861283	chr5:56184610	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs863840	chr5:56128999	C5orf35	chr5:56205103-56213010:+	0.94	8.53	1.75E-13	Type 2 diabetes	
LAML	cis	1	rs866222	chr5:56184444	C5orf35	chr5:56205103-56213010:+	0.95	8.6	1.24E-13	Type 2 diabetes	
LAML	cis	1	rs868213	chr16:67220457	RLTPR	chr16:67679030-67691470:+	-0.53	-5.18	1.17E-6	HDL cholesterol	
LAML	cis	1	rs869417	chr3:183689138	ABCC5	chr3:183637726-183735727:-	-0.41	-4.32	3.72E-5	Anterior chamber depth	
LAML	cis	1	rs873686	chr4:185638876	MLF1IP	chr4:185615220-185655286:-	0.36	4.54	1.61E-5	Kawasaki disease	
LAML	cis	1	rs876402	chr14:75601862	EIF2B2	chr14:75469612-75476292:+	-0.44	-4.38	3.0E-5	Height	
LAML	cis	1	rs876403	chr14:75602834	EIF2B2	chr14:75469612-75476292:+	0.44	4.38	3.0E-5	Height	
LAML	cis	1	rs877049	chr1:207422996	CD55	chr1:207494817-207534309:+	0.39	4.55	1.5E-5	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs877636	chr12:56480583	RPS26	chr12:56435686-56438005:+	-0.69	-6.49	3.48E-9	Cognitive function	
LAML	cis	1	rs879568	chr18:34311659	C18orf10	chr18:34366472-34409158:-	-0.4	-4.62	1.17E-5	QRS duration	
LAML	cis	1	rs882803	chr1:45976147	CCDC163P	chr1:45960581-45965646:-	-1.09	-10.84	1.65E-18	Homocysteine levels	
LAML	cis	1	rs884841	chr6:86680300	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs891376	chr1:207491489	CD55	chr1:207494817-207534309:+	0.43	4.95	3.01E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs891378	chr1:207490319	CD55	chr1:207494817-207534309:+	0.48	5.51	2.89E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs900012	chr11:116966435	TAGLN	chr11:117070040-117075507:+	0.52	4.54	1.58E-5	Protein quantitative trait loci	
LAML	cis	1	rs910316	chr14:75626042	EIF2B2	chr14:75469612-75476292:+	0.44	4.38	3.0E-5	Height	
LAML	cis	1	rs921450	chr7:50623260	FIGNL1	chr7:50511834-50518088:-	0.34	4.59	1.3E-5	Malaria	
LAML	cis	1	rs921451	chr7:50623285	FIGNL1	chr7:50511834-50518088:-	-0.34	-4.43	2.43E-5	Malaria	
LAML	cis	1	rs925130	chr1:207503432	CD55	chr1:207494817-207534309:+	0.44	5.05	2.06E-6	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs925131	chr1:207503721	CD55	chr1:207494817-207534309:+	0.51	5.43	4.09E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs9257809	chr6:29356331	MOG	chr6:29624809-29640147:+	0.94	5.57	2.17E-7	Barrett's esophagus;Barrett's esophagus  or Esophageal adenocarcinoma	
LAML	cis	1	rs9283717	chr5:56078659	C5orf35	chr5:56205103-56213010:+	0.88	7.67	1.19E-11	Type 2 diabetes	
LAML	cis	1	rs9289471	chr3:134230811	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs9289475	chr3:134236459	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs9289476	chr3:134237103	ANAPC13	chr3:134196547-134204865:-	0.39	5.27	8.01E-7	Height	
LAML	cis	1	rs9289478	chr3:134268619	ANAPC13	chr3:134196547-134204865:-	0.39	5.27	8.01E-7	Height	
LAML	cis	1	rs9296404	chr6:42925803	PEX6	chr6:42931613-42946981:-	0.69	7.89	4.04E-12	Plasma homocysteine levels (post-methionine load test)	
LAML	cis	1	rs9296616	chr6:49414235	MUT	chr6:49398994-49431031:-	0.43	6.35	6.54E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9296617	chr6:49428360	MUT	chr6:49398994-49431031:-	0.44	6.66	1.57E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9303401	chr17:56847945	RAD51C	chr17:56769963-56811690:+	0.51	6.16	1.58E-8	Cognitive test performance	
LAML	cis	1	rs9309331	chr2:61141615	AHSA2	chr2:61404553-61414058:+	-0.34	-4.19	6.08E-5	Inflammatory skin disease	
LAML	cis	1	rs9309473	chr2:73743982	ALMS1P	chr2:73872046-73912692:+	0.55	5.33	6.32E-7	Metabolite levels	
LAML	cis	1	rs9309473	chr2:73743982	NAT8	chr2:73867850-73869537:-	0.67	6.28	9.07E-9	Metabolite levels	
LAML	cis	1	rs932644	chr6:167404187	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs934093	chr3:134195885	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs9374289	chr6:112111394	FYN	chr6:111982487-112194627:-	-0.4	-4.19	6.18E-5	Anger	
LAML	cis	1	rs939336	chr3:183685534	ABCC5	chr3:183637726-183735727:-	-0.41	-4.32	3.72E-5	Anterior chamber depth	
LAML	cis	1	rs939337	chr3:183701147	ABCC5	chr3:183637726-183735727:-	-0.41	-4.31	3.79E-5	Anterior chamber depth	
LAML	cis	1	rs939338	chr3:183704068	ABCC5	chr3:183637726-183735727:-	0.41	4.31	3.79E-5	Anterior chamber depth	
LAML	cis	1	rs942457	chr1:17739586	PADI6	chr1:17698741-17728195:+	-0.51	-5.49	3.17E-7	Basal cell carcinoma	
LAML	cis	1	rs9427094	chr1:154557685	CHRNB2	chr1:154540257-154552351:+	-0.4	-4.49	1.94E-5	C-reactive protein levels or triglyceride levels (pleiotropy)	
LAML	cis	1	rs9429183	chr1:46524582	CCDC163P	chr1:45960581-45965646:-	-0.62	-5.27	7.94E-7	Body mass index	
LAML	cis	1	rs9429183	chr1:46524582	PIK3R3	chr1:46505813-46642160:-	0.37	4.53	1.64E-5	Body mass index	
LAML	cis	1	rs9457247	chr6:167392174	RNASET2	chr6:167343008-167412795:-	-0.71	-9.06	1.23E-14	Crohn's disease	
LAML	cis	1	rs9463473	chr6:49380121	MUT	chr6:49398994-49431031:-	0.45	6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9463474	chr6:49380199	MUT	chr6:49398994-49431031:-	0.45	6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9463475	chr6:49380899	MUT	chr6:49398994-49431031:-	-0.45	-6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9463477	chr6:49386446	MUT	chr6:49398994-49431031:-	0.45	6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9463479	chr6:49393275	MUT	chr6:49398994-49431031:-	0.45	6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9463480	chr6:49400795	MUT	chr6:49398994-49431031:-	0.45	6.57	2.33E-9	Folate pathway vitamin levels	
LAML	cis	1	rs946529	chr1:46485548	CCDC163P	chr1:45960581-45965646:-	-0.6	-5	2.53E-6	Body mass index	
LAML	cis	1	rs946529	chr1:46485548	PIK3R3	chr1:46505813-46642160:-	0.39	4.65	1.05E-5	Body mass index	
LAML	cis	1	rs9473549	chr6:49380020	MUT	chr6:49398994-49431031:-	0.43	6.35	6.54E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9473552	chr6:49387154	MUT	chr6:49398994-49431031:-	0.45	6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9473553	chr6:49395977	MUT	chr6:49398994-49431031:-	0.45	6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9473555	chr6:49409487	MUT	chr6:49398994-49431031:-	0.45	6.63	1.81E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9473560	chr6:49427918	MUT	chr6:49398994-49431031:-	0.44	6.66	1.57E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9473561	chr6:49428755	MUT	chr6:49398994-49431031:-	0.44	6.66	1.57E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9473563	chr6:49453651	MUT	chr6:49398994-49431031:-	0.43	6.35	6.54E-9	Folate pathway vitamin levels	
LAML	cis	1	rs9527	chr10:104623578	AS3MT	chr10:104613967-104661653:+	-0.5	-4.55	1.54E-5	Arsenic metabolism	
LAML	cis	1	rs9527	chr10:104623578	C10orf32	chr10:104613967-104624718:+	-0.71	-7.24	9.69E-11	Arsenic metabolism	
LAML	cis	1	rs955196	chr6:86729951	SNHG5	chr6:86386726-86388451:-	0.57	5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs955197	chr6:86729675	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs955227	chr6:86651032	SNHG5	chr6:86386726-86388451:-	-0.57	-5.45	3.73E-7	Response to antipsychotic treatment	
LAML	cis	1	rs9647603	chr6:86639341	SNHG5	chr6:86386726-86388451:-	-0.59	-5.74	1.04E-7	Response to antipsychotic treatment	
LAML	cis	1	rs9649362	chr7:112914209	LOC401397	chr7:112756774-112758637:-	-0.36	-4.82	5.2E-6	Metabolite levels	
LAML	cis	1	rs9653557	chr2:73795962	ALMS1P	chr2:73872046-73912692:+	0.56	5.48	3.23E-7	Metabolite levels	
LAML	cis	1	rs9653557	chr2:73795962	NAT8	chr2:73867850-73869537:-	0.66	6.16	1.59E-8	Metabolite levels	
LAML	cis	1	rs968567	chr11:61595564	FADS2	chr11:61583728-61634825:+	0.67	5.57	2.18E-7	Blood metabolite levels;Rheumatoid arthritis;Glycerophospholipid levels	
LAML	cis	1	rs9689	chr1:25688276	RHD	chr1:25598981-25656935:+	-0.68	-8.75	5.86E-14	Erythrocyte sedimentation rate	
LAML	cis	1	rs971317	chr1:207476040	CD55	chr1:207494817-207534309:+	0.48	5.51	2.89E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs971318	chr1:207475596	CD55	chr1:207494817-207534309:+	-0.47	-5.35	5.79E-7	Spherical equivalent (joint main effects and education interaction)	
LAML	cis	1	rs9805979	chr14:75566209	EIF2B2	chr14:75469612-75476292:+	0.43	4.27	4.44E-5	Height	
LAML	cis	1	rs9809619	chr3:134280948	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs9813774	chr3:134227100	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs9814567	chr3:134218557	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs9819532	chr3:134288644	ANAPC13	chr3:134196547-134204865:-	0.39	5.33	6.09E-7	Height	
LAML	cis	1	rs9826496	chr3:134224437	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs9827987	chr3:134272621	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs9828815	chr3:134265749	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs9829092	chr3:134229866	ANAPC13	chr3:134196547-134204865:-	0.39	5.41	4.32E-7	Height	
LAML	cis	1	rs9832785	chr3:134213070	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs9834755	chr3:134206845	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs9835204	chr3:134261342	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs9841212	chr3:134191938	ANAPC13	chr3:134196547-134204865:-	0.41	5.61	1.84E-7	Height	
LAML	cis	1	rs9850015	chr3:134269541	ANAPC13	chr3:134196547-134204865:-	0.4	5.66	1.46E-7	Height	
LAML	cis	1	rs9851441	chr3:134315091	ANAPC13	chr3:134196547-134204865:-	0.36	4.83	4.92E-6	Height	
LAML	cis	1	rs9854299	chr3:134206728	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs9856693	chr3:134306913	ANAPC13	chr3:134196547-134204865:-	0.37	4.97	2.83E-6	Height	
LAML	cis	1	rs9858774	chr3:183652736	ABCC5	chr3:183637726-183735727:-	-0.41	-4.51	1.78E-5	Anterior chamber depth	
LAML	cis	1	rs9863786	chr3:134247203	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs9864346	chr3:134312352	ANAPC13	chr3:134196547-134204865:-	0.38	5.22	1.0E-6	Height	
LAML	cis	1	rs9864439	chr3:134298671	ANAPC13	chr3:134196547-134204865:-	0.37	4.92	3.47E-6	Height	
LAML	cis	1	rs9869981	chr3:134248801	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs9871305	chr3:134213538	ANAPC13	chr3:134196547-134204865:-	0.39	5.41	4.32E-7	Height	
LAML	cis	1	rs9876658	chr3:134179453	ANAPC13	chr3:134196547-134204865:-	-0.38	-5.15	1.35E-6	Height	
LAML	cis	1	rs9883753	chr3:134247231	ANAPC13	chr3:134196547-134204865:-	0.39	5.27	8.01E-7	Height	
LAML	cis	1	rs9884031	chr3:134256500	ANAPC13	chr3:134196547-134204865:-	0.39	5.43	4.04E-7	Height	
LAML	cis	1	rs9901225	chr17:40755811	HSD17B1	chr17:40703984-40707224:+	-0.39	-4.49	1.91E-5	Colorectal or endometrial cancer	
LAML	cis	1	rs9904677	chr17:56873025	RAD51C	chr17:56769963-56811690:+	0.51	6.16	1.58E-8	Cognitive test performance	
LAML	cis	1	rs9919599	chr11:116745484	TAGLN	chr11:117070040-117075507:+	0.49	4.54	1.58E-5	Protein quantitative trait loci	
LAML	cis	1	rs9920762	chr15:90368171	AP3S2	chr15:90373832-90456222:-	-0.57	-4.77	6.24E-6	Type 2 diabetes	
LAML	cis	1	rs9920775	chr15:90368273	AP3S2	chr15:90373832-90456222:-	-0.57	-4.77	6.24E-6	Type 2 diabetes	
LAML	cis	1	rs9921338	chr16:11416839	C16orf75	chr16:11343506-11445617:+	-0.42	-5.38	4.99E-7	Vein graft stenosis in coronary artery bypass grafting	
LAML	cis	1	rs9939768	chr16:67219107	RLTPR	chr16:67679030-67691470:+	-0.56	-5.91	4.86E-8	HDL cholesterol	
LAML	cis	1	rs9940665	chr16:67289841	RLTPR	chr16:67679030-67691470:+	-0.63	-6.48	3.56E-9	HDL cholesterol	
LAML	cis	1	rs9968172	chr3:134231251	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.41	4.32E-7	Height	
LAML	cis	1	rs9985341	chr3:134232840	ANAPC13	chr3:134196547-134204865:-	0.4	5.52	2.67E-7	Height	
LAML	cis	1	rs9985356	chr3:134232920	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.27	8.01E-7	Height	
LAML	cis	1	rs9986596	chr6:28219661	ZNF187	chr6:28234788-28245978:+	-0.43	-4.45	2.22E-5	Depression	
LAML	cis	1	rs9989967	chr3:134238964	ANAPC13	chr3:134196547-134204865:-	0.39	5.27	8.01E-7	Height	
LAML	cis	1	rs9990351	chr3:134239191	ANAPC13	chr3:134196547-134204865:-	-0.39	-5.27	8.01E-7	Height	
LAML	trans	1	rs11895999	chr2:158876018	GSX1	chr13:28366780-28368089:+	0.37	7.19	1.26E-10	Sleep duration	
